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Controlled gene expression using acute phase response elements
Previous work in our laboratory involved the creation of an inducible gene expression 
system based on the promoter of the major acute phase protein in humans, C-reactive 
protein (CRP). The aims of this project were to further characterise the CRP based 
expression vector and to modify it for use in pigs. The green fluorescent protein 
(GFP) was also evaluated as a reporter of transient inducible gene expression.
The 30kb fragment containing the human CRP gene was sequenced and analysed for 
the presence of elements that may be responsible for the low basal levels of 
expression of the gene and for sequences that are responsible for the sexually 
dimorphic pattern of expression o f the human CRP gene in transgenic mice.
It was planned to use the information from these analyses to modify the expression 
vector for use in pigs. However, because it is not currently known how the CRP- 
based acute phase expression vector would behave in other species, the promoter of 
the major acute phase protein in pigs, ITIH4, was isolated. Due to the absence of 
homology between the pig ITIH4 promoter and the human CRP promoter, the pig 
ITIH4 promoter was further characterised.
The investigations focused on the inducibility of the promoter in response to cytokine 
stimulation and the effect modification of the promoter would have on promoter 
activity and inducibility. It was found that the promoter was induced by IL-6 but not 
IL-1 (except at low concentrations). A combination of IL-l and IL-6 was shown to 
result in a decrease in the inducibility of the construct by IL-6. Mutation of the 
promoter in order to decrease the basal level of expression and enhance inducibility 
was unsuccessful.
In order to develop a system that will facilitate studies of inducible gene expression in 
vitro a destabilised variant of GFP was evaluated as a reporter gene. Although small 
increases in fluorescence intensity could be detected following stimulation, the 
analyses suggest that GFP is not as sensitive as other reporter genes for studying 
inducible gene expression.
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Introduction
Chapter 1; Introduction
In the last 50 years there has been a large increase in animal production and animal 
densities (Knap and Bishop, 2000). This means that in areas where faiming is 
intense infections can spread rapidly from one animal to another, and it is often 
necessary to slaughter large numbers of healthy animals just to prevent the spread of 
disease. Recent examples of this scenario include the outbreak of foot and mouth 
disease in the UK in 2001, which rapidly spread throughout the country and 
necessitated the culling of 6 million animals (ITN News Report). Another example 
is the outbreak of classical swine fever in the Netherlands in 1997, which lasted for 
over a year and during which, an estimated 10 million healthy pigs were killed to 
prevent the spread of infection (Stegeman et al., 2000). The outbreak of foot and 
mouth disease in the UK in 2001 is estimated to have cost tax payers more than £2.3 
billion (BBC News Report) and it is estimated that recent outbreaks of classical 
swine fever in several EU countries have amounted to several billion Euro 
(Moennig, 2000; Saatkamp et al., 2000; Stegeman et a l, 2000).
In developing countries the economic impact of parasitic infections is reflected in a 
loss in the production potential of livestock. Climatic conditions in developing 
countries provide ideal conditions for parasite development and as a result parasitic 
infections in livestock in these countries are often endemic. Many livestock 
production systems in these countries are characterised by animals with decreased 
susceptibility to many endemic parasitic infections but with poor productivity 
performance (for example, lower outputs of meat, milk, hides, skins) (reviewed by 
Perry and Randolph, 1999). Ngategize et a l (1993) calculated that ovine fascioliasis 
in the highlands of Ethiopia resulted in a financial loss of US$23 million annually.
Antibiotics are used extensively in the livestock industry, not just as a means of 
controlling infection but also as growth enhancers. However, there is concern that 
strains of bacteria resistant to antibiotics used in animals (particularly those 
antibiotics that are also used in human medicine) could transfer this resistance to
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human pathogens. Moreover, antibiotics are not effective against viral infections. 
The other method of controlling infection currently in use is vaccination. The aim of 
vaccination is to provide the animal with protection against infectious disease before 
it encounters the infectious organism. Vaccination, if  successful, can also be used as 
a means of controlling the spread of infectious disease and eventual elimination of 
the pathogen from the population. However, in spite of the fact that there have been 
some very successful vaccination programs, it remains that for many diseases no 
vaccine is available, the available vaccine does not provide complete protection (e.g. 
Meng, 2000) or when a vaccine is available it is not desirable to use it for economic 
reasons (for example, foot and mouth vaccine, classical swine fever vaccine). 
Infectious disease remains an important threat to livestock production and as a result 
there is a need to continue to develop and investigate new control strategies.
The introduction to this thesis will first of all describe how pathogens cause disease. 
Understanding the stages of pathogenesis is important as each stage offers the 
opportunity to block the development of disease. I will then describe the current 
means for controlling infection, with a particular emphasis on vaccination. Finally, I 
will discuss novel approaches to increasing animal resistance to infectious disease 
using transgenic technology.
1,1 The stases of pathosenesis
Pathogenesis is defined as the mechanism of disease development. Pathogenesis can 
be caused in a number of different ways (discussed by Singleton, 1999) as it is 
dependent on the causative agent -  some pathogens produce toxins or other 
substances that destroy tissue or disrupt physiological processes, others invade 
particular cells or tissues. The interactions between the host and the pathogen are 
also believed to play an important role in pathogenesis. In some diseases, the 
immune system itself can play a part in cellular and tissue damage (Bergeron et al., 
1998; Thanawongnuwech et al., 2001). Pathogenesis is a multi-stage process and 
requires the pathogen to breach a number of host defences. Understanding the
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stages of pathogenesis is important as it not only informs us of how pathogens cause 
disease, it also provides us with the opportunity to develop methods to halt the 
development of disease. The various stages of pathogenesis will be discussed in the 
following sections. This discussion will be limited to infectious diseases of humans 
and swine.
1.1.1 Route of infection
The skin is usually an effective barrier to infection. However, if the skin is broken, 
this provides a way for pathogens to enter the body. The mucous membranes of the 
respiratory, intestinal and genitourinary tracts are also susceptible to infection and 
infectious disease often begins at these sites. To cause disease, the pathogen must 
first enter the body. Many infectious diseases, particularly those of the respiratory 
tract, can be spread in aerosol droplets. This allows infection to spread rapidly from 
one animal or person to another (Jemigan et al., 1996; Jobert et al., 2000; Lever et 
al., 2000; Elbers et al., 2001). Another means of infection is the ingestion of 
infected food. For example, swill feeding to pigs is believed to be a major source of 
infection (Horst et al., 1996; Fritzemeier et a l, 2000). Therefore, one area of current 
research is the conditions necessary for survival of pathogens. The classical swine 
fever virus, for example, has been shown to be capable of surviving in frozen pork 
for more than four years and that only pasteurisation or cooking is capable of killing 
the virus (Edwards, 2000). On the other hand Mycobacterium tuberculosis has been 
shown to have a poor aerosol survival rate over a period of one hour (Lever et a l, 
2000). Understanding the route of infection and the conditions for the survival of 
the pathogen provide the first opportunity to block the development of disease.
1.1.2 Adhesion
The cells of the respiratory, intestinal and urogenital tract are covered with mucous 
secretions. These secretions are moved through their respective tracts by peristalsis. 
Therefore it is important that the pathogen is able to adhere to the cells of these
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tracts in order to prevent it from being swept along and eventually being expelled 
from the body. Bacterial adherence is dependent on two factors: appendages on the 
bacterial cell surface and host cell receptors.
Appendages on the bacterial cell surface that allow binding to host cells are called 
adhesins. Bacterial adhesins are often fimbriae. Fimbriae are long protrusions built 
from protein subunits that mediate binding to mammalian cells and non-living 
surfaces. The fimbriae of Escherichia coli were reviewed recently by van den 
Broeck et al. (2000). It is believed that fimbriae are responsible for the fact that 
some strains of E. coli can only cause infections in some species or colonise a 
particular part of the intestine. Strains of E. coli possessing the K88 antigen have 
been implicated in porcine neonatal and postweaning intestinal infections (Jones and 
Rutter, 1972). The K88 antigen allows the organisms to attach and colonise the 
lower small intestine (Blomberg et al., 1993; reviewed by Jin and Zhao, 2000). The 
infection then spreads to the proximal part o f the intestine (reviewed by van den 
Broeck et al., 2000). A marked variation in the susceptibility of pigs to infection by 
K88+ E. coli strains has been observed (Rutter et a l, 1975). For example, the 
Chinese Meishan breed of pig has increased resistance compared to the Minzhu 
breed (Michaels et a l, 1994). This difference may be due to the inability of the 
bacteria to adhere to the appropriate receptor (three antigenic variants of the K88 
fimbriae have been described and they bind to different receptors on the piglet 
intestinal epithelium) or the absence of the receptor in the porcine intestine. The 
presence of receptors for the K88 fimbriae in the porcine intestinal epithelium has 
been reported to be age-dependent (Conway et a l, 1990; Willemsen and deGraf, 
1992) and explains why neonatal and post-weaning pigs are most susceptible to 
infection and disease by these strains of E. coli.
Preventing adhesion of the pathogens to the mucosal surface is one way of 
preventing the pathogenic process. Oral immunisation of piglets containing a 
receptor for K88 has shown that they were protected against a challenge with 
virulent K88+ E. coli (van den Broeck et a l ,  1999a) although this protection is
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dependent on the presence of a receptor for K88 (van den Broeck et al., 1999b). In 
addition, egg-yolk antibodies obtained from hens immunized with fimbrial antigens 
from enterotoxigenic K88+ E, coli were capable of protecting neonatal and early 
weaned pigs against enterotoxigenic E. coli infection (Marquardt et al., 1999).
It should be noted that fimbriae are not the only adhesins bacteria possess. 
Bordetella species use a filamentous haemagglutinin and pertactin for adhesion 
(reviewed by Brennan and Shahin, 1996). While fimbriae could be demonstrated on 
some isolates of Actinobacillus pleuropneumoniae, lipopolysaccharide (LPS) is 
believed to be the major adhesin involved in adherence to porcine respiratory tract 
cells (Bélanger et al., 1990; 1994). The capsular hyaluronic acid of Pasteurella 
ntultocida has also been implicated as an important adhesin (Esslinger et a l, 1994; 
Pruimboom et a l, 1996). In summary, it is believed that there are multiple adhesins 
capable of interacting with different receptors and that these may be used in a 
stepwise fashion during colonisation (Jacques and Paradis, 1998).
1.1.3 Invasion of mammalian cells
The pathogenesis of some infectious disease is caused by the ability of organisms to 
invade mammalian cells. The ability to invade and survive in mammalian cells 
protects the pathogen from the host’s immune response and may allow it to 
disseminate. Some authors have shown that virulent Streptococcus suis (a causative 
agent of meningitis in pigs) are capable of invading epithelial cells of human origin 
(Norton et a l, 1999). In addition, intracellular bacteria have been found in 
circulating monocytes of pigs (Williams and Blakemore, 1990; Basque et a l, 1998) 
and it has been suggested that this is how S. suis disseminates and reaches the blood- 
brain barrier. However, it is still not clear how S. suis breaches the blood-brain 
barrier. While high levels of bacterial adhesion to phagocytic cells have been 
observed, other authors reported that the bacteria were not ingested (Segura and 
Gottschalk, 1999; reviewed in Gottschalk and Segura, 2000). Moreover, no invasion 
of brain microvascular epithelial cells has been observed although it has been
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suggested that the secretion of toxic factors could affect the endothelial cells 
resulting in an increase in the penneability of the blood-brain barrier (Charland et 
a l, 2000).
One type of cell that is particularly prone to invasion and has been extensively 
investigated is the M cell (membranous epithelial cell). M cells transport antigens 
across mucosal epithelia to the underlying lymphoid tissues where protective 
immune responses are generated (reviewed by Jepson and Clark, 1998). In pigs, the 
follicle-associated epithelium of the terminal ileum is composed entirely of M cells 
(Jepson and Clark, 1998). M cells are targeted by bacterial species capable of 
intracellular survival, such as Salmonella. Although the major function of M cells is 
to activate an immune response at mucosal surfaces, in a non-immune host it may 
take up to a week for sufficient IgA to accumulate. By this time the invading 
organism may have already spread to other organs or invaded macrophages (Patrick 
and Larkin, 1995).
1.1.4 Evasion of the immune system
The immune system is the body’s defence against infectious disease. The immune 
system can be divided into two groups. The imiate immune response is an early 
non-specific defence mechanism which acts by changing the environment of the host 
and attacking the invading organism while the slower reacting but more specific 
acquired immune response develops (reviewed by Fearon and Locksley, 1996). The 
acquired immune response is responsible for life-long immunity to infectious 
disease. These two branches of the immune system will be discussed in the 
following sections.
1.1.4.1 Innate immunitv
The aim of the innate immune response is to destroy the pathogen, determine the 
location and extent of the challenge and facilitate the acquired immune response.
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The innate immune response employs a number of different strategies to deal with 
invading organisms. This non-specific immune response is triggered when receptors 
expressed primarily on the surface of monocytes and macrophages (but also found 
on dendritic cells and B cells among others). These receptors, known as Toll-like 
receptors (reviewed by Akira, 2001), are responsible for the expression of acute 
phase reaction products including inflammatory cytokines (Akira et al., 2001). One 
of the effects of the release of the inflammatory cytokines, which include 
interleukin-1 and interleukin-6, is induction of the acute phase response (discussed 
in section 1.1.4.1.1), which is one of the early stages of the inflammatory response. 
A summary of the non-specific defence mechanisms is as follows:
♦ Phagocytosis -  the body contains specialised cells that are involved in the 
ingestion and destruction of “foreign” material, such as microorganisms. These 
cells are known as phagocytes and include macrophages.
♦ Opsonisation -  opsonisation of bacteria, e.g. by complement or antibodies, can 
make them more susceptible to ingestion by macrophages (e.g. Rozenberg-Arska 
et al., 1986; McKinlay et al., 1993). The importance of opsonisation as a 
defence mechanism has been shown by studies in which defective opsonisation 
function has resulted in recurrent reinfection (Baker et a l, 1993).
♦ Complement -  complement consists of a number of different proteins that 
become activated in a sequential manner. The complement ‘cascade’ can be 
activated in a number of ways. Gram negative bacteria can trigger the 
alternative complement pathway (as their outer membrane contains 
lipopolysaccharide) and antibody-antigen complexes can activate the classical 
pathway. C-reactive protein, a constituent of the acute phase response has also 
been reported to be capable of activating complement (Mold et a l, 1999) and 
linkage between complement and development of the acquired immune response 
(reviewed by Carroll and Prodeus, 1998). A number of the components of the 
complement cascade have physiological functions, e.g. C3b increases the 
binding of a bacterium to a phagocyte (enhances phagocytosis); C5a is a 
chemoattractant and attracts cells of the immune system to an infected site; the 
C5b6789 complex can cause lysis of Gram-negative bacteria. The complement
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system is believed to play an important role in protection against infection from 
Neisseria meningitidis. Individuals with defects in the terminal complement 
components have been shown to be at increased risk of invasive disease (Ross 
and Densen, 1984; Sjoholm, 1990; Figueroa and Densen, 1991; Mayatepek et 
al., 1993; Fijen et al., 1999).
♦ Inflammatory response -  the inflammatory response involves the release of a 
number of signalling molecules, including the release of histamine which 
increases the penneability of small blood vessels. Cytokines are also released 
during the inflammatory response. These cytokines have pleiotrophic effects, 
including activation of macrophages, increasing the binding of leukocytes to 
endothelial cells, allowing them to pass between endothelial cells to the affected 
tissue and activation of the acute phase response which is discussed in the next 
section.
1.1.4.1.1 The acute phase response
The acute phase response is a systemic reaction induced following events such as 
infection, inflammation or tissue injury. It is characterised by changes in the serum 
levels of several plasma proteins, termed acute phase proteins. A large number of 
behavioural, physiological, biochemical and nutritional changes also occur 
(reviewed by Gabay and Kushner, 1999). These changes include fever, anorexia, 
somnolence and lethargy, anaemia in chronic disease, hypoferremia, cachexia and 
alteration of intracellular hepatic constituents. All of these changes are a result of 
and regulated by inflammation-associated cytokines. A simplified diagram of the 
acute phase response is illustrated in Figure 1.1.
The acute phase response changes the normal homeostatic enviromnent of the 
organism and it is presumed that these changes contribute to defensive or adaptive 
capabilities (Gabay and Kushner, 1999). Indeed, several studies have reported the 
ability of acute phase proteins to provide protection against bacterial infection in 
mice (Mold et al., 1981; Yother et al., 1982; Vogels et al., 1993; Szalai et al., 1995;
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Hochepied et a l, 2000). The changes in the synthesis of the acute phase proteins 
reflect the presence and intensity of inflammation and they have long been used as a 
clinical guide to diagnosis and management (Gabay and Kushner, 1999). In this 
regard, there is also immense interest in veterinary medicine in using the acute phase 
response as a diagnostic tool and indicator of infection.
1.1.4.1.2 Acute phase proteins
The main characteristic of the acute phase response is the change in the plasma 
concentration of a number of proteins synthesised by hepatocytes can be either 
increased or decreased during the acute phase response. Clinically, the term acute 
phase protein is reserved for proteins whose plasma concentration is at least 50% 
higher than normal values (Engler, 1988).
Figure 1.2 shows the kinetics of the acute phase response in humans. Normally, 
acute phase proteins are synthesised at a very low basal level. However, upon 
induction there is an increase in the serum concentration of these proteins. This is 
followed by a decrease to pre-induction levels. The level of induction and the length 
of time taken to return to pre-induction levels vary from protein to protein. At this 
stage more than 30 proteins have been identified as acute phase proteins (see Gabay 
and Kushner, 1999). However, the exact physiological function of many of these 
proteins and their role in the acute phase response is unknown. Some of the major 
acute phase proteins in humans and their putative functions are described in Table 
1. 1.
C-reactive protein is the major acute phase protein in humans. Levels of CRP can 
rise from a basal level of < Ipg/ml to more than SOOpg/ml during the acute phase 
response. Administration of CRP prior to challenge with Streptococcus pneumoniae 
has been shown to provide protection against a lethal challenge (Mold et al., 1981; 
Yother et al., 1982). CRP is thought to act by binding to phosphorylcholine residues 
on the pneumococcal surface and thereby function as an opsonin (Mold et ah, 1981).
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Figure 1.2: Kinetics of the acute phase response (adapted from Engler (1988))
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Table 1.1: Some of the major acute phase proteins in humans and their functions
Protein Fold
increase/
decrease
Function References
C-reactive protein 2 0 0 - 
1000 X 
increase
Protection against 
pneumococcal and 
other bacterial 
infections.
Other functions are 
described in section 
1.4.4.1
Mold et al. (1981); Yother 
et a l (1982); Szalai et a l 
(1995,1997,2001)
Serum amyloid A 1000 X 
increase
Influencing cholesterol 
metabolism during 
inflammatory states and 
causing adhesion and 
chemotaxis of 
phagocytic cells and 
lymphocytes. Has also 
been shown to have an 
anti-inflammatory role.
Reviewed by Uhlar & 
Whitehead (1999)
Haptoglobin 2-5 X 
increase
Facilitates the removal 
of haemoglobin by the 
reticuloendothelial 
system
Host defence response 
to infection and 
inflammation
Singh-Majkic (1998) 
Dobryszycka (1997)
ai-acid
glycoprotein
2-5 X 
increase
Immunoregulatory
functions
Inhibition of the 
transport of molecules 
through the endothelial 
layer
Protection against Gram 
negative infections
Costello et a l (1979); 
Bennett & Schmid (1980); 
Laine et a l (1990); 
Vassonera/. (1996) 
Haraldsson & Rippe 
(1987); Muchitsch et a l 
(1996)
Hochepied et a l (2000)
ai-antitrypsin 2-5 X 
increase
Protects the lower 
respiratory tract from 
damage by neutrophil 
elastase
Crystal (1990)
Fibrinogen 2-5X-.
increase
Role in inflammation -  
generation of a fibrin 
matrix to prevent blood 
loss and trap 
inflammatory cells
May prevent 
dissemination of 
inflammatory agent
Endothelial cell 
retraction
Induction of signalling 
pathways in endothelial 
cells
Dunn & Willoughby 
(1981)
Dunn & Simmons (1982) 
Dvorak et a l (1992)
Senior et al. (1986) 
Skogen et al. (1988) 
Francis et al. (1993)
Kowalski (1968); Plow & 
Edgington (1986); 
Lorenzet et al. (1992)
Albumin Maintenance of normal 
oncotic pressure 
Regulation of tissue 
fluid distribution 
Binding of substances 
e.g. bile acids, heavy 
metals
Metabolism of 
endogenous substances, 
e.g. lipids 
Maintenance of 
microvascular integrity 
Anticoagulant
Inactivation of a small 
group of compounds 
Plasma buffer
Antioxidant
Reviewed by Nicholson et 
a l (2000)
Peters (1996)
Doweiko & Nompleggi 
(1991)
Holt e ta l  (1984)
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Although CRP was initially thought to be specific for S. pneumoniae it has since 
been shown that there are phosphorylcholine epitopes on pili of N. meningitidis and 
Neisseria gonorrhoeae as well as on a protein o f Pseudomonas aeruginosa (Weiser 
et al. 1998a). CRP has been shown to bind to the phosphorylcholine residues of 
Haemophilus influenzae (Lysenko et a l 2000) and to provide protection when 
challenged with H. influenzae (Weiser et a l, 1998b) and Salmonella typhimurium 
(Szalai et a l, 2000).
The innate immune response is a short-lived response that attacks the invading 
organism while the acquired immune response, which is responsible for the life-long 
protection against an infectious agent that follows infection, develops. The acquired 
immune response will be discussed in the next section.
1.1.4.2 Acquired immunity
Lymphocytes are the most important cells of the acquired immune response. There 
are two types, which develop in the bone marrow but mature in different sites. T 
cells mature in the thymus and B cells in bone marrow. T cells can be divided into a 
number of different subsets (see Figure 1.3) and have a wide variety of roles, 
including cytotoxicity and defence against intracellular and extracellular pathogens 
(reviewed by Chtanova and Mackay, 2001). CD4+ T cells can be further subdivided 
into Thl and Th2 cells. These cells differ in the cytokines produced and 
consequently bias the immune response. For example, cytokines secreted by Thl 
cells are involved in defence against intracellular pathogens whereas those secreted 
by Th2 cells are involved in humoral immunity and the defence against extracellular 
parasites (reviewed by Chtanova and Mackay, 2001). The reduced ability of 
neonatal T cells to produce both Thl and Th2 cytokines has been proposed as the 
reason for increased susceptibility of neonates to infections such as Toxoplasma and 
herpes simplex virus (Sullender et a l, 1987; Wilson, 1991). In addition, Pollard et 
al (1999b) found that production of IL-10 and IFN-y by peripheral blood 
mononuclear cells (PBMCs) from children after a meningococcal infection was age-
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dependent. The balance of cytokine production in youngest children was skewed 
towards a Thl response whereas that of older children was skewed towards a Th2 
response. PBMCs from adults were also shown to produce more cytokine in 
response to meningococcal antigens compared to PBMCs from children. Pollard et 
al. (1999b) proposed that the poor efficacy of the serogroup B meningococcal 
vaccine in young children and the poor bactericidal response to infection in this age 
group (Pollard et a l, 1999a) may be related to impaired function of the cellular 
components of the immune system.
The acquired immune response is specific for the invading organism and results in 
the production of antibodies and life-long immunity. To produce antibodies, an 
antigen (normally a small foreign protein molecule, which is capable of inducing an 
immune response) is taken up and processed by antigen presenting cells (APCs). 
APCs include dendritic cells and macrophages. However, antigens from 
intracellular pathogens can also be processed and displayed on the surface of the 
infected cell. Antigens derived from extracellular pathogens are displayed to T cells 
via MHC Class II molecules whereas those derived from intracellular pathogens are 
displayed via MHC Class I molecules. The T cell binds to the processed antigen and 
MHC molecule via the T cell receptor. This activates the T cell and it begins to 
secrete cytokines. Some of these cytokines stimulate B cells that have bound the 
same antigen and some of these B cells differentiate into plasma cells that secrete 
antibodies. Some of the activated B cells form memory cells -  they no longer 
secrete antibodies but they are primed so that they will be able to respond rapidly 
should the organism be exposed to the same antigen again. This is the idea behind 
vaccination, which will be discussed in section 1.2.3.
In spite of all the sophisticated defence mechanisms the body has available microbes 
have still managed to devise means of evading the immune response as discussed in 
the following section.
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1.1.4.3 Microbial strategies for evading the immune response
Microbes activate the immune response because some of their surface structures are 
recognised as being “foreign”. The presence of these structures tends to activate the 
innate immune response making the bacterium susceptible to phagocytosis and 
complement-mediated cell lysis. Therefore, in order to evade the immune response 
microbes have developed a number o f strategies that prevent their host from 
recognising them as foreign as well as physical means to make them resistant to the 
immune response. Physically, Gram-positive bacteria have a thick cell wall and are 
therefore resistant to complement, as the C5b6789 complex is unable to gain access 
to the outer membrane to cause lysis. Gram-negative bacteria are more susceptible 
to complement as their cell wall is much thinner. However, their LPS is believed to 
prevent access of complement to the outer membrane of the cell by steric hindrance 
(e.g. Harvill et a l, 2000). Bacteria can also avoid complement-induced lysis by 
binding protectin (CD59), a glycolipid-tailed molecule that prevents lysis of host 
cells by complement (Rautemaa et al., 1998; Rautemaa et al. 2001). In addition, 
bacteria may encode genes that are associated with increased resistance to 
complement-mediated killing (Heffeman et al, 1992; Levin and Wessels 1998). 
Bacteria are also capable of inhibiting the complement cascade, e.g. by inactivating 
C3b (Alitalo et a l, 2001). Although bacteria appear to have developed means of 
avoiding cell lysis by complement, the deposition of complement on their surface 
may have opsonic properties. Moreover, some of the products of complement act as 
chemoattractants.
As discussed in section 1.1.4.1 opsonisation of bacteria is an important defence 
mechanism. One mechanism for evasion of opsonisation is the expression of a host­
cell receptor-like protein by bacteria called Mac (Lei et a l, 2001). Mac bound to 
CD 16 on the surface of human polymorphonuclear leukocytes and inhibited 
opsonophagocytosis and production of reactive oxygen species, which resulted in 
significantly decreased pathogen killing. While resistance of bacteria to 
complement-dependent opsonisation is a problem, there have been reports of
12
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complement-independent pathways for pathogens that are resistant to complement- 
dependent opsonisation and phagocytosis by neutrophils (Grunwald et a l, 1996).
Many virulent pathogens are encapsulated and the capsule is often targeted in an 
immune response. One of the strategies pathogens have developed is to incorporate 
sialic acid residues into the polysaccharide of their capsule. Sialic acid residues are 
found on the surface of eukaryotic cells and consequently an immune response is not 
activated against such structures. For example, the polysialic acids of the Group B 
meningococcal capsule are chemically identical to those found on some human 
tissues (Finne et ah, 1983; 1987; Firme, 1985; Bitter-Suermann and Roth, 1987) and 
are therefore poorly immunogenic. Bacteria are also capable of changing the 
structure of some of their cell surface molecules and this may affect antigenic 
structure (e.g. McNeil and Virji, 1997). If this occurs this means that even if the 
body has already been exposed to this pathogen, it may not recognise it. Another 
means bacteria employ for evading the immune response is the shedding of surface 
components. For example, N. meningitidis are known for shedding endotoxin (LPS) 
in the fonn of membrane blebs (DeVoe and Gilchrist 1973; Troelstra, 1998). The 
release of endotoxin into the bloodstream may induce a strong pro-inflammatory 
response which may be responsible for the pathophysiology of severe 
meningococcal disease (Brandtzaeg et al., 1989; reviewed by van Deuren et al., 
2000). Shedding surface components may also direct the immune response away 
from the bacterial cell.
If the microorganism evades the immune response then it is capable of causing 
disease as discussed in the next section.
1.1.5 Pathogenesis
The ability of the invading organism to cause disease appears to be dependent on a 
number of factors. These include the presence of virulence factors in the pathogen, 
the immune status of the host and the presence of other infectious agents. For
13
CHAPTER 1; INTRODUCTION
example, pigs may harbour a variety of strains or serotypes of S. suis in nasal 
cavities and virulent and avirulent forms appear to exist (reviewed by Gottschalk and 
Seguna, 2000). Moreover, virulent strains can be isolated from healthy animals, 
suggesting that clinical disease may be due to the disturbance of the immune balance 
due to other causes, e.g. other infectious diseases or stress (Gottschalk and Seguna 
2000). This idea appears to be supported by a study by Wills et al. (2000) who 
proposed that the absence of pneumonia in pigs infected experimentally with porcine 
reproductive and respiratory syndrome virus (PRRSV) may be due to the absence of 
bacterial pathogens. In their study they investigated the effect of a concurrent 
infection with PRRSV and Salmonella choleraesuis. They found that animals 
infected with both organisms showed more severe signs of disease compared to 
those infected individually. PRRSV replicates preferentially in macrophages leading 
to destruction and it has been proposed that this affects the ability of the immune 
system to function effectively and leaves the animal more susceptible to infection 
and clinical disease. Bordetella bronchiseptica has also been implicated in 
increasing susceptibility to infection with P. multocida and to be capable of acting in 
synergy with PRRSV to predispose pigs to infections of the upper respiratory tract 
(Brockmeier et al., 2001). There are a number of ways that pathogens can cause 
disease and these are described in the following sections.
1.1.5.1 Toxin-mediated pathogenesis
Different bacteria secrete different types of toxins. Some act by altering the cellular 
activities of the host cell, others are cytotoxic. S. suis produces a haemolytic toxin 
known as suilysin (SLY) (Gottschalk et al., 1995). This is a thiol-activated toxin 
that forms transmembrane pores and has relatively high similarity to the well- 
characterised thiol-activated toxin of S. pneumoniae, pneumolysin (Jacobs et al., 
1994; Segers et al., 1998). Antibodies against SLY appear to protect against 
infection (Jacobs et al., 1994), suggesting this toxin is an important virulence factor. 
However, while most European strains are SLY+ there is variability in virulent 
North American strains (Gottschalk et al., 1998; Staats et al., 1999; reviewed in
14
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Gottschalk and Segura, 2000). In addition, it has been shown that a S. suis mutant 
lacking the Sly gene was non-haemolytic and non-cytotoxic for cultured 
macrophage-like cells, avirulent in a mouse infection model but only slightly 
attenuated in a porcine model of systemic infection (Allen et al., 2001). This 
suggests that other virulence factors may be involved in disease and the importance 
of SLY remains to be clarified. SLY+ strains have been shown to be cytotoxic 
(Norton et a l,  1999) but the mode of action remains to be determined. SLY may 
contribute to the development of meningitis in pigs by damaging the endothelial 
cells of the blood-brain barrier and thereby increasing the permeability of the blood- 
brain barrier (reviewed by Gottschalk and Seguna, 2000).
The adenylate cyclase toxin of Bordetella pertussis has been shown to cause 
apoptosis in macrophages infected with B. pertussis (Khelef et a l, 1993; Khelef and 
Guiso, 1995). B, bronchispetica has also been shown to be cytotoxic for murine 
macrophages and it has been proposed that this may be due to the adenylate cyclase 
produced by this organism (Brockmeier and Register, 2000). Brockmeier and 
Register (2000) propose that destruction or cytotoxicity to alveolar macrophages 
could lead to increased survival of the virulent phase of B. bronchiseptica by 
avoiding innate immune clearance.
Cholera toxin acts on mucosal cells in the small intestine. It stimulates the enzyme 
adenylate cyclase and this results in an increase in the intracellular levels of cAMP. 
The increase in cAMP appears to stimulate secretion of chloride ions in the gut 
lumen. This is followed by an outflow of water to the gut and the characteristic rice- 
water stools (Patrick and Larkin, 1995). Other toxins, such as botulism and tetanus 
toxins act on muscle cells causing either paralysis (botulism) or uncontrollable 
contractions (tetanus).
15
CHAPTER 1; INTRODUCTION
1.1.5.2 Release of other bacterial products that contribute to disease
Bacteria may secrete a range of other products that contribute to their invasiveness 
or lead to tissue destruction. For example, S. pneumoniae secretes neuraminidase 
and hyaluronidase. Neuraminidase has been shown to cleave the N~ 
acetylneuraminic acid from glycolipids, lipoproteins and oligosaccharides on cell 
surfaces and in body fluids (Camara et a l, 1994). Neuraminidase has been shown to 
play a role in the colonisation of the nasopharynx and development of otitis media in 
the chinchilla model (Tong et al., 2000). Hyaluronidase breaks down the hyaluronic 
acid component of mammalian connective tissue and extracellular matrix. This may 
aid the spread of bacteria. Moreover, breakdown products of hyaluronic acid have 
been shown to stimulate chemokine production by macrophages in vitro (McKee et 
a l, 1996).
1.1.5.3 Adverse effects as a result o f induction of the immune response
One of the key questions in the study of the pathogenesis of meningitis caused by S. 
suis is how the organism breaches the blood-brain barrier. Gottschalk and Seguna 
(2000) suggest that S. suis may have two mechanisms for breaching the blood-brain 
barrier. In SLY+ strains, the toxin may destroy the endothelial cells as mutants 
lacking SLY have been shown to be non-cytotoxic (King et a l, 2001; section 
1.1.5.1). As adhesins have also been shown to be associated with the virulence of 
this organism Gottschalk and Segima (2000) suggest that adherence of SLY - strains 
to the endothelial cells results in the stimulation of cytokine production from these 
cells (possibly cyto-necrotic cytokines, such as TNF-a) and alterations of the blood- 
brain barrier allowing the passage of leukocytes to the brain. These alterations have 
been proposed as being responsible for entry of S. suis into the brain (discussed by 
Gottschalk and Seguna, 2000).
The ability of microorganisms to stimulate the production and over-production of 
pro-inflammatory or tissue-destroying cytokines is often associated with
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pathogenesis (reviewed by Svanborg et a l ,  1999). For example, release of 
endotoxins in the blood stream, which sometimes follows chemotherapy of Gram 
negative infections with antibiotics, is associated with septic shock e.g. in severe 
meningococcal disease (reviewed by van Deuren et al., 2000). Septic shock is a 
result of endotoxins acting on macrophages and other cells and inducing the 
secretion of cytokines such as IL-ip and TNF-a. These cytokines can recruit others 
and a fall in blood pressure and blockage of blood vessels by white blood cells leads 
to organ failure.
This section has described how microorganisms cause disease. The following 
section will describe methods currently in use for controlling and preventing 
infectious disease.
L 2 Controllins infectious disease
1.2.1 Culling
Culling remains the method of choice when there is an outbreak of a highly 
infectious disease that is capable of infecting large numbers of animals and 
spreading over large distances. This was the method of choice for controlling the 
outbreaks of foot and mouth disease in the UK in 2001 and classical swine fever in 
the UK in 2000 and The Netherlands in 1997. When an infected animal is detected 
all animals on the farm are killed and destroyed. In addition the premises and 
equipment are disinfected. Around infected herds a protection zone with a radius of 
around 3km and a surveillance zone are established. In these zones no movement of 
animals is allowed. Herds in a protected zone are checked weekly (reviewed by 
Stegeman et al., 2000). The aim is to create a ring that allows rapid detection of 
infected herds and prevention of the spread of the disease. However, it appears this 
method is only effective if the outbreak is detected before any movement of animals 
occurs. The rapid spread of foot and mouth disease in the UK and classical swine 
fever in The Netherlands is believed to be due to a lack of awareness and the
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presence of the virus for a number of weeks before the first infected herd was 
detected and the length of time taken to cull infected animals, thereby allowing the 
virus to spread (Stegeman et al., 2000; Ferguson et al., 2001). While this method 
may be suitable for controlling contained outbreaks of highly infectious diseases, if  
there are a large number of infected herds, this method proves to be a costly and 
challenging way of eliminating the infection.
1.2.2 Antibiotics
Antibiotics are microbial or synthetic products that selectively kill certain 
microorganisms. Some antibiotics are effective against a broad range of 
microorganisms whereas others have a more limited range. Antibiotics function by 
disrupting some normal bacterial physiological process. For example, the p-lactam 
antibiotics, which include penicillin, act by binding to enzymes involved in 
peptidoglycan synthesis and this results in a weakening of the bacterial cell envelope 
in growing cells and eventually lysis of the bacterium. However, many bacteria 
have acquired genes encoding enzymes known as P-lactamases which inactive the P- 
lactam antibiotics (reviewed by Bush, 1999).
Although some bacteria are naturally resistant to some antibiotics, e.g. Mycoplasma 
species are resistant to penicillins because they lack a cell wall; Mycobacterium 
leprae is resistant to isoniazid because the katG gene, whose gene product is 
responsible for the toxicity of isoniazid, is a pseudogene (Eiglmeier et a l, 1997), 
resistance to antibiotics can also be acquired. Bacteria can become resistant to drugs 
as a result of a mutation that alters the target site of the antibiotic. For example, 
missense mutations in the katG gene of Mycobacterium tuberculosis are associated 
with isoniazid resistance (Heym et a l,  1995; Heym and Cole, 1996). These type of 
mutations normally only lead to resistance to a single antibiotic. However, antibiotic 
resistance can also be transferred on plasmids and this may result in a bacterium 
acquiring a number of antibiotic resistance genes and thus becoming resistant to a 
wide-range of antibiotics. For example, many p-lactamase-producing Gram-
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negative bacteria have become multidrug resistant due to the acquisition of 
additional resistance determinants (reviewed by Bush, 1999). Acquisition of 
resistance determinants has also been the means by which methicillin-resistant 
Staphylococcus aureus have emerged (Ayliffe, 1997; Chambers, 1997; Smith and 
Jarvis, 1999). This is why there is concern about the use of antibiotics used both in 
human and veterinary medicine as growth enhancers in animals. For example, 
vancomycin and erythromycin are two antibiotics used as growth enhancers in 
animals and in human medicine for treatment of methicillin-resistant S. aureus 
(vancomycin) and Gram-positive infections (erythromycin). The use of 
glycopeptide antibiotics as growth enhancers has been shown to be associated with 
increased occurrence of resistance. Avoparcin was used extensively in the EU as a 
growth enhancer in animals and it is noteworthy that when use of this antibiotic was 
banned in the late 1990s due to fear of the spread of vancomycin-resistant 
enterococci to humans, the number of vancomycin-resistant enterococci decreased 
(Aarestrup et a l, 2001). However, the exact risk of transmission of vancomycin 
resistant strains from animals to humans remains to be clarified (Stobberingh et a l,
1999).
The emergence of multi-drug resistant strains of bacteria has lead to concern that a 
super-bug will emerge that is resistant to all available drugs. Moreover, antibiotics 
are not effective against viruses and viruses have the ability to mutate rapidly and 
quickly acquire resistance to anti-viral drugs. The other means of protection against 
infectious disease is vaccination, which is discussed in the following section.
1.2.3 Vaccination
As discussed in section 1.1.1.4 the end result of exposure to an infectious organism 
is the production of memory B cells which are primed to activate the immune 
response rapidly should the individual be exposed to the same pathogen again. The 
aim of vaccination is to induce the same response but without requiring the 
individual to suffer the disease.
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Protection against infectious disease by vaccination can be done in two ways: (i) 
exposing the individual to antigens from the infectious agent and (ii) administering 
preformed antibody from an immune animal. Vaccination, if successful, can also be 
used as a means of controlling the spread of infectious disease and eventual 
elimination of the pathogen from the population. However, before deciding to use 
vaccination to control a specific disease it must be established that the vaccine will 
induce an immune response that will give protection against the disease in question 
and also that the risks of vaccination are lower than those of contracting the disease 
itself. There are a number of different types o f vaccine available (reviewed by Ellis,
1999) and these will be discussed in the following sections.
1.2.3.1 Live vaccines
Live vaccines are the ideal vaccine as they induce lifelong immunity with minimal 
reactogenicity and usually only one or two doses are required. Live vaccines are 
normally viral vaccines (polio, measles, PRRSV, swine influenza) although there are 
a few bacterial ones (BCG and Ty21a). The vaccines are made by attenuating the 
organism by technical or biological means so that while it can replicate similarly to 
the wild virus or bacterium it will at most cause a mild disease. The organism can 
be attenuated by passaging it in cell culture until it is attenuated (e.g. Weill-Halle, 
1957). Other means of obtaining an attenuated virus for use in a vaccine are 
selecting for temperature sensitive strains that do not replicate at 3TC  (e.g. Maasab 
and DeBorde, 1985). In the case of live bacterial vaccines, the bacterial strain used 
in the BCG vaccine is Mycobacterium bovis bacille Calmette-Guerin which was 
attenuated by 231 successive in vitro subculturings over 13 years. The Ty21a 
Salmonella typhi vaccine strain was created by chemical mutagenesis followed by in 
vitro selection (Gennanier and Purer, 1975). One of the concerns regarding live 
attenuated vaccine strains made by passaging or chemical mutagenesis is that the 
mutation responsible for attenuation is unknown and there is a possibility that the 
vaccine strain could revert to the wild type strain. These concerns have been 
relieved due to recombinant DNA technology, which allows the creation of defined
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mutations. In addition at least two mutations located in different parts of the 
genome are carried out in order to reduce the possibility of the strain reverting. 
Recombinant DNA technology can also be used to create recombinant bacteria 
where the genes responsible for virulence are eliminated or are not expressed in vivo. 
An example is the live attenuated cholera vaccine currently in use (Levine et al., 
1988; Tacket et a i, 1999; reviewed in Ryan and Calderwood, 2000).
1.2.3.2 Dead vaccines
The advantage of dead or inactivated vaccines is that the organism cannot replicate 
in the host. They are generally well tolerated although if the vaccine components are 
not purified they made cause reactogenicity (e.g. whole cell pertussis vaccine) if 
given by the parenteral route. Cultivated bacterial cells are inactivated by heat or 
chemical agents; virus particles are inactivated chemically, usually with formalin 
and then adjuvanted by an aluminium salt. Inactivated viral vaccines are particularly 
attractive, as viral epitopes conferring immunity are usually conformational and 
therefore difficult to reproduce by, for example, recombinant technology. Both live 
and inactivated polio vaccines have been produced and these have been shown to be 
equally effective in providing protection against polio (reviewed by Murdin et al.,
1996). One of the major concerns regarding dead vaccines is that it is absolutely 
essential that all viral particles or bacterial cells are inactivated.
1.2.3.3 Acellular vaccines
Acellular vaccines consist of purified components from bacterial cultures that are 
capable of inducing an immune response. In addition, advances in recombinant 
DNA technology and the identification of immunogenic virulence factors means that 
these components can now be expressed and purified from cultures of E. coli, for 
example. These vaccines are attractive because it is not necessary to work with large 
amounts of hazardous material. An acellular vaccine currently in use is the pertussis 
vaccine. This vaccine consists of various combinations of purified proteins from B.
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pertussis^ including pertussis toxin and various combinations of filamentous 
haemagglutinin, pertactin and adenylate cyclase toxin (e.g. Sato et al., 1984; Podda 
et al., 1991; Edwards, 1993; Edwards, e? al., 1995; Decker et ah, 1995). Other 
subunit vaccines are tetanus and diphtheria. These vaccines are produced by 
detoxifying the tetanus and diphtheria toxins with formalin or glutaraldehyde (e.g. 
Ramon, 1923). Toxins can now also be inactivated using recombinant DNA 
technology so that they lose their toxicity but maintain their immunogenicity (e.g. 
pertussis and cholera toxins; Rappuoli et a l, 1996). Other bacterial components 
used in vaccines are the capsular polysaccharide. The vaccine currently in use 
against 5”. pneumoniae contains polysaccharide against 23 serotypes of pneumococci 
although this vaccine has low efficacy in young children due to their immature 
immune system (White, 1988; Alonsodevelasco et a l, 1995). Conjugation of 
capsular polysaccharide to a protein carrier as in the case of the Haemophilus 
influenzae type b vaccine, has resulted in improved immune responses in young 
children (Goldblatt, 1998) and similar vaccines for use against S. pneumoniae have 
been licensed for use in the United States (Black et a l, 2001).
1.2.3.4 New vaccines -geneticallv modified Salmonella and DNA vaccines
One of the problems with vaccines against mucosal pathogens administered via the 
parenteral or oral route is that a mucosal immune response is not induced. As 
discussed in section 1.2.3.1 one of the advantages of the live vaccine is that it 
mimics natural infection and induces a good immune response. With recombinant 
DNA technology it has become possible to engineer viral and bacterial vectors to 
express foreign antigens. The most commonly used vectors are vaccinia and 
adenoviral (viral vectors) (e.g. Lubeck et a l, 1994) and Salmonella (bacterial) (e.g. 
Roberts et a l, 1994). However, an improved understanding of the pathogenesis and 
physiology of other bacteria mean that there is now a wider range of vectors in use 
(e.g. Gentschev et a l,  2000). These viral and bacterial vectors are designed to only 
survive long enough in the host to induce protective immunity. They are particularly 
useful because different species can be used to infect different parts of the
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mammalian system (respiratory, intestinal or genitourinary tract) resulting in a 
potent immune response against the expressed antigen.
The possibility of introducing naked DNA, i.e. plasmid DNA containing the 
bacterial antigen under the control of a eukaryotic promoter is also being 
investigated (revie^ved by Donnelly et al., 2000; Gurunathan et al., 2000). DNA 
vaccination has been particularly successful against viral diseases.
This section has discussed the various types of vaccines currently available and 
those under development. While there are some effective vaccines available, some 
of the existing ones are not so effective, e.g. the efficacy of the BCG vaccine ranges 
from 0-80% (discussed by Behr, 2001) and there have been outbreaks of PRRS 
despite vaccination leading to concern about the efficacy of this vaccine (Meng,
2000). Moreover, vaccination against some viral infections, e.g. influenza, is 
difficult due to the ability of the influenza virus to imdergo antigenic drift and shift. 
In the case of the foot and mouth and classical swine fever vaccines, it is not 
desirable to use them in EU countries for economic reasons. Therefore, attention is 
turning to other methods of improving disease resistance, particularly in animals, 
using transgenic technology.
1,3 Increasins disease resistance in animals usins transsenic 
technolosv
Selective breeding has been the traditional way for improving desirable traits in 
livestock such as production potential and disease resistance. Until recently 
selective breeding has focused on improving production potential. However, there is 
concern that selecting traits which improve animal production could be having a 
negative effect on animal health by selecting against traits that could be involved in 
immunocompetence (reviewed by Knap and Bishop, 2000). Attention is now being 
drawn to using genetic variation in immunocompetence to select for animals with 
increased resistance to infectious disease. Resistance to infectious disease is
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controlled by additive quantitative trait loci (QTL). Genetic variation in resistance 
to infectious disease is therefore a result of additive effects of QTLs that regulate 
innate and acquired immunity (Wilkie and Mallard, 1999). This means that not only 
will there be genetic variation in susceptibility to disease between breeds but also 
between individuals. For example, as discussed in section 1.1.2, the ability of K88+ 
strains of E. coli to cause disease in pigs is dependent on the presence of a receptor 
in the porcine intestine. Although selective breeding can produce animals with 
increased resistance to infectious disease (Pryzytulski and Porzeczkowska, 1980) 
this is generally not successful or advisable because some pathogens (e.g. 
intracellular pathogens) induce the cell-mediated immune response whereas others 
(i.e. extracellular pathogens) induce the acquired immune response. Consequently, 
selection for resistance to one pathogen may result in susceptibility to another. This 
is discussed by Wilkie and Mallard (1999) and they propose that simultaneously 
selecting for cell-mediated immunity and acquired immunity may have more 
advantages than selecting for each individually. This was supported by the finding 
that pigs with a high immune response responded better to vaccination and also had 
the best weight gain. Müller and Brem (1991) also discuss the advantages and 
disadvantages of selective breeding and conclude that improving disease resistance 
in livestock by genetic means is a difficult and time-consuming task requiring long­
term strategies.
Transgenic technology offers a new approach to increasing the disease resistance of 
farm animals. The strategies aim at the stable or transient expression of components 
known to influence non-specific or specific host defence mechanisms against 
infectious pathogens, such as those genes inducing or conferring innate and acquired 
immunity as well as specific disease resistance genes (Müller and Brem, 1996). The 
following sections will describe first of all the various methods currently being 
investigated and used in the generation of transgenic animals and secondly, some of 
the strategies being used to increase the resistance of animals to infectious disease.
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1.3.1 Methods used for generation of transgenic animals
The methods currently in use and those under investigation for generating transgenic 
animas were reviewed recently by Wheeler and Walters (2001) and W olf et al. 
(2000). Transgenic technology is used widely to create transgenic mice in order to 
investigate things such as complex signalling pathways, gene expression and the 
effect of gene mutations on for example, physiology or progression of a disease. 
Transgenic mice are relatively easy to produce and have a short generation time and 
a large number of mice can be quickly obtained. The creation of transgenic farm 
animals has been hampered to some extent by technical difficulties, the expense and 
the long generation time. However, in recent years there have been advances in 
transgenic technology and new approaches have been proposed to facilitate the 
generation of transgenic livestock. The various methods used to create transgenic 
animals will be discussed in the following sections.
1.3.1.1 Pronuclear DNA microinjection
Pronuclear microinjection is the classic method of gene transfer in farm animals and 
was developed by Brem et al (1985) and Hammer et a l (1985). In this method 
DNA fragments are injected into the pronuclei of a zygote. As a result the DNA 
fragments can integrate randomly, which is a drawback of this method. In addition, 
species-specific modifications of this technique are necessary. For example, the 
cytoplasm of zygotes from cattle and pigs is opaque and these zygotes have to be 
centrifuged prior to microinjection so that the pronuclei become visible (Wolf et al,
2000). The efficiency of this technique in farm animals is lower than in mice. One 
of the drawbacks of this technique as mentioned above has been the random 
integration of the introduced DNA fragment into the genome, which can have major 
effects on expression of the introduced gene or alter the expression of endogenous 
genes if the introduced DNA inserts itself within a gene. However, new techniques, 
such as Cre recombinase system and matrix attachment regions (discussed in 
section 1.3.2) may overcome this limitation.
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1.3.1.2 Viral vectors
Retroviral vectors function by transferring the genetic information as an RNA 
molecule. This is then reverse transcribed and integrated into the host genome. 
Integration of the DNA into the host genome occurs mainly in dividing cells. 
Therefore, there were problems with infection of early embryo cells which resulted 
in delayed integration and genetic mosaics characterised by different insertion sites 
in different tissues (reviewed in Chan et al., 1998). To overcome these problems the 
Moloney murine leukaemia virus has been used. Although Chan et al. (1998) 
reported a high efficiency of gene transfer using this virus, there were questions 
regarding the proper expression of the transgene. A major drawback of retroviral 
vectors is that they can only accommodate less than lOkb of sequence and this limits 
the type of DNA that can be transferred. In addition, the long terminal repeats 
flanking retroviral genomes have been reported to interfere with mammalian 
promoters (Wells et al., 1999).
1.3.1.3 Spenn-mediated transfer
This approach is based on the ability of mammalian spermatozoa to bind exogenous 
DNA. The ability of spermatozoa to bind endogenous DNA is believed to be due to 
the presence of DNA-binding proteins on the sperm surface. Internalisation of 
exogenous plasmid DNA appears to result in extensive rearrangement of the DNA 
before it undergoes recombination with genomic DNA (Zoraqi and Spadafora,
1997). This method has not fulfilled expectations and has low efficiency and 
repeatability. Alternatives to this method are intracytoplasmic spenn injection 
(Perry et al., 1999) and intratesticular transfection of genn cells (Kim et a i,  1997).
1.3.1.4 Pluripotent stem cells
Embryonic stem (ES) cells are important tools in experimental genetics. They form 
the basis for the generation of knockout mice, site-directed insertions and
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chromosomal rearrangements. Attempts have therefore been made to isolate ES 
cells from livestock species. However, so far germ-line competent pluripotent cell 
lines have not been established for any mammalian species other than the mouse 
(reviewed in Wolf et al., 2000).
1.3.1.5 Nuclear transfer using transfected cells
Nuclear transfer experiments were initially described by Willadsen (1986) and 
Prather et al., (1987; 1989). Modifications of the method were described by 
Campbell et al. (1996) and Wilmut et a l, (1997). This method involves the 
transfection of the DNA into cultured cells. A nucleus from these cells is then 
transferred into a metaphase II oocyte from which the genetic material has been 
removed. The embryo is then transferred to the animal. This method results in the 
production of 100% transgenic offspring. However, the method is also associated 
with a high incidence of abortions and premature death. This method appears to 
offer the best prospects in the future development of transgenic technology.
1.3.2 Improving transgenic technology
One of the problems until recently with transgenic technology was the inability to 
determine the site of integration of the transgene. This was a problem because 
insertion of the transgene in a region under strong negative control could mean that 
the transgene would not be expressed. Moreover, there was the possibility that the 
transgene could insert itself within a coding gene and disrupt the function of this 
gene. In order to prevent the effects of long range controls on expression of the 
transgene it has been attempted to create transgenic animals using yeast artificial 
chromosomes (Brem et al., 1996; Fujiwara et al., 1999). Another approach has been 
the use of matrix attachment regions or scaffold attachment regions which can bind 
the nuclear matrix and/or chromosome scaffold and act as boundary elements, 
protecting the transferred DNA constructs from regulatory effects of the 
neighbouring chromatin (McKnight et al., 1996). More recently, there have been
27
CHAPTER 1: INTRODUCTION
reports of the use of the Cre-recombinase system to allow site-specific introduction 
of the transgene. This means that the inserted gene has the correct chromatin 
structure and regulatory elements required for gene expression and avoids the 
problems associated with randomly integrated transgenes (Kolb et a l, 1999; Kolb,
2001).
1.3.3 Embryonic transfer
There are two methods in use for obtaining embryos and embryonic transfer -  
surgical and non-surgical. These methods have been discussed by Hazeleger and 
Kemp (2001). The simplest method for embryo collection is flushing of the uterus 
after the donor has been slaughtered. This method results in high recovery rates but 
it means that the donor can only be used once. Hygienic collection of the embryo is 
important and those that have been collected immediately after slaughter have higher 
developmental rates in vitro (Hazeleger and Kemp, 1999). In surgical collections 
the genital tract is exposed and the oviducts and/or upper parts of the uterine horns 
are flushed retrograde. More recently, an endoscope has been used. This allows the 
collection and transfer of embryos through a small incision in the abdominal wall. 
Surgical embryo transfers carried out by exposing the reproductive system result in a 
mean pregnancy rate of 60%. Endoscopic procedures result in a mean pregnancy 
rate of 14 - 40% for transfers into the uterus and 33% for tubal transfers (reviewed 
by Hazeleger and Kemp, 2001). A disadvantage of surgical collections and transfers 
is that skilled personnel, anaesthesia and surgical facilities are required. Non- 
surgical transfer of embryos involve transfer of embryos into the uterus 
transcervically. Factors affecting the success rate of non-surgical transfers have not 
yet been investigated fully. However, Yonemura et al (1996) found that their 
technique, which involves putting the catheter deeply into the cervical canal gave 
good results because it prevents embryos sticking to the cervical mucus. Other 
factors that are thought to be important are the developmental stages of the embryo 
and it appears to be important that the recipients have ovulated approximately 24h 
before to 12h after the donors (Hazeleger and Kemp, 1999). In addition, hygiene
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has also been reported to be important with most successful transfers obtained by 
groups that use antibiotics in the transfer medium and prevent contamination of the 
uterus with vaginal material (Hazeleger and Kemp, 1999).
1.3.4 Transgenic approaches for increasing the disease resistance of animals
A wide variety of methods have been proposed for increasing the disease resistance 
of animals using transgenic technology as shown in Figure 1.4. This section will 
discuss some of these methods including, the identification of disease resistant genes 
or genes that are responsible for susceptibility to infection, congenital immunisation, 
and intracellular immunisation.
1.3.4.1 Identification of disease resistance genes
Resistance or susceptibility to infectious disease is thought to be not only due to 
genetic differences resulting in variation of the immune response (discussed in 
section 1.3) but is also due to the presence or absence of specific “disease resistance” 
genes. Probably the best characterised protein giving protection against infectious 
disease is the Mxl protein, which confers resistance to influenza virus. This is a 
highly conserved protein that is present in all eukaryotes examined including 
humans, cattle, pigs, rats, horses, hamsters, fish and yeast (Horisberger & Gunst, 
1991). However, it remains unclear why, despite the presence of Mx proteins, that 
some species, for example, humans and pigs, remain susceptible to influenza virus 
infection.
A variation on this theme is the identification of genes that predispose the animal to 
infection. Improvements in transgenic technology, as discussed in section 1.3.1.4 
and 1.3.1.5 mean it may now be possible to create animals where the disease 
susceptibility gene has been knocked out, e.g. pigs lacking the gene that encodes the 
receptor for the K88 antigen of E. coli.
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Figure 1.4: Transgenic approaches for increasing disease resistance in animals 
(Müller & Brem, 1996).
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Identification of disease resistance genes is not an easy task (discussed by Malo and 
Skamene, 1994). The difficulty in identifying disease resistance genes is reflected 
by the limited number of such genes that have been identified to date. However, the 
availability of animal genetic maps and the generation of genetic markers may 
facilitate the discovery of new disease resistant genes.
1.3.4.2 Congenital immunisation
Congenital immunisation is defined as transgenic expression and germ line 
transmission of a gene encoding an immunoglobulin specific for a pathogen. 
Although early studies showed that expression of the transgene could result in 
significant inhibition of gene rearrangement and expression of endogenous 
immunoglobulin genes (Ritchie et a i 1984; Rusconi & Kohler, 1985; Nussenzweig 
et al. 1987; Stall et al. 1988), work by Lo et al. (1991) showed that it was possible to 
express murine IgA in pigs without affecting expression of the endogenous porcine 
immunoglobulin genes. Weidle et al. (1991) also reported the successful expression 
of a mouse monoclonal antibody in pigs. The ability to produce transgenic animals 
that constitutively express recombinant antibodies or antibody fragments against 
pathogens of the species in question may improve its resistance to infectious disease 
(e.g. Castilla et al. 1998; Lorenzen et al. 2000). More recent variations on this 
theme are the creation of transgenic commensal bacteria expressing antibodies 
against mucosal pathogens and these transgenic bacteria may provide protection 
against mucosal infections as long as they remain present (Whaley & Zeitlin, 2000). 
One of the main limitations of congenital immunisation is that the antibody 
expressed is pathogen-specific. This means that the pathogen can evade the 
transgenic animal's immunity simply by changing its antigenic determinants, e.g. the 
ability of influenza virus to undergo antigenic shift and drift.
Other approaches to improving animal resistance to infectious disease include the 
expression of protein-based antimicrobials that are specific for a particular pathogen. 
An example is the peptidoglycan hydrolase lysostaphin. This protein is secreted by
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Staphylococcus simulons and has bactericidal activity against Staphylococcus 
aureus, a major cause of mastitis in cattle. Investigations have shown that 
transgenic mice expressing this protein under the control of the ovine p- 
lactoglobulin gene, not only express and secrete this protein in milk but also they 
have enhanced protection when challenged with S. aureus (Kerr et a l 2001). 
Therefore, transgenic animals expressing this protein may be protected from mastitis 
caused by S. aureus.
1.3.4.3 Intracellular immunisation
Intracellular immunisation is defined as the intracellular expression of transgenic 
products that inhibit the replication of pathogens in host organisms (Müller and 
Brem, 1996). This approach can include the transfer of cytokine encoding gene 
constructs or the introduction of specific disease resistance genes into the germ line, 
for example, transfer of the M xl gene, a murine gene that confers resistance to 
influenza virus infection, into pigs (Müller et a l 1992).
Although there are several transgenic approaches for producing animals with 
increased resistance to infectious disease the limiting factor in all of these 
approaches is that the animals will only be protected against a specific pathogen. In 
an attempt to overcome the limitations of these approaches we have designed and 
created an inducible expression system that will allow the controlled expression of 
protective cytokine genes in response to infection. The generation of the expression 
system is described in the next section.
L4 Generation o f the CRP-based acute phase expression vector
Cytokines are the signalling molecules of the immune response and have a wide 
variety of roles, including the activation of phagocytes and other immune cells and 
controlling the immune response -  pro-inflammatory and anti-inflammatory 
cytokines have been reported. Because cytokines can stimulate the innate immune
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response it is reasoned that administration of cytokines prior to infectious challenge 
will activate the innate immune response and result in protection against a wide 
range of pathogens. Indeed, it has been shown that the cytokine GM-CSF, when 
administered prior to an infectious challenge is capable of providing protection 
against a variety of pathogens (Tanaka et al., 1989; Frenck et al., 1990; Fontt et al., 
1996; Hebert and O’Reilly, 1996). For example, Hebert and O’Reilly (1996) 
showed that administration of GM-CSF enhanced bactericidal activity of alveolar 
macrophages and that pre-treatment with GM-CSF significantly improved the 
survival of mice challenged with pneumococci compared to mice pre-treated with 
saline (Figure 1.5).
Although administration of cytokines has been shown to provide protection against 
an infectious challenge in small animals, it is not feasible to administer cytokines to 
farm animals routinely because of the high cost. Therefore, transgenic technology 
offers a new approach for “administering” cytokines to animals. Because cytokines 
play a critical role in the regulation of the immune response, it is not surprising that 
constitutive expression of cytokines in transgenic mice has resulted in a number of 
undesirable side-effects (Taverne, 1993; Lang et al., 1987). The study by Lang et al. 
(1987) which investigated the constitutive expression of GM-CSF in transgenic mice 
revealed that this resulted in a number of pathologies including opacity of the eye, 
wasting muscles and eventually death around six weeks of age. These studies 
indicated that controlled expression of the cytokine gene in transgenic animals is 
essential. Our work has focused on the cytokine GM-CSF and exploited the kinetics 
of the acute phase response to control expression of the gene.
The acute phase response was chosen as the basis for our inducible expression 
system for two reasons. Firstly, the acute phase response is induced by infection. 
This means that the cytokine gene will be “switched on” naturally in response to 
infection and therefore, does not require the administration of exogenous substances 
to induce the expression of the gene. The second reason was because of the kinetics 
of the major acute phase protein in humans, C-reactive protein in transgenic mice
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Figure 1.5; Ability of GM-CSF to provide protection against a pneumococcal 
infection (adapted from Hebert & O’Reilly, 1996). Mice were administered 
GM-CSF at various concentrations (Ing to Ipg) twice daily for 14 days 
following exposure to an aerosol of type III pneumococci. Treatment with 
lOng and lOOng of GM-CSF resulted in a significant increase in survival of 
the mice. However, treatment with lower or higher doses of GM-CSF did not 
result in a significantly higher survival rate compared to controls.
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(Figure 1.6). In the absence of a stimulus CRP is expressed at very low levels. 
However, following stimulation (infection, inflammation, and tissue injury) levels of 
CRP can rise 1000-fold within 24 hours and return to normal levels within 48 hours. 
Therefore, by using the promoter of the CRP gene to control the expression of the 
GM-CSF gene it was expected that the GM-CSF gene would be regulated with CRP 
kinetics. Expression of the GM-CSF gene under the control of the CRP promoter 
should stimulate the animal's immunity during the early stages of infection because 
GM-CSF will be induced earlier than normal during an infection and may therefore, 
enhance protection against the infectious agent. Controlled expression of the GM- 
CSF gene should prevent the deleterious side effects observed following long-term 
expression of GM-CSF (Lang et a l, 1987). Although GM-CSF may not seem to be 
an ideal choice for use in an acute phase expression system, the fact that the 
biological effects of constitutive expression of this cytokine are known means that it 
will give an early indication of how controlled the expression system is.
The creation and analysis of the CRP-GM-CSF construct is described in detail by 
Williams (2001) and Burke et a l (manuscript in preparation) and is based on 
constructs made and investigated by Murphy et a l (1995 and Figure 1.7). The 5.6kb 
BamHI-BamHI fragment containing the human CRP gene was used for cloning the 
CRP-GM-CSF construct into the background of the 30kb fragment. The CRP gene 
was removed by inverse PCR with primers that had engineered Not\ sites at each end 
to facilitate cloning. The promoter and signal peptide of the CRP gene were fused to 
the murine GM-CSF gene using primers that also had engineered Notl sites at each 
end. The CRP-GM-CSF fusion was then cloned into the Not\ sites of the shuttle 
vector and it was then attempted to clone this into the background of the 30kb 
fragment. However, since attempts to do this were unsuccessful, the CRP-GM-CSF 
fusion was instead cloned into the smaller construct C79 (Figure 1.7). C79 exhibited 
low basal levels of expression and high levels of induction in vivo and it was the 
construct whose kinetics most resembled the 30kb fragment. The C79 construct 
containing the CRP/GM-CSF fusion was termed GM-C79 and was used to generate 
a line of transgenic mice.
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Figure 1.6: Regulation of the human CRP gene in transgenic mice (Ciliberto et 
al. 1987b). This group analysed expression of the human CRP gene in 
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CHAPTER 1; INTRODUCTION
Transgenic mice carrying the GM-C79 construct were identified by PCR and 
Southern blotting (Williams, 2001) and these founder mice were used to establish 
our current lines. To determine if the GM-CSF gene was regulated with acute phase 
kinetics in transgenic mice the mice were administered LPS to induce the acute 
phase response and the amount of GM-CSF produced was measured over a 48 hour 
time period (Figure 1.8)
From the graph it can be seen that following administration of LPS the levels of 
GM-CSF rise with peak expression occurring 12 hours post-stimulation. By 24 
hours the level of GM-CSF is starting to fall and by 48 hours it is back to pre­
induction levels (in the case of female transgenics). This indicated that the CRP 
promoter was driving expression of the GM-CSF gene with acute phase kinetics. 
However, it is also seen that the male transgenics exhibit higher basal levels o f GM- 
CSF compared to female transgenics prior to stimulation (1146 ± 571 pg/ml (male) 
compared with 266 ± 53 pg/ml (female)). This phenomenon, whereby male 
transgenics have higher basal levels of expression of the transgene, has already been 
reported by Szalai et al. (1995) in mice harbouring the human CRP transgene.
In summary, previous work in our laboratory has resulted in the creation of an 
inducible expression system that results in expression of GM-CSF with acute phase 
kinetics following an inflammatory stimulus. Although the male transgenics have 
higher basal levels of expression (possibly a consequence of using the CRP promoter 
as the backbone to the vector), the system is controlled enough to avoid the 
deleterious effects reported by Lang et al. (1987). The majority of our GM-CSF 
transgenics survive for at least 12 months and they do not have the pronounced 
bilateral opacity of the eye that was also reported by this group. We now wish to 
develop the system further, to see if we can eliminate the sexually dimorphic pattern 
of expression and secondly, to develop the system for use in pigs.
34
1000000-
100000-
I
u_(/)
95
10000-
Ü
1000-1
1 0 0 -r
o o so
T ransgenic male 
Transgenic female 
Non-transgenic male 
Non-transgenic female
Time (hours)
Figure 1.8: Levels of GM-CSF in the serum of GM-C79 transgenic and non- 
transgenic mice (log scale) following stimulation with LPS (Burke et al. in 
preparation). The levels of GM-CSF in the serum of non-transgenics is much 
lower than that of GM-C79 transgenics following stimulation with LPS. In 
addition, while the basal level of expression of GM-CSF in the serum of female 
transgenics is similar to that of non-transgenics, the basal level of expression of 
GM-CSF in male transgenics is about 5-fold higher. It should be noted that 
although the increased basal level of expression in male transgenics is only 0.6% 
of the maximal amount of GM-CSF produced this is still sufficient to cause 
pathology.
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1.5 Aims o f thesis
The aims of this thesis are illustrated in Figure 1.9. We have shown that the acute 
phase expression system is functional in transgenic mice and we now wish to see if 
it is possible to modify the expression vector for use in animals of economic 
importance. This project investigates the modification of the expression vector for 
use in pigs. Modification of the expression vector may be necessary for use in pigs 
for a number of reasons. First of all, we do not know how this construct will behave 
in pigs “  will it be regulated the same way as in mice (i.e. as a human acute phase 
reactant) or will it be regulated as the porcine CRP gene is (CRP is not regulated in 
the same manner in pigs and humans)? Secondly, due to the current controversy 
surrounding genetically modified foods, transgenic pigs containing human DNA 
sequences may be unacceptable to consumers. The acute phase expression vector 
will therefore be developed in two ways;
• Analysis of the sequences involved in regulating the CRP gene with a view to 
identifying elements that are critical for the low basal levels of expression of the 
gene and those responsible for the sexually dimorphic pattern of expression. 
Due to the expense and difficulty in making transgenic animals it is desirable 
that the acute phase expression vector is as perfect as possible before attempting 
to make transgenic pigs.
• In parallel, it was decided to isolate the promoter from the major acute phase 
protein in pigs and examine its potential to drive expression of heterologous 
genes with acute phase kinetics. If it turns out that the acute phase expression 
vector based on the human CRP gene is not functional in pigs, then there is the 
possibility of creating one based on the porcine major acute phase protein. 
Alternatively, our knowledge of the elements involved in regulating the CRP 
gene could be used to modify the expression vector for use in pigs.
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Sequence analysis of 
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Figure 1.9: Proposed strategy for the project “Controlled gene expression using 
acute phase response elements”
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To modify the expression vector for use in pigs, an understanding of the regulation 
of pig-MAP or ITIH4, the major acute phase protein in pigs, as well as identification 
of the sequences involved in its regulation needs to be carried out.
The work described above will necessitate a large number of gene expression studies 
to be carried out. Therefore, a system that is cheap to use with high throughput is 
desirable. The green fluorescent protein (GFP) has been marketed as an ideal 
reporter gene for studying gene expression as it does not require the use of 
exogenous substrates for detection and allows real-time analysis. The final aim of 
the project is therefore, to evaluate GFP as a reporter gene for studying inducible 
gene expression.
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Chapter 2: Materials and Methods
2.1 Materials
All chemicals were supplied from Sigma and Fisher Scientific unless otherwise 
stated. Restriction enzymes were supplied by Promega and Boehringer Mannheim 
(Roche).
2.2 Bacterial strains
The bacterial strains used in this project were for transformation purposes.
Epicurian Coli® XL-1 blue competent cells (Stratagene): Genotype recAl endoAl 
gyrA96 thi-1 supE44 relAl lac\¥" proAB lacBZAMl5 Tn70 (Tet^
Epicurian Coli® SoloPack® Gold competent cells (Stratagene); Genotype Tef 
lS.imcrA)183 D(mcrCB-hsdSMR-mrr)173 endAl supE44 thi-1 recAl gyrA96 relAl 
lac Hte[F’ proAB lacBZAMlS TnlO (Tef) Amy Cam")
Novablue Singles (Novagen); Genotype endAl hsdR17(r](]2mk}2^) supE44 thi-1 
recAl gyrA96 relAl lac\¥' proA^B^ lacBZAM15 . .Tn70]
2.3 Cell lines and primary porcine hepatocytes
Hep 3B, a human hepatoma cell line that has been used extensively for studies of the 
acute phase response was obtained from the European Collection of Animal Cell 
Cultures (ECACC 86062703), Cambridge, UK.
COS-7 (ECACC 87021302), a monkey kidney cell line, was supplied by Dr C Rush. 
Primary porcine hepatocytes were supplied by Mr L Nelson and Mr S Keach, Liver 
Research Unit, Department of Medicine, University of Edinburgh, UK.
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2.4 L ist o f vectors used
Vector Description Manufacturer
pPCRScript Cloning vector for PCR products Stratagene
pBluescript (S/K-) General purpose cloning vector Stratagene 
(supplied by Dr C 
Gray)
pZero General purpose cloning vector Invitrogen 
(supplied by Dr C 
Gray)
pCAT-Control Chloramphenicol acetyltransferase 
(CAT) mammalian expression vector 
where CAT gene is under the control of 
the SV40 promoter
Promega
(supplied by Dr A 
Pridmore)
pCATS-Basic 
(pCATBB)
Promoterless CAT mammalian 
expression vector
Promega
C3:EGFP Enhanced GFP mammalian expression 
vector where GFP is under the control 
of CMV promoter
Clontech
(supplied by Dr C 
Rush)
pd2EGFP-Control
(GFP-C)
Destabilised GFP mammalian 
expression vector where GFP is under 
the control of the SV40 promoter
Clontech
pd2EGFP-Basic
(GFP-B)
Promoterless GFP mammalian 
expression vector
Clontech
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2.5 Methods
2.5.1 Molecular Biolo2V Techniques
2.5.1.1 Small scale preparation of plasmid DNA
A single colony was used to inoculate 3-5ml of Luria broth supplemented with the 
appropriate antibiotic and grown overnight at 37®C with shaking (approximately 230 
rpm). The plasmid DNA was extracted from the cells using the alkaline lysis 
method described by Sambrook el al (1989). The overnight culture was transferred 
to a 1.5ml eppendorf and the cells were harvested by centrifugation at 13 000 rpm 
for 3 min in a microfuge. The supernatant was removed from the cells and the cells 
resuspended in lOOpl GTE solution (25mM Tris, pH8; 50mM glucose; lOmM 
EDTA) containing lOOmg/ml Rnase A by vortexing. Then 200pl 1% SDS/0.2M 
NaOH was added and the tubes mixed by inversion before being placed on ice for 5 
mins. To neutralise the solution 150|ul KAc was added and the solution was mixed 
and placed on ice for a further 5 mins. After this incubation the tubes were 
centrifuged at 12 000 x g for 10 mins. The supernatant (0.4ml) was removed and 
transferred to a fresh microfuge tube. To this, 0.8ml of 100% ethanol was added and 
the solution was incubated at room temperature for 2 mins before being centrifuged 
at 12 000 x g for 3 mins. The supernatant was removed, taking care not to disturb 
the pellet, and 1ml of 70% ethanol was added. The tubes were centrifuged at 12 000 
x g for 3 mins and the supernatant removed and the pellet left to air-dry. The pellet 
was the resuspended in 30pl of TE. The resuspended DNA was then stored at 
-20°C.
DNA prepared by this method was suitable for restriction enzyme digest and PCR. 
However, for DNA to be sequenced DNA was prepared using the Qiagen Spin 
Miniprep Kit (Qiagen, Hilden, Gennany) according to the manufacturer’s 
instructions.
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2.5.1.2 Large scale preparation of plasmid DNA
Colonies from a freshly streaked agar plate were used to inoculate 100ml Luria broth 
supplemented with the appropriate antibiotic and grown at 37®C overnight with 
shaking (230 rpm). The cells were then harvested by transferring the cell suspension 
to 50ml Falcon tubes and centrifuging at 1 500 x g for 10 mins. Plasmid DNA was 
obtained using the Stratagene Midiprep Kit according to the manufacturer's 
instructions. DNA was eluted in either 1ml or 0.5ml elution buffer. If the DNA was 
to be used for transfection the eluate was divided between a number of tubes (each 
containing 200-250pl eluate) and 0.1 volume of NaAc pH 4.8 was added followed 
by 0.2 volumes of ice-cold 100% ethanol. The solutions were mixed and incubated 
on ice for 30 mins. The tubes were then centrifuged at 12 000 x g for 10 mins at 
4°C. The supernatant was removed and the pellets were washed twice with 0.5ml 
70% ethanol (12 000 x g for 2 mins at 4°C). The supernatant was removed and the 
pellet left to air-dry. Once dry, the pellet was resuspended in 30pl sterile dHiO.
2.5.1.3 Small scale preparation of bacterial artificial chromosome (BACI DNA
BAG DNA, obtained from the clones isolated from the library screen (sections
2.5.1,7 and 4.2.3), was prepared using a modified Qiagen protocol and the reagents 
supplied with the Qiagen DNA prep kits. A single colony from a freshly streaked 
agar plate was used to inoculate 3ml Luria Broth supplemented with 12.5pg/ml 
chloramphenicol and grown overnight with shaking at 37°C in a plastic universal. 
The following day the universal was centrifuged at 3 000 rpm for 10 mins. The 
supernatant was removed and the pellet was resuspended in 0.3ml Buffer PI and the 
resuspended pellet was transferred to a 1.5ml eppendorf. To lyse the cells, 0.3ml 
Buffer P2 was added and the tubes were mixed by inversion. The tubes were left at 
room temperature for 5 mins. After this time, 0.3ml Buffer P3 was added and the 
tubes mixed by inversion before being placed on ice for 5 mins. The tubes were 
then centrifuged at 10 000 rpm for 10 mins at 4°C. The supernatant was added to an 
equal volume of ice-cold isopropanol and mixed by inversion. The tubes were
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placed on ice for 5 mins and then centrifuged at 10 000 rpm for 15 mins at 4°C. The 
supernatant was removed and the pellets washed with 0.5ml 70% ethanol and 
centrifuged at 10 000 rpm for 5 mins at 4°C. The pellet was left to air-dry and 
resuspended in 30-40pi elution buffer.
2.5.1.4 Cloning DNA
2.5.1.4.1 Digestion of DNA with restriction enzvmes
Digestions were carried out in 0.5ml eppendorf tubes. A typical 20pl reaction 
consisted of:
l-3pl DNA
2pl lOX enzyme buffer (supplied with the enzyme)
0.5pi enzyme (normally supplied at a concentration of 10 units/pl) 
sterile distilled water to 20 pi
The reaction mixture was centrifuged briefly and placed at 37°C for 1-3 hours. 
Reactions were typically carried out in a volume of 20pl. If larger amounts o f DNA 
were to be digested then the volumes of reagents used were scaled up accordingly. 
If a double digest was carried out Ipl of each restriction enzyme was used in multi­
core buffer (Promega) if the enzyme buffer was not compatible with both enzymes 
being used.
2.5.1.4.2 Separation of DNA bands through agarose gels
DNA fragments were separated by agarose gel electrophoresis using 1.5 % (w/v) 
agarose for smaller fragments (<lkb) and 0.5% (w/v) agarose for larger fragments 
(>lkb). Agarose was made up in IX  TAB (Amresco) with ethidium bromide added 
to a final concentration of 0.5pg/ml. Electrophoresis was carried out in a tank of 
TAB. Before loading the DNA samples onto the gel 0.2 volumes of loading buffer
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(0.25% bromophenol blue; 0.25% xylene cyanol FF; 40% (w/v) sucrose in water) 
was added. The agarose gels were run at lOOV for an appropriate time until the 
bands were clearly separated. The DNA bands were located using UV light.
To identify bands of the correct size a Ikb ladder (Gibco) was used. This has a 
range of 0.075-12.216kb.
2.5.1.4.3 Purification of DNA from agarose gels
DNA samples were run out through the agarose gel and the band to be purified was 
located under UV light and cut out using a scalpel. The DNA was then extracted 
from the gel using the Qiagen Gel Extraction Kit (Qiagen, Hilden, Germany) 
according to the manufacturer's instructions.
2.5.1.4.4 Ligation
DNA that had been purified from agarose gels was used to set up the ligation 
reaction with an insert to vector ratio of approximately 3:1. The insert to vector ratio 
was determined by running various volumes of the purified DNA  ^on an agarose gel 
and comparing the intensity of the bands by eye. The ligation reaction was set up as 
follows:
X pi insert 
X pi vector 
1 pi ligase buffer 
1 pi ligase
X pi water (to bring final volume to lOpl)
The reactants were mixed gently together and then incubated at room temperature 
for 3-4 hours. The reaction was stopped by incubating the mixture at 70”C for 10 
mins. The mixture was then used for transformation or stored at -20°C.
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2.5.1.4.5 Bacterial transformation
Epicurian Coli XL 1-blue competent cells or Epicurian Coli XL-10 competent cells 
(Stratagene) or Novablue Singles Competent cells (Novagen) were used for 
transformation. The DNA (Ipl from a ligation reaction) was transformed into the 
cells according to the manufacturer's instructions. The transformation mixtures 
(200pl for XL 1-blue and XL-10 competent cells; 50pl for Novablue cells) were 
plated on Luria agar containing the appropriate antibiotic. The plates were then 
incubated at 37^3 overnight. For blue/white colour screening lOOpl 2% X-gal 
(supplied by Melford Laboratories and made up in DMF) and lOOpl ImM IPTG 
(Melford Laboratories) were spread on the plates 1 hour before plating the bacteria.
2.5.1.4.6 Screening colonies for recombinants
If no colour screening was used random colonies were picked and if blue/white 
screening was used white colonies were picked from the plate and grown overnight 
in 3ml Luria broth with the appropriate antibiotic. DNA was prepared as described 
in section 2.5.1.1 and digested with enzymes that would release the insert. Positive 
clones were identified as those that gave bands of the expected size for insert and 
vector when analysed on an agarose gel and compared with the known molecular 
weights of a DNA marker. Additional confirmatory experiments included PCR on 
the putative positive clones and sequencing of the inserts.
Occasionally recombinants were screened by PCR using the method of Kim (1996). 
Colonies were picked from an agar plate using a sterile toothpick and streaked on a 
fresh agar plate containing the appropriate antibiotic before being inoculated in 20pl 
DNA Extraction buffer (pH 8.0) [IM  KCl; lOOmM Tris-HCl; lOmM EDTA] in 
0.5ml eppendorf tubes and heated to 99°C in a PCR machine for 10 mins. The tubes 
were then placed on ice for 5 mins before being centrifuged for 5 mins to pellet the 
denatured cell debris. The supernatant was then transferred into a 1.5ml eppendorf 
and diluted 10-fold with sterile dH20. For PCR, 3 pi of this was used in a 50pl PCR
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reaction volume as described in section 2.5.1.5. The results of the PCR were 
confirmed by taking a colony from the streaked agar plate and preparing the DNA as 
described for screening recombinants by DNA digestion.
2.5.1.5 Polymerase Chain Reaction fPCR)
PCR reactions were carried out in 0.5ml eppendorfs and cycled in a thermocycler. 
Reactions were typically carried out in lOOpl volumes but if  a large number of 
reactions were to be carried out the volume was reduced to 50pl.
PCR reaction with Tag DNA polymerase (Gibco) 
lOpl lOX reaction buffer (supplied with the enzyme)
3pl lOOmMMgCb
4pl dNTP (5mM dATP, dCTP, dGTP, dTTP)
2pi Primer 1 (60pmol/pl)
2 pi Primer 2 (60pmol/pl)
2pl DNA 
0.5pl Tag
76.5pi sterile distilled water
PCR reaction with Vent DNA polymerase (New England Biolabs) 
lOpl lOX reaction buffer (supplied with the enzyme)
2pl 50mM MgS0 4
4pl dNTP (5mM dATP, dCTP, dGTP, dTTP)
2pi Primer 1 (60pmol/pl)
2 pi Primer 2 (60pmol/pl)
2pl DNA 
0.5 pi Vent
77.5pi sterile distilled water
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The reactions were centrifuged briefly and were then overlaid with 30pl of mineral 
oil to prevent evaporation of the reaction during cycling. The reactions were heated 
to 94°C to denature the DNA; then cooled to allow annealing of the primers (this 
temperature was dependent on the annealing temperature of the primers and varied 
from 50-60°C); then heated to 72^3 to allow primer extension. The length of time at 
72°C was dependent on the size of the sequence to be amplified (as a rough guide 1 
min. was allowed for every Ikb of DNA to be amplified). A typical reaction was 
cycled at:
95°C for 3 mins 
94°C for 45 sec )
55°C for 30 sec ) 30 cycles 
72°C for 1 min )
72‘^ C for 5 mins
For analysis, lOpl of the PCR product were run through an agarose gel by 
electrophoresis.
2.5.1.5.1 Cloning PCR products in PCR Script
For analysis and sequencing the PCR products were cloned in PCR Script according 
to the manufacturer’s instructions.
2.5.1.6 DNA sequencing and analysis
DNA sequencing was carried out by BaseClear (Leiden, the Netherlands), at the 
PNACL (Leicester University, UK) or at the MB SU at Glasgow University, UK. 
The reactions were carried out on either LiCor or ABI Sequencers with a 
combination of Dye-primer and Dye terminator chemistry. DNA sequences were 
assembled using SeqMan (DNAStar software package) and sequences were analysed 
using other programs from the DNAStar package, GCG (Devereux et a i, 1984),
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NIX (HGMP), BLAST (Altschul et al.^ 1997) and various transcription factor search 
programs found on the TRANSFAC home page. The website addresses of these 
search engines are given in Table 2.1.
2.5.1.7 Screening the porcine PigE BAC genomic library
The PigE BAC library (Anderson et a l,  2000) was screened with the assistance of 
Dr S Anderson, Roslin Institute, Edinburgh, UK using the porcine ITIH4 cDNA 
clone described by Buchman et al. (1990) as a probe. Details of the library can be 
found at: http://www.hgmp.mrc.ac.uk/Biology/descriptions/pig_BAC.html
2.5.1.7.1 Preparation of the filters
The genomic library has been gridded on Hybond N nylon membranes, which are 
stored at -20°C. The filters were allowed to thaw and were placed in hybridisation 
solution (7% SDS; 0.5M NaHP0 4  (pH7.2); ImM EDTA). The filters were 
separated from each other with nylon mesh. This prevents a lot of background if the 
filters overlap and also allows the probe to bind more efficiently. The filters were 
rolled up and placed in the hybridisation tube (3 filters per tube) with 15ml of 
hybridisation solution and the tubes were placed at 65°C.
2.5.1.7.2 Hybridisation and identification of positive clones
While the procedure described in section 2.5.1.7.1 was carried out, the probe was 
labelled using the High Prime System (Boehringer/Roche) ^^P-labelled dCTP 
according to the manufacturer’s protocol. SOOpl of the hybridisation solution was 
added to the labelled probe and 250pl of this solution was added to each 
hybridisation tube and incubated overnight at 65°C with gentle rotation.
The following day the filters were washed twice with Wash 1 (2x SSC; 0.1% SDS) 
and then washed twice for 15 mins with Washl at 65°C. The filters were then
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Table 2.1: Website addresses for sequence search engines
Search engine Web address
BLAST http: //WWW.ncbl .nlm.nih.gov/BLAST
L d X  http ://WWW.hgmp.mrc.ac.uk
TRANSFAC http://transfac.gbf.de
Matlnspector Accessed via the TRANSFAC home page
Alibaba 2 http;//wwwiti.cs.uni-magdeburg.de/~grabe/alibaba2
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washed twice with Wash 2 (Ix  SSC; 0.1% SDS) at 68®C for overnight. The filters 
were then exposed at -70°C for approximately 5 hours. The films were developed 
and positive clones were identified by aligning the films with the original filters and 
working out the position of the clone using the guide supplied by the HGMP. The 
putative positive clones were then picked from the glycerol stock at -70°C and 
streaked onto Luria agar plates containing chloramphenicol (12.5jLig/ml) and 
incubated at 37®C overnight.
2.5.1.8 List of primers used
A list of primers used during this project is given in Appendix 1.
2.5.1.9 List of constructs made
A list of constructs made during this project is given in Appendix 2.
2.5.2 Tissue Culture Methods
2.5.2.1 Standard passage of Hep 3B cell line
Hep 3B cells were obtained from the ECACC and grown in Minimal Essential 
Medium Eagle M2279 (Sigma) supplemented with 10% foetal bovine serum 
(Gibco), 1% non-essential amino acids (Gibco), 1% L-glutamine (Gibco) (referred to 
here as the growth medium). Once the cells were confluent the growth medium was 
removed and the cell monolayer washed twice with sterile PBS (PBS tablets 
(Oxoid) dissolved in dHzO and autoclaved). To split the cells, 5ml trypsin/EDTA 
(Gibco) was added to the flask and any excess was removed. The flasks were then 
incubated at 3TC for 5 mins. The cells were resuspended in 10ml growth medium. 
The resuspended cells were divided between a number of 75cm^ flasks and 25ml 
growth medium added. The caps were loosely closed and the flasks were incubated 
at 37"C with 5% CO2.
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2.5.2.1.1 Standard passage of COS-7 cell line
COS-7 cells were grown in Dulbecco’s Modified Eagles Medium (Gibco) 
supplemented with 10% FBS and 1% L-glutamine (Gibco) (referred to as the growth 
medium). Once the cells were confluent they were split as described for Hep 3B 
cells in section 2.5.2.1. When the cells had detached from the flask the cells were 
resuspended in 10ml growth medimn. The resuspended cells were divided between 
a number of 75cm^ flasks and 25ml growth medium added. The caps were loosely 
closed and the flasks were incubated at 3TC  with 5% CO2.
2.5.2.1.2 Isolation and growth of primary porcine henatocvtes
Primary porcine hepatocytes were isolated by Mr L Nelson and Mr S Keach from a 
non-fasting pig weighing approximately 13kg using the method of Nelson et a l 
(2000). The isolated hepatocytes were transported from Edinburgh to Glasgow on 
ice and then seeded in 6 well or 60mm plates immediately at a density of 
120 000 viable cells /cm^. The cells were grown in Williams E medium with 
supplements as described by Nelson et a l (2000). The following day the cells were 
washed using Hanks Balanced Salt Solution and fresh medium was added. The cells 
were incubated for a further 24 hours before transfections were carried out.
2.5.2.2 Cryopreservation of mammalian cells
The cells were grown until confluent in 75 cm^ flasks and were then trypsinised (as 
described in section 2.5.2.1.1) and resuspended in 10ml growth medium. The cells 
were pelleted by centrifugation (3 000 rpm for 4 mins) and the supernatant was 
discarded. The cells were then resuspended in l-3ml (depending on the size of the 
pellet) growth medium. The cells were aliquoted into 900pl quantities in cryotubes 
and lOOpl DMSO was added. The cells were then frozen to -70®C by placing them 
in a box surrounded by isopropanol in a -70'"C freezer overnight. The cryotubes 
were then transferred to a liquid nitrogen store.
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2.5.2.3 Recovery of cells from liquid nitrogen storage
A vial of cells was removed form liquid nitrogen storage and quickly defrosted at 
37°C. The cells were resuspended in 10ml growth medium and then pelleted by 
centrifugation at 200 x g for 10 min. The supernatant was discarded and the pellet 
resuspended in 5ml of growth medium. The cell suspension was transferred to a 
25cm^ flask and incubated at 37°C with 5% CO2.
2.5.2.4 Counting cells using a haemocytometer
Following resuspension of the cells in growth medium as described in section
2.5.2.1 and 2.5.2.1.1, 200pl were transferred to a 1.5ml eppendorf containing 300pl 
growth medium. In order to visualise the cells 500jul Trypan Blue was added and 
the contents of the tube were mixed. With the coverslip of the haemocytometer in 
place a small volume of the suspension was transferred to the counting chambers by 
capillary action. The number of cells in 10 squares was counted. Each square 
represents a total volume of O.lmm^ (lO"'^  cm^). The cell concentration per ml was 
determined as follows:
Cells per ml = average number of cells per square x dilution factor xlO^
2«5.2.5 Transfection of DNA into mammalian ceils
2.5.2.5.1 Seeding cells for transfection
Once the cells became confluent, the cells were split as described in section 2.5.2.1. 
Following resuspension in 10ml growth medium the cells were centrifuged at 1 500 
rpm for 3 mins. The supernatant was removed and the cells were resuspended in 
5ml PBS and centrifuged again. The cells were then resuspended in 5ml growth 
medium and the number of cells per ml was determined using a haemocytometer. In 
6 well plates cells (both Hep 3B and COS-7) were seeded at a density of 2x10^ cells
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in a final volume of 2ml and in 24 well plates the cells were seeded at a density of 
4x10^ cells in a final volume of 1ml. The cells were then incubated at 3TC  with 5% 
CO2 overnight. The next day the cells were normally 60-80% confluent and ready 
for transfection.
2.5.2.5.2 Transfection of mammalian cells
Transfections were carried out using GenePorter-2 transfection reagent (Gene 
Therapy Systems) according to the manufacturer’s instructions. Experiments were 
carried out to determine the optimal amount of DNA to use for transfection of Hep 
3B cells. In the experiments described in this thesis, 2|Lig DNA was used for 
transfections in 6 well plates (experiments using the CAT reporter gene) and 0.75pg 
DNA for transfections in 24 well plates (experiments using the GFP reporter gene).
2.5.2.6 Interleukin stimulation of transfected cells
Stocks of human recombinant interleukin-6 (Sigma) and human recombinant 
interleukin-1(3 (R&D Systems) were made up in PBS/0.1% BSA and frozen in single 
use aliquots at -70°C. Approximately 24 hours post-transfection the growth medium 
was removed from the cells and the cells were washed with PBS. Sufficient medium 
for the experiments was pre-warmed to 37°C and supplemented with 1% non- 
essential amino acids, 1% L-glutamine (no FBS was used in these experiments in 
control or test samples) and with or without (controls) the appropriate concentration 
of cytokines. For cells growing in 6 well plates 2ml stimulation medium was added. 
For cells growing in 24 well plates 1ml stimulation medium was added. The cells 
were then incubated at 37°C with 5% CO2 for a further 24-48 hours.
2.5.2.7 Harvesting of transfected cells
Cells were harvested using the lysis buffer (solution 8) supplied with the CAT 
ELISA kit (Roche Molecular Biochemicals) diluted 1:5 prior to use. The cells were
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washed 3 times with 2ml of cold PBS (4®C) and 0.5ml lysis buffer was added to each 
well of a 6 well plate. The cells were left at room temperature for 30 mins and the 
supernatant, was then transferred to a 1.5ml eppendorf. The cell extract was 
centrifuged at 13 000 x g for 10 mins at 4°C. The supernatant was transferred to a 
fresh eppendorf and frozen in an ice/ethanol bath before being stored at -70°C until 
analysis.
2.5.2.8 Analysis of cell extracts using CAT ELISA
For measuring promoter activity using the CAT reporter gene a CAT ELISA (Roche 
Molecular Biochemicals) was used according to the manufacturers instructions. 
Briefly, the microtiter plates are supplied with pre-bound antibody to CAT. The cell 
extracts containing the CAT enzyme are added to the wells and the enzyme binds to 
the anti-CAT antibodies on the surface o f the microtiter plate. A digoxigenin- 
labelled antibody to CAT (anti-CAT-DIG) is then added and binds to CAT. Then an 
antibody to digoxigenin conjugated to peroxidase (anti-DIG-POD) is added and 
binds to digoxigenin. The peroxidase substrate ABTS is added and the peroxidase 
enzyme catalyses the cleavage of the substrate giving a coloured reaction product. 
The absorbance of the sample was detennined using a Dynatech Microplate Reader 
at 450nm (reference wavelength 490nm).
2.5.2.9 Total protein determination using Bradford Reagent
The results from the CAT ELISA were nonnalised with respect to protein 
concentration using the method of Bradford (1976). Standard curves were prepared 
by diluting a 3mg/ml stock solution of BSA in PBS 1:2 giving a range from 
3000jLig/ml to 46.875pg/ml. 5pi of sample, standard or PBS (blank) were added to 
the wells of a flat bottomed 96 well plate. To correct the calibration curve (due to 
interference with the assay by the cell lysis buffer) 5 pi of the diluted lysis buffer was 
added to the wells containing the standards and the blank and 5pi PBS was added to 
the wells containing the test samples. 200pl of Bradford Reagent was then added to
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each well and the samples were incubated at room temperature for approximately 10 
mins. The absorbance was then read at 600nm on a Dynatech microplate reader. 
Total protein concentrations of the samples was determined using BioLinx software.
2.5.2.10 Quantitating GFP fluorescence
GFP fluorescence was detected using a Zeiss Axioskop 20 microscope equipped 
with a HB50 microscope illuminator. Filter set 09 (Zeiss) was used. The filters 
used were as follows:
• Excitation: BP450-490nm
• Beamsplitter: FT510
• Emission: LP520
Fluorescent cells were visualised using a PC-CAM video camera and the 
fluorescence quantitated using Openlab software (Improvision). To quantitate GFP 
fluorescence, an image from a field of view of cells transfected with the GFP-B 
vector was taken. This image served as the background and it was “subtracted” 
from images containing fluorescent cells using the ‘subtract background’ function in 
the Openlab program. This meant that the fluorescence being measured was actual 
GFP fluorescence rather than GFP fluorescence plus background fluorescence. The 
fluorescence from a number of cells (at least 100 if possible) was measured using the 
‘Measurement’ function in Openlab. To carry out this procedure individual cells 
were outlined to create a ‘region of interest’ (ROI). The software calculated the 
fluorescence present by calculating the mean number of pixels present in the ROI. 
To calculate the total fluorescence intensity per cell, the mean number of pixels of 
the ROI was multiplied by the area of the ROI. The results presented in this thesis 
are the mean values of the total fluorescence intensity of the selected cells.
2.5.2.11 Statistical analysis
Statistical analysis was carried out using StatView software. The results in this 
thesis are reported as the mean ± standard error of the mean and are the results from
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one set of experiments performed in triplicate. For statistical analysis, samples 
receiving treatment were compared individually with the sample containing no 
treatment using the Mann Whitney U Test. The ANOVA Test (with Bonferroni 
correction) was used to compare samples with each other. P values <0.05 were 
deemed significant.
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Chapter 3; Further characterisation of the CRP-based 
acute phase expression vector
3 d  Introduction
Ciliberto et al. (1987b) screened a human genomic library and isolated a clone 
containing a 30kb insert containing the CRP gene. They subsequently showed that 
this 30kb fragment contained all the sequences required for correct regulation of the 
human CRP gene as an acute phase protein in transgenic mice (Ciliberto et al., 
1987a). Further work by Murphy et al. (1995) to delineate the regions necessary for 
controlled expression in transgenic mice revealed that there were sequences both 
upstream and downstream of the CRP gene involved in regulating its expression. As 
discussed in section 1.4 we have developed an expression system based on the 
constructs analysed by Murphy et al. (1995). Although the system is functional in 
transgenic mice, it requires some modification in order to obtain more tightly 
regulated expression and to eliminate the sexually dimorphic pattern of expression 
seen in the transgenic mice.
This chapter will describe the sequencing and analysis of the 30kb fragment 
containing the human CRP gene in order to identify regions of the fragment that are 
important for the controlled expression of the CRP gene and the sexually dimorphic 
pattern of expression that is seen in transgenic mice.
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3.2 Sequencing of the region approximately 15kb upstream of the human 
CRP gene
3.2.1 Background and strategy
The 30kb fragment can be subdivided into four smaller fragments as illustrated in 
Figure 3.1 -  a 15kb CM -  Bam}3l fragment, a 5.6kb BamlBl -  BaniHl fragment, a 
6.6kb BamYil -  BamYYi fragment and a 3kb BamEl -  C M  fragment. Previous work 
in our laboratory by Dr B Burke involved the subcloning of the 5.6kb, 6.6kb and 3kb 
fragments into the pUC vector, which were then sequenced by primer walking. In 
this method of sequencing, sequencing commences from each end of the fragment to 
be sequenced. Primers are then designed from the newly generated sequence to 
continue sequencing and so on until the sequences overlap. The sequences are then 
assembled into contigs using sequence assembly programs.
This section of the project continued the work started by Dr B Burke to complete the 
sequencing of the 30kb fragment. Before commencing to sequence the 15kb 
upstream region of the 30kb fragnent the sequence obtained by Dr B Burke was 
compared with those in the nucleotide database. This analysis was carried out to see 
if it was possible to identify a clone being sequenced as part of the human genome 
sequencing project containing the human CRP gene. The sequences were analysed 
using the NDC program in late 1998 but no evidence was obtained that such a clone 
existed at that time. Therefore, it was decided to proceed with sequencing the 15kb 
upstream region of the 30kb fragment.
For sequencing the upstream region of the 30kb fragnent, the clone 15kb3D was 
used (see Figure 3.1). This clone had been made previously by Mr D Hayward and 
it lacks the 5.6kb and 6.6kb BœnYYi - BamHY fragnents. For sequencing the 15kb3D 
clone there were two possibilities;
1. Sequence the entire clone by primer walking and
2. Subclone the 15kb3D clone and sequence the subclones.
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Figure 3.1: Illustration of the 30kb CRP fragment and the creation of clone 15kb3D. 
The CRP gene and the CRP pseudogene (vg) are indicated by pink boxes. Clone 
15kb3D was created by digesting the 30kb fragment with BamHl to release the 5.5kb 
and 6.5kb BamHl-BamHl fragments. The 15kb Clal-BamUl fragment was then 
ligated to the 3kb BamHl-Clal fragment.
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It was decided to take the second approach. This involved making a restriction map 
of Clone 15kb3D, cloning fragnents of a suitable size and then sequencing the 
clones by primer walking. This work is described in the following sections.
3.2.2 Restriction man of Clone 15kb3D
Clone 15kb3D was first of all digested with Clal and BamYYi to verify the DNA was 
indeed from Clone 15kb3D. The plasmid DNA was subsequently digested with 
enzymes not located in the vector because this would allow mapping of the insert 
and identification of fragments for subcloning. Initially the clone was digested with 
a single enzyme. The enzymes chosen were: Accl, Apal, Kpnl, Ndei and Spel. 
Figure 3.2 shows the results of these digests.
As seen in Figure 3.2, most of the fragnents formed were geater than 12kb. This 
suggested that combinations of these enzymes could be suitable for creating a 
restriction map. To begin mapping, a double digest with one of the chosen enzymes 
and Clal was carried out because the position of the restriction sites for this enzyme 
in the clone was already known. In addition, a double digest with Kpnl and Spel 
was also carried out. An example of these digests is illustrated in Figure 3.3. Table
3.1 summarises the results from a number of digests and from these results a 
putative restriction map was drawn (Figure 3.4).
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3054bp
1635bp
lOlSbp
M = marker
1 = A cc l  digest
2 = Apal digest
3 = Kpnl digest
4 = Nc/el digest
5 = Spel digest
Figure 3.2; Digest of 15kb3D with Accl, Apal, Kpnl, Ndel and Spel. 
Relative bands on the DNA ladder are indicated with arrows.
Gel A M 1 2 3 4 5 6 7 8 9 M
2036bp
i
G e l B M 1  2 3 4 5 6 7 8 9 M
2036bp
1018bp
M = marker 
1= uncut DNA
2 = Spe\ digest
3 = Spel digest
4 = Clal digest
5 = SpellClal digest
6 = Kpnl digest
7 = KpnUSpel digest
8 = Kpnl/Clal digest
9 = BamHl/Clal digest
Figure 3.3: Digest of 15kb3D with Kpnl, Spel and Clal to make a restriction map. 
Gel A shows the digested fragments on a 0.5% agarose gel and Gel B shows the 
digested fragments on a 1.5% agarose gel. Relative bands on the DNA ladder are 
indicated by arrows.
Table 3.1: List of enzymes and size of fragments obtained following digestion of 
the 15kb3D clone.
Enzyme(s) Size of fragments formed after digest (bp)
Spel 15,000; 10,000; 2,000
Kpnl 13,000; 13,000
Clal 18,000; 8,000
KpnllClal 13,000; 8,000; 3,500; 1,900
KpnUSpel 10,000; 8,000; 2,500; 2,000; 570; 394
Clal 0.00
.Spel 4.50Vector
Spel 6.50
Clal 18.00
Kpnl 13.50
Figure 3.4: Putative restriction map of 15kb3D
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3.2.3 Subcloning 15kb3D and identification of positive clones
Analysis of the restriction map showed that there were a number of fragments that 
were of suitable size for subcloning. It was decided to subclone the following 
fragments: Spel! Clal (4.5kb) named CSX; Spel! Spel (2kb) named SI; Kpnl! Spel 
(7kb) named SK7; Clal/ Kpnl (3.5kb) named CKI as illustrated in Figure 3.5 (Gel 
A).
Following digestion of the 15kb3D clone and the standard cloning vector, 
pBluescript SK- (Stratagene), with the appropriate enzymes the CSX, CKI, SK7 and 
SI fragments and the digested vector were cut from the agarose gel and the DNA 
extracted using the Qiagen Gel Extraction Kit. The digested vector was then ligated 
to the appropriate 15kb3D digest and transformed in XL 1-Blue competent cells. 
Following transformation a number of colonies were picked and plasmid DNA was 
isolated from each. Positive CKI and CSX clones were identified following digestion 
of the DNA with Clal to linearize the plasmid, which gave a fragment of 7.5kb 
(CSX) and 6.5kb (CKI). The result was confirmed by digesting the clone with the 
appropriate enzymes to release the insert (Figure 3.5, Gels B, C and D).
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Figure 3,5: Isolation of fragments for cloning and identification of positive CKI 
and CSX clones. A small arrow indicates the 1.6kb band (the brightest band) of 
the DNA ladder in each picture.
Gel A: Digestion of 15kb3D with the appropriate enzymes to release fragments 
of a size suitable for subcloning. The fragments chosen for cloning are indicated 
with arrows.
Gel B: Identification of positive CKI clones. M = marker; Lanes 1 and 2 contain 
undigested pBluescript. Lanes 3-6 contain DNA digested with Clal from 
putative positive clones containing the 3.5kb CKI fragment. The expected size 
of a fragment from a positive clone is 6.5kb. Therefore, lanes 3, 4 and 6 appear 
to be positive.
Gel C: Identification of positive CSI clones. M = marker; Lanes 1-12 contain 
DNA digested with Clal from putative positive clones containing the 4.5kb CSI 
fragment. The expected size of a fragment from a positive clone is 7.5kb. 
Therefore, lane 5 appears to be positive.
Gel D: Confirmation of positive clones. The sample in Gel B lane 6 was 
digested with Clal and Kpnl to release the insert (lane 1). This reaction gives 
two fragments of the expected size (3kb vector and 3.5kb insert). Sample 5 in 
Gel C was digested with Clal and Spel to release the insert (lane 2). This 
reaction also gives two fragments of the expected size (3kb vector and 4.5kb 
insert).
M 1 2 3 M
Gel  A
M = marker
1 = Clal/Kpnl digest
2 = ClalfSpel digest
3 = Spel digest
M l  2 3 4 5 6
1635bp
Ge l B
M l  2 3  4 5 6 7 8  9 10 11 12
» : Il 1635bp
1635bp—
GelC
Gel D
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Attempts to clone the 2kb SpeVSpel fragment into pBluescript SK- were not 
successful This was thought to be because Spel was the only enzyme cutting the 
vector thus increasing the probability of the vector self-ligating. Therefore, it was 
decided to clone the SI fragment into a different vector, pZErO-2 (Invitrogen). This 
vector encodes a protein that is lethal to the cell unless the gene is disrupted by the 
insertion of foreign DNA. Theoretically any surviving cells should contain the 
insert. Cloning the SI fragment in pZErO-2 was successful and positive clones are 
shown in Figure 3.6. Cloning the SK7 fragment into pBluescript was also difficult, 
possibly due to the large size of this fragment. Although subcloning this fragment 
was considered, it was first of all decided to try cloning this fragment into pZErO-2. 
This strategy was also successful and positive clones are shown in Figure 3.6.
3.2.4 Sequencing the subclones
The subclones were sequenced by BaseClear (Leiden, the Netherlands) by primer 
walking on one strand only. The first set of reactions was carried out using standard 
primers located in the vectors (T7 and M l3 reverse). For the next round of 
sequencing primers were designed from near the end of the newly generated 
sequence and used to amplify the middle sections of the subclones. These PCR 
products were then cloned in PCRScript and sequenced using standard primers. The 
reason for this additional cloning was that longer sequencing runs could be obtained 
using standard primers. The only exception to this strategy was the SK7 fragment, 
which was sequenced entirely by primer walking by BaseClear. The sequences were 
assembled into contigs using the sequence assembly program SeqMan. When the 
subclones had been sequenced primers were designed to link the fragments together 
and then to link the 15kb upstream region to the 15kb downstream region that had 
been sequenced by Dr B Burke. The assembly of the 30kb fragment is illustrated in 
Figure 3.7.
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Figure 3.6: Identification o f positive SI and SK7 clones for sequencing
Gel A: Identification of positive SI clones by digesting DNA from putative 
positive clones with Spel, Lanes 1-3 show plasmid DNA from different clones 
digested with Spel. Positive clones are those which give two fragments of 3.3kb 
(vector) and 2kb (insert). Therefore, samples in lanes 2 and 3 are positive. The 
1.6kb band of the ladder is indicated with an arrow.
Gels B and C: Identification of positive SK7 clones by digesting DNA from 
putative positive clones with Kpnl. Lanes 1-9 of Gel B show plasmid DNA from 
different clones digested with Kpnl. Positive clones are those which give a 
fragment of 10.3kb. Therefore, samples in lanes 2-9 are positive. This result 
was confirmed by digesting one of the clones with Kpnl and Spel (Gel C). Lane 
1 of Gel C shows undigested DNA. Lane 2 shows a positive clone digested with 
Kpnl and Spel, which gives two bands of the expected size of 3.3kb (vector) and 
7kb (insert). The 1.6kb and 3 kb bands of the ladder are indicated with arrows.
3054bp
1635bp
M l  2 3 4 5 6  7 8 9 M 1 2
1635bp.
3054bp
1635bp
Gel B Gel C

Figure 3.7: Assembly of the sequences of the 15kb ClaVBamUll CRP fragment 
and linkage to the downstream BanMUClal fragment sequenced by Dr B Burke. 
The sequences were assembled using the sequence assembly program SeqMan. 
The arrows refer to the DNA strand on which the sequencing reactions were 
carried out (forward facing arrows refer to sequencing on the positive strand and 
backward facing arrows refer to sequencing on the negative strand).
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3.2.5 Sequence details
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The sequence has been lodged in the GenBank database (accession number 
AF442818) and the length of the sequence is 30234 bases. The CRP gene in this 
sequence is located from 18026-18980, the bone fide cap site (Arcone et al., 1988) 
at position 17922, FolyA at position 20195 and the CRP pseudogene is from position 
26533 to 27357. A restriction map of the 30kb fragment using the enzymes used to 
map the 15kb upstream region shows that the rough restriction map created in 
section 3.2.2 was quite accurate (Figure 3.8) although this region appears to be 
slightly longer in length than first predicted (16kb rather than 15kb). One difference 
between this sequence and that reported by Murphy et al. (1995) is the absence of 
the site in the 15kb upstream region at position -12.7kb. The sequencing
result confirms the experimental findings of Dr B Burke who noticed that this site 
appeared to be absent in the 30kb CRP fragment that we have.
3.2.6 A restriction map of the 3Qkb CRP fragment
In order for the heterologous gene to be controlled with acute phase kinetics it is 
desirable to clone the fusion construct (acute phase promoter-heterologous gene) in 
the background of the 30kb fragment. Initial attempts at using the 5.6kb BamHl -  
Bat?îHl fragment as a shuttle vector have been unsuccessful as the fragment was 
incorporated into the 30kb fragment in the wrong orientation (Williams, 2001). 
Therefore, the ability to identify unique restriction sites that may facilitate the 
incorporation of a shuttle vector in the correct orientation may facilitate cloning the 
fusion construct in the background of the 30kb fragment. Since we now have the 
entire sequence of the 30kb CRP fragment it is possible to create a detailed 
restriction map.
The 30kb fragment was searched for unique restriction enzyme sites using the 
MapDraw progiam. A list of the unique restriction sites found is given in Table 3.2. 
The results show that there are two unique sites flanking the CRP gene, Bco 631 at
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Figure 3.8: A restriction map of the Clal -  BamHl upstream region of the 30kb 
CRP fragment with the restriction enzymes Kpnl and Spel.
Table 3.2: Location of unique restriction enzyme sites in the CRP 30kb fragment
Position Restiiction enzyme site
414 Ahy AI
414 Bsu MI
415 Xhol
417 Scil
2614 5/y SKI
3581 Eco Kl
8902 Pme I
9248 A gel
9248 Pin AI
9742 Act I
15283 Bsr BI
15283 M bil
17907 Bco 631
17912 B srB m
18312 Eci AI
18315 Sna BI
20725 5/ySQ
22183 5/ySJ
22997 Uba 1220 I
22998 Cfr9l
22998 psp AU
22998 Xma I
23000 CfrU l
23000 Sma I
23050 Bbe AI
23051 K asl
23052 N arl
23053 Ehe I
23055 Bbel
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position 17907 and Sty SQ at position 20725. However, a search of the REBASE 
database (Roberts & Macelis, 1999) showed that neither of these restriction enzymes 
is currently available commercially. Commercially available isochizomers for Bco 
631 that only cut the 30kb fragment once were sourced (B^-aBI and Maml are two 
examples) but isochizomers of Sty SQ that only cut the 30kb fragment once were not 
found.
The absence of usable restriction enzyme sites in the 30kb fragment suggests that if 
the CRP/GM-CSF construct cannot be cloned in the background of the 30kb 
fragment, the 30kb fragment or the existing acute phase expression vector will have 
to be modified to some extent. One approach would be the introduction of 
restriction enzyme sites not currently present in the 30kb fragment using long range 
PCR to facilitate cloning of the CRP-GM-CSF fusion. An alternative approach 
could involve either the removal o f sequences that are responsible for the high basal 
levels of expression in the existing expression vector or the addition of sequences 
that are necessary for low basal levels of expression. The following sections 
describe the analysis of the 30kb fragment for such elements.
3.3 Comparison of the 30kb sequence with the first working draft of the human 
genome
The sequencing of the 30kb CRP fragment was completed in June 1999. Although it 
was anticipated that sequencing o f the human genome would be complete at some 
stage during this project, we did not know when. As it turns out, the first working 
draft of the human genome was not released until 20 months after we had completed 
sequencing the 30kb fragment (International Human Genome Sequencing 
Consortium, 2001). Sequencing the 30kb CRP fragment was deemed necessary in 
order to identify the elements involved in regulating the human CRP gene. I also 
wanted this information for the parallel studies to modify the expression vector for 
use in pigs (as discussed in section 1.5).
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When the working draft became available the 30kb fragment was compared with the 
human genome using the BLAST search engine. As expected, the 30kb sequence 
mapped to a region on chromosome 1 containing the CRP gene (Figure 3.9). There 
was good agreement between the CRP sequence reported here and those of the 
human genome sequence (99% homology). An interesting observation was that the 
GT repeat found in the CRP intron (Lei et a i, 1985) is shorter in the 30kb CRP 
fragment compared with that of the human genome sequence (Figure 3.10). This fits 
in with the recently published findings of Szalai et a l (2001) that polymorphisms in 
the GT region of the intron of the human CRP gene occur.
3.3.1 Comparison of the 30kb CRP sequence with other sequences in the 
nucleotide databases
The 30kb sequence was compared with other sequences in the nucleotide databases 
to see if  there were any other genes or potential regulatory elements present in the 
fragment. These analyses were done using BLAST and NIX (section 2.5.1.6).
The sequences were first analysed using the NIX program which is a combination of 
a number of different nucleotide search programs and gives a good overview of the 
types of sequence present (Figure 3.11). The sequence was analysed a number of 
times throughout this project as the nucleotide databases are updated on a regular 
basis. The last analysis on the 30kb fragment was carried out in June 2001. Most of 
the non-coding regions of the 30kb fragment appear to be composed of the repeated 
elements that are found throughout the human genome. The only regions in the 
30kb fragment with homology to genes or pseudogenes are the regions containing 
the human CRP gene and the human CRP pseudogene. This result confirms the 
finding in Figure 3.9. A BLASTx search, however, revealed that there was a region 
of approximately 2kb (from nucleotides 1 to 2056) with homology to p40, one of the 
open reading frames of a LlNE-1 (long interspersed nuclear element). Although LI 
elements were initially believed to be non-functional, in the past few years there 
have been reports of these elements affecting the regulation of downstream genes.
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Figure 3.9: Mapping the SOkb fragment containing the human CRP gene 
to a region on chromosome 1 of the human genome containing the CRP 
gene using BLAST. It is evident from this figure that there do not appear 
to be any genes in the vicinity of the CRP gene.
Query: 18197 acagtggagcatccttcatgg-------- tgtgtgtgtgtgtgtgtgtgtgtgtgt 18244
il I I I I I I I I I I I I I I I I 1 I I I I I I II I I II I I I I I I IIIIII II I II
Sbjct: 62713 acagtggagcatccttcatggtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 62768
Query: 18245 gtggtgtgtaactggagaaggggtcagtctgtttctcaatcttaaattctatacgt 18300 
I II I IM I I I I I I I I I I I I I I I I I! I I M I I I I I II I I I i I I I I) I I I I II M I II 
Sbjct: 62769 gtggtgtgtaactggagaaggggtcagtctgtttctcaatcttaaattctatacgt 62824
Figure 3.10: Comparison of the GT repeat of the CRP intron in the 30kb CRP 
fragment (Query sequence) and in the working draft of the human genome 
(Sbjct).
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Yang et al. (1998) published the first report of a LINE element affecting the 
regulation of a downstream gene. This was found to be due to the presence of an 
enhancer region 20kb 5’ to the apolipoprotein(a) transcription start site and was 
located within the LINE element. This element responded to members of the Ets 
transcription factor family and is important for enhancing the expression of the 
apolipoprotein(a) gene. The 30kb fragment was searched for the sequence 
CCCGGAAG, which was shown by Yang et al. (1998) to be functionally active. 
However, this sequence was not found in the I5kb upstream region of the 30kb CRP 
fragment.
The second report of a LI element affecting regulation of a downstream gene 
investigated was the one by Speck (2001). Speek reported that an antisense 
promoter (ASP) of human LI retrotransposons could drive the transcription of 
adjacent cellular genes and also possibly modulate their expression. The presence of 
this promoter upstream o f the CRP gene could therefore theoretically influence its 
expression. Therefore, the region of the 30kb CRP fragment containing ORFl of the 
LI element was compared with the consensus sequence of the antisense promoter 
region described by Speek (2001) using the GCG Gap program. It was found that 
there was 90% homology between the sequence found in the 30kb CRP fragment 
and the consensus sequence given by Speek (2001) (Figure 3.12).
Analysis of the 30kb fragment using the BLAST search engine allowed the 
identification of one factor that may have an effect on the regulation of the CRP 
gene. However, BLAST does not allow the identification of transcription factor 
binding sites and other regulatory regions because the program was designed for 
similarity not motif searches. Searching for transcription factor binding sites must 
be done manually or by using specialised transcription factor and regulatory element 
search engines that are widely available on the Internet. Analysis of the 30kb 
fragment for transcription factor binding sites and regulatory sequences is described 
in the following sections.
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1423 ............ ACTACTCTCTTCAAAGCTGTCAGACAGGGACGTTTAAG 14 60
III I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
650 gctgggagaaccactgctctcttcaaagctgtcagacagggacacttaag 601
14 61 TCT.CAGAAGTTTCTGCTG.CCTTTTGTTCAGCTATGCCCTGCCCCCAGA 1508 
III I I I I III I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I 
600 tctgcagaggttactgctgtctttttgtttgtctgtgccctgcccccaga 551
1509 GGTGGAGTCTACAGAGGCAGGCAGGCCTCCTTGAGCTGCGGTGGGCTCCA 1558 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
550 ggtggagcctacagaggcaggcaggcctccttgagctgtggtgggctcca 501
1559 CCCAGTTCAAGCTTCCCAGCTGCTTTGTTTACCTACTCAAACCTCAGCAA 1608 
I I I I I M I I I I I I I I I I I I I I I I I I I I I I I I I I III ill I I I I 
500 cccagttcgagcttcccggctgctttgtttacctaagcaagcctgggcaa 451
1609 TGGTGGACGCCCCTCCCCCAGCCTTGCTGCCACCTTGCAGTTTGATCTCA 1658 
III II I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I 
450 tggcgggcgcccctcccccagcctcgttgccgccttgcagtttgatctca 401
1659 GACTGCTGTGCTGGCA.....................................  1674
I I I I I I I I I I I I III 
400 gactgctgtgctagcaatcagcgagattccgtgggcgtaggaccctccga 351
Figure 3.12: Comparison of the 30kb CRP fragment (top) with the consensus 
antisense promoter found in human LI elements as described by Speek (2001)
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3.3.2 Analysis of the sequence for regulatory elements
Gene expression can be controlled in a number of ways and at a number of different 
levels -  transcription and translation and the steps in between and following these 
processes. CRP is believed to be regulated at the transcriptional level (Ciliberto et 
al., 1987a) and transcription factors affecting regulation of the CRP gene have 
already been described (e.g. Morrone et aL, 1988; Majello et al, 1990; Li and 
Goldman, 1996). For transcription to occur DNA must be dissociated from 
nucleosomes, DNA must be unwound to enable transcription factors to bind and 
negative regulators of transcription must be removed while positive regulators must 
bind to the DNA. Factors governing all these processes have been identified. CRP 
has been reported to be under negative control (Arcone et ah, 1988) and that 
elements involved in repressing transcription in the absence of stimulation are 
located both upstream and downstream of the CRP promoter (Murphy et ah, 1995). 
This work focused on analysis of the 30kb sequence for elements that may be 
involved in processes governing the negative regulation of the CRP gene.
The 30kb sequence was analysed by searching the sequence manually for the 
consensus binding sequences o f transcription factors and regulatory elements that 
have been reported in the literature to be involved in regulation of eukaryotic genes. 
This approach was favoured over using the available transcription factor databases 
and search engines mainly due to the large volume of sequence to be analysed. The 
30kb fragment was initially searched for the transcription factor binding sites that 
have been reported by Arcone et ah (1988); Li et ah (1990) and Li and Goldman 
(1996). Following this the 30kb fragment was searched for the consensus sequences 
of a number of transcription factor binding sites and regulatory elements. The 
consensus sequences used in these analyses are shown in Table 3.3 and the locations 
of these sites in the 30kb fragment (coding strand) are given in Appendix 3.
As illustrated in Figure 3.13, which only takes into account a few of the potential 
transcription factors that could bind in this region, the distribution of the
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Table 3.3: Consensus binding sequences for transcription factors and other 
regulatory elements known to be involved in regulating gene expression and used 
for analysis of the 30kb CRP fragment and porcine ITIH4 promoter region (see 
Chapters 4 and 5).
Factor/
binding
site
Recognition
Sequence
Function of binding 
factor
Reference
ARE TGTTCT Androgen response 
element. This is only half 
of the element 
GGTACAnnnTGTTCT. 
However, half of the 
sequence can function in 
co-operation with other 
enhancer elements nearby.
(Zhou e/ a/. 1997) 
(Zilliacus et al. 
1995)
CACCC
box
ACACCC Important in
transcriptional regulation
(Horie & Takeishi, 
1997)
GAGA
box
GAGGAGGGAGG
AG
Growth hormone 
sensitivity
(Le Cam et al. 
1994)
HIPl ATTCN(i.30)GCCA Acts on TATA-less 
promoters of housekeeping 
genes to specify the site of 
transcription initiation
(Faisst & Meyer, 
1992)
HNF-5 T(G/A)TTTG(C/T) This factor is liver- 
specific. Binding sites for 
this factor are located 
close to other liver-specific 
factors.
(Faisst & Meyer, 
1992)
IL-6 RE CTGGGA Implicated in the 
regulation of Class 2 acute 
phase genes; sequence 
recognised by factors such 
as IL-6 RE binding protein 
and STAT3
(Wegenka et al. 
1993)
Simar-Blanchet et 
a l 1996) 
(Weinhold et al. 
1997)
LF-Al TGAACC
TGGCCC
Binding factor that has 
been shown to interact 
with the promoter regions 
of several liver-specific 
genes - haptoglobin and 
ai-antitrypsin
(Harden et al. 
1988)
TGAGAGA
TGAGAA
T/AGGAAAA
Motifs found in rabbit
CRP
promoter
( U e ta l  1990)
TGAAGCA
TGGAAAA
TGGAGGA
Motifs found in the three 
IL-6 responsive elements 
of human haptoglobin
(Oliviero & 
Cortese, 1989)
TGGGAAA Distal regulatory element 
for rat a 1-acid 
glycoprotein
(Prowse & 
Baumann, 1988)
NF-lL-6 TT/GNNGNAAT/
G
This factor is involved in 
acute phase reactions and 
a homologue of this 
factor may play a role in 
the glucocorticoid 
induction of the a 1-acid 
glycoprotein gene
(Faisst & Meyer, 
1992)
STAT3
(acute
phase
response
factor)
TTCC(G/C/A/T)G
GAA
(palindromic
sequence)
Originally defined as a 
protein that binds to an 
IL-6 RE in the promoter 
o f several acute phase 
genes and can confer IL-6 
responsiveness to a 
heterologous promoter. 
Growth hormone can also 
induce binding of STAT3 
containing complexes to 
APRE. Therefore, 
possibility that GH may 
also regulate the 
expression of acute phase 
response genes in the 
liver.
(Wegenka et al. 
1993)
(Campbell et 
a/. 1995)
(Subramanian et al. 
1995)
Spl GGGCG Transcription factor that 
has a loose binding 
specificity to G-rich 
sequences upstream of 
TATA boxes
(Faisst & Meyer, 
1992)
Universal
silencer
TCTCTCCNA 
5’ANCCTCTCT 3'
negative regulation of 
eukaryotic genes
(Haecker et al. 
1995)
(Ogboume & 
Antal is, 1998)
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CHAPTER 3; RESULTS
transcription factor binding sites appears to be numerous and complex. This makes 
it difficult to assign a role for these elements. Nonetheless, regions where there is a 
cluster of consensus binding sites are potentially important because interactions of 
transcription factors with each other are important. As well as acting to positively 
regulate gene transcription, transcription factors can modulate gene transcription by 
preventing other transcription factors binding (steric-hindrance) and by competing 
for overlapping binding sites. One such region is located approximately 2kb 
upstream of the CRP gene and contains a number of putative regulatory elements 
that will be discussed in the following sections. While understanding the 
mechanisms involved in regulating the CRP gene is desirable, this knowledge is not 
essential in order to make an improved expression vector. However, knowledge of 
the regions that are involved in regulating expression (particularly, the negative 
regulation) of the gene is important if we cannot clone the CRP-GM-CSF fusion into 
the background of the 30kb fragment and need to use a smaller construct. This 
information may also be useful for modifying the expression vector for use in pigs.
Using information from the literature on the influence of various regulatoiy elements 
on gene expression a picture can be drawn of regions in the 30kb fragment that may 
be involved in its regulation. Comparing the 30kb fragment with for example, the 
GM-C79 construct, for the presence and absence of these elements can further 
enhance this analysis. A more detailed analysis of the 30kb fragment was therefore 
confined to a number of transcription factor binding sites and regulatory elements 
that had the potential to be important and relevant based on information from the 
literature. The sequence analysis, therefore, focused on the following potential 
regulatory elements: polypurine/polypyrimidine rich regions due to the fact that they 
have the potential to adopt secondary structures that may affect gene expression; a 
silencer element identified by Haecker et al, (1995); ST AT binding sites and a 
growth hormone responsive element identified by Le Cam et a l (1994).
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3.3.2.1 Polvpurine/volvuvrimidine repeats
Polypurine/polypyrimidine repeats may affect eukaryotic gene transcription by 
forming unusual structures that may affect the formation or dissociation of 
nucleosomes and/or the binding of transcription factors to the DNA (reviewed by 
Wells et al., 1988; Brahmachari et al., 1997). Since these structures have been 
shown to be formed only under certain conditions in vitro this may determine when 
gene transcription occurs. The only published polypurine/polypyrimidine repeat in 
the CRP 30kb fragment is the GT repeat that is found in the CRP intron. However, 
analysis of the 30kb fragment showed that it also contained a number of 
polypurine/polypyrimidine rich regions as shown in Table 3.4.
CA repeats are very common in human DNA and account for 0.5% of the genome 
and are often highly polymorphic. CT repeats are also common (0.2% of genome) 
and occur approximately every 50kb. As a result, this makes interpretation of the 
results shown in Table 3.4 difficult. For example, there are five homopyrimidine 
rich regions in the 30kb fragment, but the significance of this is not clear. Therefore, 
analysis of these regions has taken into account the location of the 
polypurine/polypyrimidine rich region in the 30kb fragment and the transcription 
factor binding sites located nearby. As a result, the analysis has focused on the 65bp 
CT rich region located at positions 15982-16046, approximately 2kb upstream of the 
CRP gene. This region is absent from all the constructs made by Murphy et al. 
(1995) apart from construct C61. C61 had extended upstream sequences which were 
believed to contain a negative regulatory element that functioned independently of 
the negative element located downstream of the CRP gene. The CT rich region is 
also located in a segment of the 30kb fragment containing a number of consensus 
sequences for transcription factors and regulatory elements as illustrated in Figure 
3.14.
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Table 3.4: Polypurine/polypyrimidine rich regions in the CRP 30kb fragment
Position Sequence
13164-13177 CAGGAGAGAGACAG
15982-16046 TTTTCCTTCCTTCCTCCCTCTCTCCCTCCCATCCTTC
CTTTTTTCTCTTTTCTTTCTTCTTTCTCT
16528-16558 AAAGGGAAAAAGGGGGAAGTGGGAGGGGAAA
17283-17309 TTGTGGGGTGGGGGGAGGGGGGAGGGA
24602-24620 AGGAGGAAGAGAGAAGAGG
24840-24882 CTCTCTCCATCTCTATTTCTCTCTGCCTCTCCCTCTC
TTTTTC
25743-25696 ACACAT GCACACACACACACACT CACGT AAACACACA 
CACTTCA
28746-28779 TCTCTCTCTTCCCTCTCTGGTCCCTGCTCTCGCC
5 ' TAGATTTAATGAGAGAGGTGTTTGTTTATGTTGGCTTCACTAGAGTGGTGAA
GGCCAATGGCTGATTTCCATGGATTGAGGAGGGAACAGGAGATGGAAAATAGA 
GGTTGTCAACCCACGTAAACTTTTCCTTCCTTCCTCCCTCTCTCCCTCCCATCC 
TTCCTTTTTTCTCTTTTCTTTCTTCTTTCTC 3'
Figure 3.14: Putative transcription factor binding sites in a region approximately 
2kb upstream of the CRP gene (Positions -2065 to -1876 relative to cap site are 
shown). Putative binding sites include a motif found in the promoter of the 
rabbit CRP gene, ST AT binding site, the GAGA box, one of the motifs found in 
the lL-6 responsive element of the human haptoglobin gene and a silencer 
element. The CT rich region is underlined.
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Figure 3.15: Putative H-DNA structure that could be formed from the 
homopyrimidine mirror repeat located in the 65bp CT rich region. Watson-Crick 
base pairs are indicated with straight lines and Hoogsteen base pairs are indicated 
by ♦. The silencer element reported by Haecker et al. (1995) is shown in blue.
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The ability to form H-DNA (i.e. triple stranded DNA) is dependent on the presence 
of a mirror repeat in the polypurine/polypyrimidine rich region. Such a repeat is 
present in the 65bp CT rich region and the H-DNA structure that could be formed is 
shown in Figure 3.15. It should also be noted that the consensus sequence reported 
by Haecker et al. (1995) (section 3,3.2.2) as a silencer element fonns part of the H- 
DNA structure. Therefore, if this DNA structure was formed in vivo there is the 
possibility that transcription factors binding to this site or in this region would be 
affected. As mentioned above and shown in Figure 3.14, the region 5’ of the CT 
repeat contains putative binding sites for a number of transcription factors. 
Therefore, binding of these transcription factors could be affected if this structure 
was formed. Although the mirror repeat is only 8 bases in length, the mirror repeat 
reported by Glaser et al. (1990) was 11 bases in length and Bhaumik et al. (1998) 
reported polypurine repeats as short as 6 bases being capable of adopting a triplex 
confomiation in vitro.
3.3.2.2 Silencer elements
As well as being controlled positively by enhancer elements, gene transcription can 
also be controlled negatively by silencer elements. Haecker et al. (1995) reported a 
silencer element that was believed to act with other regulatory elements in strongly 
repressing synthesis of the ovalbumin gene in hens when eggs are not being laid. 
Regulation of the ovalbumin gene is therefore somewhat similar to that of CRP in 
that it is under strong negative control while also being capable of being strongly 
induced.
The 30kb fragment was searched for the consensus sequence of the universal 
silencer element defined by Haecker et al. (1995). Two of these elements were 
located upstream of the CRP gene, one on the coding strand and one on the non­
coding strand. Another three elements are found in the coding sequence of the CRP 
gene (one on the coding strand and two on the non-coding strand). The sixth 
element is found in the CRP pseudogene. The results reported here are those that
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matched the consensus sequence 100%. However, there are several more putative 
silencer elements in the 30kb fragment as elements that differ from the consensus 
sequence by a single base have been found also.
3.3.2.3 Comparison of the GM-C79 construct with the 30kb CRP fragment
It is known that the GM-C79 construct contains most but not all of the sequences 
required for tightly controlled expression. Therefore, this construct was compared 
with the 30kb fragment for the presence of the previously described regulatory 
elements.
There are two putative silencer elements on the coding strand of the GM-C79 
construct -  at position + 139 and + 4843 and none on the non-coding strand. The 
GM-C79 construct obviously lacks two of the silencer elements located in the CRP 
gene as well as one located 5’ of the BamEl site. The transcription factor-rich region 
(Figure 3.13), including the CT rich-region present in the 30kb CRP fragment, is 
also absent from the GM-C79 construct.
3.3.2.S Growth hormone responsive elements
The second aim of the sequence analysis was to identify regions that may be 
responsible for the sexually dimoiphic pattern of expression seen in the CRP and 
GM-C79 transgenic mice. Since this pattern of expression is seen in both the CRP 
and GM-C79 transgenics this analysis focused on the GM-C79 construct.
33.2.5.1 STATS
The STAT family is an important family of transcription factors with the ability to 
affect transcription in a number of ways. Their potential role in mediating the 
growth hormone signal was investigated because several of the STAT family 
members have been reported to be themselves regulated by growth hormone
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(STATS, STAT5). STAT5 itself has also been implicated as being the “major 
transducer of the pulsatile pattern of growth hormone secretion seen in male rodents 
into sex-specific patterns of gene expression” (Herrington et a/. 2000).
The GM-C79 construct was searched for binding sites for STAT5. This analysis 
was done using the transcription factor search programs Matlnspector (Quandt et 
a l, 1995) and Alibaba 2. These analyses have shown that there are a number of 
putative binding sites for STATS.
Three putative STATS binding sites were found in the GM-C79 construct and are 
shown in Table 3.5. Two of the STATS binding sites are located upstream of the 
CRP cap site (approximately 1.2 and 0.9kb respectively) and one of them is 
approximately 1.3kb downstream. The two STATS binding sites upstream of the 
CRP cap site flank a GAGA-like box (section 3.3.2.5.2), being located 
approximately lOObp upstream and downstream, respectively. The putative STATS 
binding sites in the GM-C79 construct exhibit considerable homology to those 
reported by Varin-Blank et a l (1998) as being involved in the growth hormone 
mediated expression of the C4~Slp gene (Table 3.5).
33,2.5.2 GAGA box
The GAGA box was shown by Le Cam et a l (1994) to be involved in both growth 
hormone stimulation and activation of the rat serine protease inhibitor 2.1 gene since 
mutations that destroy the symmetry of the GAGA box or partial deletion of the 5’ 
end of the GAGA box motif abolish growth hormone stimulation and reduce 
promoter activity by at least 90%.
Two putative GAGA boxes have been identified in the 30kb CRP fragment. One 
GAGA box is located approximately 2.1 kb upstream of the CRP gene and the other 
is located about 1.2kb upstream. This is a lot further upstream that that of the
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GAGÀ box of the rat serine protease inhibitor 2.1 gene which is located about 50 
bases upstream of the gene.
The GAGA boxes in the 30kb fragment differ slightly from that reported by Le Cam 
et al. (1994) (Table 3.5) although the 5' and V  regions are conserved. The GAGA 
boxes may be involved in controlling promoter activity or possibly proteins bound to 
this box could interact with the STAT5 proteins as a STAT5 binding site has been 
located on either side of one of the GAGA boxes.
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Summary o f  results
1. The 15kb 5’ region of the 30kb CRP fragment was sequenced and linked to the 
downstream region, thereby completing the sequence of the 30kb CRP fragment.
2. Analysis of the 30kb fragment has identified a number of putative regulatory 
elements;
• An ORF from a retrotransposon that contains an antisense promoter
• A number of polypurine/polypyrimidine rich regions
• A region containing a number of consensus sequences for a nmnber of 
transcription factors involved in inducing acute phase gene expression
• A number of putative silencer elements have been identified that may have a 
negative effect on CRP expression
3. Analysis of the GM-C79 constmct for elements that may be involved in the 
sexually dimorphic pattern of expression in the transgenic mice identified two 
elements that may be responsible for this:
• STAT5 binding sites with considerable homology to those already 
reported in the literature to mediate sexually dimorphic patterns of 
expression
• GAGA box which has been reported as a growth hormone responsive 
element
As mentioned in section 1.5, one of the aims of the sequence analysis was to identify 
regulatory elements that may facilitate modification of the expression vector for use 
in pigs. The next chapter describes the first step to modify the expression vector, the 
isolation of the promoter of the major acute phase protein in pigs.
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Chapter 4; Isolation and characterisation o f the 
porcine ITIH4 promoter
4,1 Introduction
Characterisation of the porcine acute phase response has only begun in the last 10 
years and it remains to be investigated at the molecular level. The major acute phase 
protein in pigs is known as pig-MAP or ITIH4. A number of studies have reported 
the isolation of cDNA clones containing the porcine ITIH4 gene (Buchman et a l, 
1990; Hashimoto et a l, 1996). However, no work was done to isolate the promoter. 
The aim of this work was to isolate the promoter region of the pig ITIH4 gene with 
the view to using this creating an acute phase expression vector. By analysing the 
promoter and comparing it with the human CRP promoter, we also hoped to answer 
the following question:
Are the regulatory elements that control expression o f  the human CRP gene also 
controlling expression o f the pig ITIH4 gene?
If the regulatory elements were the same as the human CRP gene then an expression 
vector could be more easily created since the regulation of the human CRP gene is 
partially understood. The sequence analyses described in the previous chapter 
would also facilitate the modification o f the acute phase expression vector. On the 
other hand, if the regulatory elements were different to the human CRP gene then 
the pig ITIH4 promoter would have to be further characterised before an acute phase 
expression vector could be made.
This chapter will describe the isolation and analysis of the promoter of the porcine 
ITIH4 (pig-MAP) gene. To isolate the promoter two strategies were employed. 
First of all I attempted to make a probe that could be used to screen a porcine 
genomic library constructed in the lambda vector. Because problems were
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experienced making a probe, it was instead decided to screen a pig BAG genomic 
library using the ITIH4 cDNA clone described by Buchman et al. (1990) as a probe. 
An advantage of this approach was that the BAG clones contained inserts of 
approximately 150kb. Therefore there was a good chance that an isolated clone 
would contain all the elements required for regulation of the porcine ITIH4 gene.
4,2 Isolation of a clone containins the vis~'MAP/ITIH4 sene
4.2.1 Amplification of a section of the nig ITIH4 gene to make a probe for screening 
a porcine genomic librarv
When work began on this section of the project it was believed that the major acute 
phase protein in pigs was called pig-MAP and that the only sequence available was 
the N-terminal amino acid sequence reported by Gonzalez-Ramon et a l  (1995). 
Therefore, to make a probe degenerate oligonucleotides were designed from this 
sequence. Due to the extensive homology reported between the N-terminal of pig- 
MAP and the human protein PK-120 (Nishimura et al., 1995; Gonzâlez-Ramôn et 
al., 1995), oligonucleotides were also designed from the cDNA sequence of PK-120 
that corresponded to the region o f pig-MAP the degenerate oligonucleotides had 
been designed from. The porcine genomic DNA used in these experiments was 
supplied by Dr R Wales (PIG).
Based on the cDNA sequence of PK-120 the expected size of the PGR product was 
approximately 500bp. However, successive PGRs failed to give a product of the 
expected size. Ghanging the reaction conditions and reagents used also failed to 
give a positive result. It was suspected that one or more introns could be located 
between the primer pairs and that the PGR product to be fonned was much larger 
than expected. This was confirmed when it was realised that pig-MAP and the 
ÏHRP protein reported by Hashimoto et al. (1996) were the same protein. This 
realisation gave us access to a wealth of DNA sequence data, including the genomic 
organisation of the homologous human ITIH4 gene (Saguchi et a l, 1995). The
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oligonucleotides designed from the PK-120 (human ITIH4) cDNA sequence actually 
amplify a region of approximately 3kb (this calculation is based on the length of the 
introns reported by Saguchi et a i, 1995) rather than 500bp. This meant that the 
extension time being used in the PCR was too short to amplify the region that the 
oligonucleotides were binding to.
Resolving the nomenclature of the pig-MAP/ITIH4 gene opened up a lot of 
possibilities for obtaining a clone containing the ITIH4 gene. First of all, knowledge 
of the genomic structure of the human ITIH4 gene would facilitate the designing of 
oligonucleotides to ensure they bound in the same exon (assuming the structure of 
the porcine and human ITIH4 genes was the same). In addition, knowledge of the 
cDNA sequence of the pig ITIH4 gene meant that the oligonucleotides could be 
porcine rather than human specific. However, although information was available 
regarding the DNA sequence of the pig ITIH4 gene, none of the reported sequences 
contained any information on the sequence of the promoter region.
At this stage of the project two slightly different strategies were employed in 
parallel. The first was the amplification of a polymorphic microsatellite from an 
ITIH4 clone and secondly, screening a porcine genomic library using an ITIH4 
cDNA clone.
4.2.2 PCR usins oligonucleotides from a polymorphic microsatellite
The pig genome is currently being mapped and a large database is maintained at the 
Roslin Institute (Hu et a i, 2001). From this database it was possible to source a set 
of primers that had been used to amplify a polymorphic microsatellite that has been 
identified in a clone containing ITIH4. The primers were supplied by Professor 
Merete Fredholm (The Royal Veterinary & Agricultural University, Fredriksberg, 
Demnark) and give a PCR product of 160-174bp. Using these primers with the pig 
genomic DNA gave a band of the expected size as shown in Figure 4.1. This band
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was then cloned and sequenced. Sequencing of this clone revealed that it came from 
the ITIH4 gene.
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1 M
Band of 
approximately 
170bp
1635bp
Figure 4.1: PCR using oligonucleotides from a polymorphic satellite. The 
bands of 1.6kb and 220bp of the ladder are indicated with arrows. A PCR 
product of approximately 170bp can be seen in Lane 1.
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From this PCR product a probe could have been made to screen a porcine genomic 
library. However, while sourcing these primers we became aware of the existence of 
a porcine genomic BAC library that had been constructed by the PiGMAP research 
group at the Roslin Institute, UK. Screening this library had the advantage that due 
to the large size of the inserts (approximately 150kb) there was a good chance that 
any isolated clone would contain the entire porcine ITIH4 gene (useful for future 
analysis) and also possibly all the elements required for regulation of the gene itself. 
The following sections describe the library screen and isolation of positive clones,
4.2.3 Screening the PisE BAC library
The library screen was carried out at the Roslin Institute, UK, using the ITIH4 
cDNA clone described by Buchman et al. (1990) (EMBL accession number 
M29507) as a probe. The filters and the probe were prepared as described in section 
2.5.1.7.1 and 2.5.1.7.2 and details of the library screen are given in section 2.5.1.7. 
The PigE BAC library has been gridded on filters (for example, see Figure 4.2) and 
positive clones are identified by first of all identifying which filter the positive clone 
is on. The filter is then orientated so that the panel in which the positive clones are 
located in can be identified. The microtitre co-ordinates of the 4 x 4  array are then 
worked out to identify the putative positive clones. The library screen resulted in the 
identification of eight putative positive clones, which are shown in Table 4.1
Although, eight putative positive clones were identified it was noted that some 
signals were weaker than others. A possible reason for this was the ITIH4 clone 
binding to sequences that are similar to ITIH4 such as other members of the ITI 
family. Therefore, before proceeding to isolate the ITIH4 promoter it was necessary 
to confirm the clones actually contained the ITIH4 gene.
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Figure 4.2: Example of one of the panels on a filter, illustrating the 4 x 4 array
Table 4.1: Putative positive BAC clones
PigE BAC library clone identification Clone renamed as;
PigE BAC 037a02 BAC 1
PigE BAC 044h21 BAC 2
PigE BAC 049g22 BAC 3
PigE BAC 096n06 BAC 4
PigE BA C203bll BAC 5
PigE BAC 231107 BAC 6 (did not grow and was excluded 
from further analysis)
PigE BAC 246106 BAC 7
PigE BAC 258cl5 BAC 8
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4.2.4 Confirmation of positive clones
To confirm the clones were positive two PCRs were carried out. For the first PCR, 
primers were designed from near the beginning of the cDNA sequence of the probe 
(ITIH4 FI and ITIH4 Rl). Because it was suspected that several introns were 
located in the porcine ITIH4 gene (based on information from the genomic 
organisation of the human ITIH4 gene) the primers were designed relatively close 
together to increase their chances of binding to sites within the same exon. The 
expected size of the PCR product based on the cDNA sequence of the ITIH4 gene 
was 105bp. The results suggested that BACl, BAC2 and BAC7 were positive as 
bands of this size were obtained but the small size of the PCR product meant that it 
was difficult to distinguish the PCR product from the primers (Figure 4.3).
However, the sequence reported by Buchman et a l (1990) is actually much shorter 
than the cDNA sequence of the pig ITIH4 gene reported by Hashimoto et a l  (1996). 
Consequently, the primers used in the first PCR are located approximately 700bp 
from the start of the cDNA sequence reported by Hashimoto et a l  (1996). For the 
second PCR primers PK-120 FI and ITIH4 R l were used. Their locations are 
indicated in Figure 4.4. The size of the PCR product expected to be formed based 
on the cDNA sequence of the pig ITIH4 gene was approximately 764bp whereas the 
expected size of the PCR product based on the genomic structure of the human 
ITIH4 gene was 4.3kb. PCR on the BAC clones using these primers confirmed that 
BACl, BAC2 and BAC7 were positive because they gave a PCR product of 4.3kb 
(Figure 4.4).
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M 1 2 3 4 5 6 7
1635bp
220bp
M = marker
1 = BAC 1
2 = BAC 2
3 = BAC 3
4 = BAC 4
5 = BAC 5
6 = BAC 7
7 = BAC 8
Figure 4.3: PCR to confirm isolated BAC clones contain the ITIH4 gene. 
The expected size of the PCR product was approximately 100 bp. 
Therefore, BACl, BAC2, BAC7 and BAC8 appear to be positive. The 
reason for the difference in size of the PCR products is not known.
— I— I— I— I— I— I— I— I— I—
PK-120F1 ITIH4F1 ITIH4R1
M 1 2 3 4 5 6 7
M = marker 
1 = BAC 1
4072bp 2 = BAC 2
1635bp   3 = BAC3
4 = BAC 4
5 = BAC 5
6 = BAC 7
7 = BAC 8
Figure 4.4: Location of primers in the cDNA sequence of the porcine 
ITIH4 gene used to confirm the isolated BAC clones contain the porcine 
ITIH4 gene (each line represents lOObp) and the PCR carried out to 
confirm the isolated BAC clones contain the ITIH4 gene. The expected 
size of the PCR product was 4.3kb. Therefore, BACl, BAC2 and BAC7 
are positive.
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Before proceeding to try to isolate the promoter region of the porcine IT1H4 gene it 
was decided to confirm that the 5’ end o f the ITIH4 gene was present in the BAC 
clones (BACl was chosen for this analysis). This was done using a primer set 
(MAP.IN and MAP.OUT) aimed at amplifying a region of lOObp based on the 
cDNA sequence of the pig ITIH4 gene. However, the expected size of the PCR 
product based on the structural organisation of the human ITIH4 gene was actually 
1.4kb due to the presence of an intron. The presence of the intron in the pig ITIH4 
gene and the 5’ end of the pig ITIH4 gene in BACl were confirmed by this PCR as a 
PCR product of the expected size of 1.4kb was formed (see Figure 4.5) with this 
primer pair. This region was also shown to be present in BAC 7 but not BAC 2. 
The clone BAC 1 was therefore chosen as the template for all further experiments.
This section has described the isolation of a clone containing the porcine ITIH4 gene 
and confirmation that the 5’ end of the gene is present in BACl, the clone selected 
for further characterisation. The following section will describe the strategies 
employed to isolate the promoter and upstream sequences of the porcine 1TIH4 
gene.
4,3 Isolation o f the promoter o f the v is  ITIH4 sene
To isolate the promoter of the ITIH4 gene a number of strategies were considered. 
The most obvious one was to digest the BAC clone and probe for fragments that 
contained the 5’ end of the pig ITIH4 gene. The main problem with this approach 
was that it was difficult to obtain sufficient quantities of BAC DNA for this work. 
At the time tins work was carried out commercially available kits for the large scale 
preparation of BAC DNA were not readily available. I also considered sequencing 
out from the 5’ end of the pig ITIH4 gene but there was concern that DNA prepared 
using our methods or the modified alkaline lysis method described by Brosch et a i 
(1998) would not be suitable for DNA sequencing. Therefore, our first strategy for 
isolating the promoter of the pig ITIH4 gene was based on the available sequence for 
the human ITIH4 promoter.
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M l  2 3 4 M
1635bp
M = marker 
1 = BAC 1
2 = BAC 2
3 = BAC 7
4 = negative control
Figure 4.5: Confirmation by PCR that the proposed intron of 1.4kb and the 
5’ region of the pig ITIH4 gene are present in BAC 1. This region is also 
present in BAC 7 but absent in BAC 2.
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4.3.1 Using the sequence from the promoter of the human ITIH4 gene to isolate the 
corresnondine sequences from the nig gene
A primer, 5’ IHRP, was designed from the promoter of the human ITIH4 gene 
(EMBL U42015) [Saguchi et a l (1995)] and a primer ITIH4.0UT was designed 
from the cDNA sequence of the pig ITIH4 gene. PCR was carried out using BACl 
DNA as template and this gave a product of the expected size of 1.7kb (Figure 4.6). 
The purified PCR product was then cloned in PCRScript and sequenced.
4.3.2 Sequence results and analvsis using BLAST
The sequence was first of all analysed by comparing it with other nucleotide 
sequences in the database using the BLAST program. For this analysis a 7 word 
search was used with an expect value of 10. The results from the BLAST search 
were surprising due to the apparent limited homology to the promoter of the human 
ITIH4 gene (Figure 4.7). As expected the 3’ end of the sequence has homology to 
the 5’ end of the pig ITIH4 gene. After that, there are only a few regions of the 
promoter with homology to the human ITIH4 promoter and upstream sequences. 
Therefore, it appears that I was fortunate to isolate the porcine ITIH4 promoter as 
the oligonucleotide designed to amplify the 5’ end of the promoter is located in a 
region with little homology to the human ITIH4 promoter. In spite of these findings 
the fact that there is some homology to the human ITÎH4 promoter and particularly 
the homology in the T  end to the published cDNA sequence of the pig ITIH4 gene 
suggested that the promoter of the porcine ITIH4 gene had been isolated. The 
porcine ITIH4 promoter was also compared with the working draft of the human 
genome when it became available. Parts of the porcine ITIH4 promoter isolated 
here mapped to a region on chromosome 3 containing the human ITIH4 gene 
(Figure 4.8). However, it should be noted that only a small section of the porcine 
ITIH4 promoter is mapping in this region. This is to be expected as a comparison 
between DNA sequences from two different species is being made.
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M  1
1635bp
M = marker 
1 = PCR product following clean-up
Figure 4.6: Isolation of the promoter region of the pig 1TIH4 gene. The PCR 
product formed (Lane 1) was of the expected size of approximately 1.7kb. 
Other bands may be non-specific PCR products. The 1.6kb band of the DNA 
ladder is indicated with an arrow.
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Figure 4.8: Comparison of the pig 1TIH4 promoter with the working draft of the 
human genome using the BLAST program. This figure shows a segment of 
human chromosome 3 (region 54,308,695 to 54,310,491 bp). The location of the 
human ITIH4 gene is indicated. Regions of the pig ITIH4 promoter exhibiting 
homology in this region are referred to in the diagram as Blast hit. It is evident 
from this figure that parts of the isolated pig ITIH4 promoter are mapping to the 
promoter of the human ITIH4 gene.
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4.3.3 Sequence analysis using GCG Gap program
The sequence was analysed using BLAST to determine if the isolated sequence had 
any homology to other sequences in the nucleotide database. In order to determine 
exactly where the human and pig ITIH4 promoters differed, the human and the pig 
1TIH4 promoters were compared using the GCG Gap program (Figure 4.9). This 
analysis suggested that the promoters were more homologous. Homology between 
the two promoters is calculated to be 65%. The reason for the different results 
obtained with the BLAST and Gap programs is probably due to how the data is 
analysed. Gap creates a global alignment that maximises the number o f matched 
residues and minimises the number and size o f gaps. BLAST on the other hand is a 
local alignment tool that searches for regions of similarity and only reports 
sequences where the alignment score meets or exceeds a threshold or cut off score 
(details of this can be found on the BLAST website (Table 2.1)). The smallest 
search sequence used by BLAST is 7 letters. Therefore, it appears likely, as shown 
in Figure 4.9, that because many of the regions exhibiting homology are only a few 
nucleotides in length BLAST calculated that they were below the cut off score and 
so they were not reported. Moreover, it is clear from Figure 4.9 that without the 
introduction of gaps to maximise the number of matched residues the homology 
between the promoters would be much less. Therefore, these results indicate that 
caution must be taken when interpreting the results as the results depend on the 
method used for analysis.
The final experimental procedure carried out to confirm that the sequence isolated 
was the pig ITIH4 promoter was a series of PCRs. For these reactions primers were 
designed against the newly generated sequence (some with homology to the human 
ITIH4 promoter, others without) and primers designed from the published cDNA 
sequence of the pig ITIH4 gene. All of the PCRs give products of the expected size 
as shown in Figure 4.10.
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Figure 4.9; Comparison of the pig ITIH4 and human ITIH4 promoter regions 
using the GCG Gap program. The human ITIH4 promoter sequence is on the top 
row and the porcine ITIH4 promoter sequence is on the bottom row.
1 TCCCGTTGTGATGGCAAGACCATGACCATGGACAGGCTGACAGTGGCTCT 50
I I I II I I II I I I I I I I I I I ! 1 
1 .CCCGTTGTGATGGCAAGACCA................................................................................ 2 1
5 1  TTTCGGAGCTGGACTGCGAGAGCCTGCGCTTGTGGTGCCTGGCTCGGGGC 1 0 0  
I I I I I I I II II I II I I I II I I I I I
2 2  .........................TGGACGGTCCAGGGCTGGAGTGGCAGTGACTGGCTAGGGGC 62
1 0 1  TGATACCTGCTG.. . .GGGATGCCCTTCTCGTCCCCAGGAAGGTCTGGCT 1 4 6  
III I I I I I I I I I I I I I I I I I I I I I I I I I
63  CGATGCCTGCAGTGACGTCCTGCCAGTCCCCTGGGCAGGTGGGACGGGCT 1 1 2  
1 4 7  GCCCAGAAGGTTTCCCACAGTC..CGCCAGCCTGGCCACCTTATAATGAG 1 9 4
II II I I I I I I I II I I I I I I I I I I I I I I I I I I
1 1 3  GCATGGAGGCTTTCCCACGTTCTTGGCCAGCCCGGCCTCCTTATTTAG.. 1 6 0
1 9 5  CTGAGTCGGGGGGTGGGGCTGTGCTCTCTGCCCCAAGGGAGCACCCCTGC 2 4 4  
II II II II I I I I I I I I I I I I I I I I  I I I I I I I I
1 6 1  .CTATTTTGAGGCCAGGCCTGTGCTCTCTGCCCCAAGGGAGCAGAC.. .C  2 0 6
2 45  TGTGAGGGAAGGGCACAGTCCTACTTGCTGG...................ATCTATGGGGAG 2 8 7
I II I I I I II I I III III II III I Mill
2 0 7  TGTGGGGAGAGGGGCGAGGGCTGCTCACTAGGCTGCTCAGGGTTGGGGGC 2 5 6
2 8 8  ACTCTTAGGTGGAGAGAGTGAAAGGAGGGTGTTCGCCTGTGTAATCGCAA 3 3 7  
I I I I I I I I I I I II I I I I M M I I I I
2 5 7  GGCTGTTTCCCCAGATTGCTGTAGGAGTACGTCTTCCCGTTTAATCGCAG 3 0 6
33  8 TGGTATCCAGAGCCAAAAGGGTGAGGAGTGGAGAGGTGGGGAGAGATGAG 3 8 7
II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I
3 0 7  TGATATGCAGAGCC.AAAGGGCGGGCAGTACAGGTGCTCACAGAGATGAG 3 5 5
3 8 8  GCTTGTGGC. . CAGTCATGGTAAGGAAGGGGAACGTCTTCCTTGCAGGTG 4 3 5  
I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I
3 5 6  GGTTTTGGGTGTGGTCATGGTAAGGAAGGGGAATGT.TCACTTGGAAGCA 4 0 4
4 3 6  TAGAAATAGGTCT..AGTGTATGGGACCTTTGCCCGAGGCC.. .TGCCGC 4 8 0  
I I I I I I I I I I I I I I I M M II II II M i l l
4 0 5  CAGACACAGCTCTGAGGTCTATGATGCCGTTCCCTAGAGGCGTGTGCTGC 4 5 4
4 8 1  CACCTGTAATGGAGAGAGGAGTGGTGGAGAAAG. .GCTGCGGAGCCTGTG 5 2 8
I II I I I I M I II I ! II I I Ml II II I I
4 5 5  TGGGATTGAGCGAGGGAGGGCTAGAAGGGAAGCCGGCTTCCTGACCCTTG 5 0 4
5 2 9  GAAG..GAGTGGGTGGGGGAAGGCCCCCGATAGGTTCCCAAGGGAGCTGG 5 7 6  
Ml II I II 1 I! M M II I 1 I I I I I Ml II
5 0 5  CAAGTAAAGTCACTGGGGGAAGACCGCGAGTAGGGGCTGAAGATGGCGCG 5 5 4  
5 7 7  GGGGCTGAGGGCTGGTGTGACGGAGCCGGCGTGCTTCGGTGAAGGAGGAC 62 6
I II I II I I I II I I I 11 I II I M I I II I I
5 5 5  GTGCCCTAGCTCCCCTAGTGCGACTGAGGGCT.CTTCGGTGAGGGAGGAT 60 3  
62 7  TTGGCATGTGGCGAGAGTTTTATGAGTGATGTTTA.GGGATGTGTGGGCA 6 7 5
I 11 II 1 Mill I M I II III I II II M I I I i II II M I N I
6 0 4  TTGGCAGGTGGC..CAGTTTGCTGAAGCATCTTTATGCGATGTTTGGCCA 6 5 1
67 6 CAGAGTCAGGAGCTGCTTC.CCCAGAGCGACGAGGGAAGACGAGCGCAGC 7 2 4  
I I I I I I I I I II I II II I I I Ml I I I  I
6 5 2  TGGACTGAGGAGGGAAGGGTTTCAAAGGGAGAAGGAGATAAG. . .GACTA 69 8
7 2 5  GGTGCCCAGAGCGCATAATATGTACTCACTGGATCCCAGTTTACAAGGAG 7 7 4
II 11 I I I I M It II I I II I II I I I II I I
6 9 9  GGTGGGTGAGAAGGGTAATATTTATTGACTTTAT. . . TATTTGTTAGGAA 7 4 5  
7 7 5  AGAGGACTTCAACTTTAGGAAG......................................................... GCGGGGAC 8 04
II I M : I i It I! II I I I I
7 46  AGAGGNTTTGACTTTATTAAAGGAAAACTGAAAAAAGTCATTGGTAGTCC 7 95

8 0 5  CCACCCCAGGCTTTGGGCAGCGCTCCCCTGGGTCTGGGCT.. . .GTGGCA 8 5 0  
III II II I III I I I I I I I I I I I I I II
7 9 6  TACCCCAGACCCTCTAGCCACCCTCTCGTGGGTCTGGGCTCACAACAGCG 8 4 5
8 5 1  GCATCACACTGCTCATTACAACAATTCTGCCCTCTCTCAACCAGCGATTC 9 0 0  
III III I [ I II I I I I I I I I I I I I I I I ! I
8 4 6  GCACCACCTTGGCATGGATCGGCCTTCTACCCGTTCTCAAGCTGTGACTC 8 9 5
9 0 1  CTGGGCTCCCTCTGCTCCAGCAAATGACTCCCCAGTCA................................. 9 3 8
I I I I II I I II II I II : : I I I
8 9 6  ACGGACTCCCTTGGCGTGACTGACCTCCACGTNNGCCACCTAAGCATACA 9 4 5
9 3 9  ................ CCCCTCAGGAGCTGCTGGCACTGTCAGGTCTGTCTTCTGTTCCA 9 8 2
I I I I II ! I I I I I I I I I I
9 4 6  TACCCCCCACCCCCAAGTCACCCCTTTCAAGAGCTCTGTGCTTTCTGTTC 9 95
9 8 3  TGCTCTTCTGTCAAT2\AACTCCCCGCATGGAGACCTCCTCGCGACAGGAT 1 0 3 2
II I I I I I I I I III III I II III I I I I I
9 9 6  TGTGCTTCTGTTCAGAAATTCCTTGGATCGAGTGAGACCTCGGGCGGAAA 1 0 4 5
1 0 3 3  GTG.GCAGGTTTATGACTCA.GTTGTATTGCCA,.TTCTTGTTTTGGGGG 1 0 7 8
III II I I I I I I III I I I I I I I I I I I I I I I I I I I I
1 0 4  6 GTGTGCCTCTTTATGCTTCACTTTGTATTGCGAACCACATGTTTAGGAGG 1 0 9 5  
1 0 7  9 CCTTGCTGGGGTTGAACCTAAAGCCCTGGCTAGATTAATGGCACCCAAAC 1 1 2 8
I I I I I I I I I I I I I II I II I I I I I I I I I I II III I I I I I
1 0 9 6  CCTTGCTGGAGTTGCACAAAGAGTCCTGGCTAGAATAGTGGGGCCCAA.. 1 1 4 3
1 1 2 9  AGCAACCTGGGACCCCAGGAGAGAGAAGGAGGCGCCCCGTGCCCAGCACC 1 1 7 8
I I I I I I I I I I I II II III! II
1 1 4 4  ....................................................CAGAGAGAAGGGAGGCCCTTTGGCTCAGCCCC 1 1 7 5
1 1 7  9 TCTCACTTC.AGAAATACGGCGTAT..CTATCCTGACTCTAGATCTGC.. 1 2 2 3
II II I I I I I I I I I I II I I! I I I I I I I I III
1 1 7 6  TCTCGCTCCAAGAAGTAAGGCATATAGCCATCCTGCTTTGGCCCCAGCAG 1 2 2 5
1 2 2 4   CCCACACAGACACCTCCCAGAGTCACTCCATGCCTTTGGGCCCTC 1 2 6 8
II III I I I I I II I I I I I II i I I I I I
1 2 2 6  AGCGTGCCCCACTCGGCACCCCAAGGACTGCTGGGTGCCTTTGGGGCC.C 1 2 7 4  
1 2 6 9  CCATCAGCCAGTCACACTTACCCGTGTGCGCAAGCCCCCTTCTTCCGGGA 1 3 1 8
I I I I I I I I I I I I I I I I III I I I I I I I III III
1 2 7 5  CCACTGCCCAGTCACTCTGACC.. . .TGCCTCTGGCCCCTGCCTCCTGGA 1 3 2 0  
1 3 1 9  AGCCGCTAGGGTAGCCCTGTAGCCCTAGTCTTCCCCACCATCCCCCGCTG 1 3 6 8
I I I I II I I I I I I II III II I I I I I I I
1 3 2 1  AGCC........................ACCCTCTGGCCCTCCTCTGCCTGGCTATCGCTC. . .T  1 3 5 8
1 3 6 9  TTTCTCCCCGGGCTGGACTTAGGGAGAGCAGACTGACATCTTCACTGTCA 1 4 1 8
I III I I I I I I I I I I I I I I I I 111
1 3 5 9  GCTTCACCCATTCTGGGCTTAAAGAGAGCTGGCCAGTTACTGC.................. 1 4 0 1
1 4 1 9  ATTCCCTCCCAGCCCTGTGGAGCTTGGTGGAATGCCTGGTGTGAAGGGTC 1 4  68
I I I I I  I  I I  I I I I I  I  I I I I I I I I !  I I I I  I I I I I I  I I I 1
1 4 0 2  .GTGTCCCCCAGCCCTGGGAGGCTTAGTGGAATGACTGGTATGAGGGGTG 1 4 5 0
14  69  CTGGTG................AAGGTTTCGCACTTTTCAGAAGGGGCACGTACCCCCAC 1 5 1 2
I I I I I I I I I I I I I I I II I I’l I I I I I I I
1 4 5 1  GTAGTGGCCTGAGAAGGTTCTGGACTTTCAGGTGGGGCGCCAATACCCAC 1 5 0 0
1 5 1 3  TCCAAACTG.AGCCTACCCTTCTTTGGTATACATTCCTGCCCCCAGCCAA 1 5  6 1  
I I I III I I I I I III II I III I I I I I I I I I I I I III
1 5 0 1  TGCCACCTGAAGCCTGCCCCTCCTCAGTACATGTTCCCGTCCCCAG'TCAA 1 5 5  0
• 1 5 6 2  G G TC C  A T6G G CG TTC G TC A TTTG C TTA TCTG A G G TC A CTG TG G TT 1 6 0 6
I I I I I i I I I I I I I I I I I I I III I II I
1 5 5 1  GGTCCACAGGATGTTCATAGTTTGCCTGCTTATCTGA.GCCGCTGGGGTT 1 5 9 9  
1 6 0 7  TTTGGCTTGTAGATCCCAATTTCCCAGAACCTGCCCCCATGTGGGTGGGG 1 6 5 6
I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
I I
I I
I I I I I I I I I I I I I I I I I I I III II
I I I I I III II I I I I I I I I I I I I I III
I I I
1 6 0 0  TTTGGCGTGCAGATCCCAATTTCCCAGAACCTGCCCCCACAGGGGCGGGG 1 6 4 9  
1 6 5 7  CAGGAAACAAGTTACTAATCCATTCCCCACTTGCTGTCGCGTTCAGAAGC 17  0 6
I I I I I
1 6 5 0  CAGCAGGCAAGTTACTAATTCATTCCACGCTTCTTCTTAAGTTCAGAAGC 1 6 9  9 
1 7 0 7  C.TCCTGGCAGACACTGGAGCCACGATGAAGCCCCCAAGGCCTGTCCGTA 1 7 5 5
I I
1 7 0 0  CAGCCTGACAGGCAGAGGAGCCAAAATGAAGACCCTCTCCCCTACTGGNT 1 7 4 9
1 7 5 6  CCTGCAGCAAAGTTCTCGTCCTGCTTTCACTGCTGGCCATCCACCAGACC 1 8 0 5
I I I I I
1 7 5 0  ACGGCCTTCTGCTGGT..................................................................................................  17  65
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CHAPTER 4: RESUI.TS
4.4 Sequence analysis o f  the promoter resion o f the v is  and 
human ITIH4 senes
Comparison of the porcine ITIH4 promoter with other sequences in the nucleotide 
database did not reveal any homology to other acute phase promoters (apart from the 
human ITIH4 promoter). The lack of homology to the human GRP promoter was 
confirmed when the pig ITIH4 promoter was compared with the 30kb GRP fragment 
using the GGG gap program.
The results of the sequence analysis of the porcine ITIH4 promoter can be 
summarised as follows:
• Some but limited homology to the human ITIH4 promoter
• No homology to the human GRP promoter
These findings were somewhat unexpected because the ITIH4 gene in pigs and the 
GRP gene in humans are the major acute phase proteins in these species. Therefore, 
it was expected that they would have some sequences in common and that this 
would allow us to perhaps identify an “acute phase regulatory element” that was 
common to all acute phase genes and responsible or at least involved in their 
induction and regulation. The limited homology of the porcine ITIH4 promoter with 
the human ITIH4 promoter was also surprising and it seems I was actually fortuitous 
in isolating the porcine ITIH4 promoter using an oligonucleotide from the human 
ÏTIH4 promoter, as homology in the region the oligonucleotide was designed from is 
very low. However, the differences in the promoters of the human and pig ITIH4 
genes is in part to be expected because in pigs ITIH4 is a major acute phase proteins 
whereas in humans ITIH4 is only a minor one.
These observations suggested that analysis of the promoters of the human GRP gene 
and the porcine and human ITIH4 genes could give some insights into the different 
regulation of these genes. This analysis was carried out by searching the region Ikb 
upstream of the translational start site of each gene for binding sites for
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inflammation-induced transcription factors. In addition, binding sites for reported 
regulatory elements found in the promoters of acute phase genes and for binding 
sites for .ubiquitous transcription factors that have been reported to interact with 
inflammation-induced transcription factors were also searched for. The pig IT1H4 
promoter was also searched for binding sites that had been reported by Saguchi et al 
(1995) in the human 1TIH4 promoter. Most of these transcription factor binding 
sites have already been described in Table 3.3.
The results of these analyses are illustrated in Figures 4.11, 4.12, 4.13. The most 
striking observation is the completely different organisation of the promoter region 
of each gene. Although all of the promoters contain binding sites for IL-1 and IL-6 
inducible transcription factors, such as NFIL-6 and IL-6RE, the location o f these 
factors varies in each promoter. All of the promoters differ in the number and/or 
location of other ubiquitous transcription factor binding sites, such as Spl and liver- 
enriched transcription factors such as HNF-5 and LF-Al. An interesting observation 
is that the acute phase response elements identified by Arcone et a l  (1988) as being 
essential for induction of the CRP gene are absent from the promoter of both the 
ITIH4 genes. A motif found in the rabbit CRP promoter is found in both the human 
CRP promoter and the pig ITIH4 promoter but not the human ITIH4 promoter.
A big difference between the CRP and ITIH4 genes is that the ITIFI4 promoters lack 
a TATA box. Although this is not unusual, TATA-less promoters are normally 
associated with “housekeeping” genes. The exact function of the ITIH4 genes is 
unknown but it is not expected that a major acute phase protein would fall into this 
category. Both the human and pig ITIH4 promoters contain binding sites for a 
transcription factor that binds to TATA-less promoters. It is interesting that there 
are two putative binding sites for this transcription factor in the porcine ITIH4 
promoter whereas there is only one in the human ITIH4 promoter. This could result 
in greater activation of the pig ITIH4 promoter compared to the human ITIH4 
promoter.
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CHAPTER 4: RESULTS
Summary o f  results
1. A clone containing the porcine ITÎH4 gene was isolated by screening a porcine 
BAG genomic library.
2. The promoter of the porcine ITIH4 gene was isolated
3. Comparison of the porcine ITIH4 promoter with the human ITIH4 promoter 
revealed that there was limited homology between the two promoters
4. No homology was observed between the pig ITIH4 promoter and the human 
CRP promoter
5. Comparison of the transcription factor binding sites in the promoter regions of 
the human CRP gene and the porcine and human ITIH4 genes reveals a very 
different structural organisation
The main aim of this analysis was to investigate if the porcine ITIH4 promoter 
contains the same regulatory elements as the human CRP promoter. Since this is not 
the case it is now necessary to further characterise the porcine ITIH4 promoter to 
understand its regulation and to establish a system that will facilitate these studies in 
vitro.
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Chapter 5; Biological analysis of the porcine ITIH4 
prom oter in tissue culture
In Chapter 4 the isolation and sequence analysis of the promoter of the porcine 
ITIH4 gene was described. In this chapter, a functional analysis of the promoter will 
be described as well as the establishment of an in vitro system for studying the 
porcine acute phase response. Although an immortalised porcine hepatocyte cell 
line has been made (Liu et al. 1999), this cell line is not available commercially at 
the present time. Therefore, we have examined the potential of the human hepatoma 
cell line. Hep 3B, as an in vitro system for studying expression of the porcine ITIH4 
gene.
5.1 Creation o f the expression vector
To confinn the ITIH4 promoter was functional and responded to an inflammatory 
stimulus a number of expression studies were carried out using the chloramphenicol 
acetyltransferase (CAT) reporter gene. The vector used in these studies, pCAT3- 
Basic (pCAT3B) vector (Promega), is a promoterless vector containing the CAT 
gene and has been designed for studying mammalian gene expression. This vector 
has a MCS that facilitates the cloning of the desired promoter.
The pig ITIH4 promoter isolated in section 4.3.1 was amplified with primers 5’PPR 
and PPR 3% which were designed to introduce a Kpnl site at the 5’ end of the 
promoter and a Xhol site at the 3’ end to allow cloning in the MCS of the pCAT3B 
vector. It is important to note that the region amplified for expression studies did not 
contain any of the signal peptide sequence of the pig ITIH4 gene. This was to 
ensure that the reporter gene product was retained in the cell and not secreted into 
the medium.
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The amplified PGR product gave a band of the expected size of 1.8kb. This was 
cloned into PCRScript and transformed into XL-10 competent cells. Following 
selection on agar containing X-gal/IPTG, a number of white colonies were screened 
for clones containing the insert. Once a positive clone had been isolated DNA was 
prepared and digested with Kpnl and Xhol to release the insert. The purified DNA 
was then cloned into the pCAT3B vector, which had also been digested with Kpnl 
BXiàXhol. Following ligation of the insert to the vector and transformation in XT-10 
competent cells, the resulting colonies were screened by PCR (Figure 5.1, Gel A). 
Positive clones were confirmed by digesting the DNA with Kpnl and XJtol (Figure 
5.1, Gel B). To confirm the clone contained the promoter of the pig ITIH4 gene it 
was sequenced. This clone was tenned PPR-CAT3B. This clone was then tested in 
Hep 3B to see if it was functional and how it responded to an inflammatory stimulus.
5.2 Establishing H ey 3B as a model system for studvins sene 
expression
Because there are no immortalised porcine cell lines currently available, the 
expression studies were carried out in the immortalised human hepatoma cell line 
Hep 3B. This cell line has been used extensively in studies of the acute phase 
response in vitro. The first sets of experiments looked at the expression of the 
pCAT-Control vector, pCAT3B vector (with no insert) and the CRP-CAT construct. 
The pCAT-Control served as a positive control. In this vector the CAT gene is 
under the control of the SV40 promoter and this results in constitutive expression of 
the CAT gene. The pCAT3B vector is a promoterless vector into which the pig 
ITIH4 promoter was cloned. This vector also served as a negative control and the 
background expression from pCAT3B was subtracted from the results obtained in 
the expression studies with the pig ITIH4 promoter. The CRP-CAT construct was 
made by Shirley Hanley and contains the minimal sequences necessary for acute 
phase expression of the human CRP gene in tissue culture systems (Arcone et a/., 
1988; Li et a l, 1990). The construct has been tested previously in this system
84

Figure 5.1: Identification o f putative positive clones containing the pig ITIH4 
proihoter in the pCAT3B vector by PCR (Gel A). The expected size o f the PCR 
product from positive clones was Ikb. Other bands present may have been due 
to non-specific binding of the primers to the template DNA. Clones 6,7 and 8 
appeared to be positive. This result was confirmed by digesting DNA from these 
clones with Kpnl andJtTzoI to release the insert of l.Skb as shown in Gel B.
1635bp
M 1 2 3 4  5 6 7 8 Gel A
M = marker
1-8 = putative positive 
clones
2 3 M G e l B
1 = Clone 6 from Gel A digested 
1635bp with Kpn\ and Xho\
2 = Clone 7 from Gel A digested
with Kpnl and Xhol
3 = Clone 8 from Gel A digested
with Kpnl and Xhol
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(Williams, 2001) is known to be expressed and induced in Hep 3B following 
stimulation with cytokines. Figure 5.2 illustrates the results of these experiments.
These results show that:
• CAT is expressed in Hep3B and can be detected using a CAT ELISA
• The pCAT“3B vector with no insert has very low backgroimd levels of 
expression. This means that in future experiments where a promoter is cloned in 
this vector any CAT detected above this level is due to promoter activity rather 
than background expression
• The cell line Hep 3B is responsive to stimulation with IL-1 and IL-6
It should be noted that although the induction of the CRP-CAT construct is only 2- 
fold, which is much lower than seen in vivo, this finding is in agreement with the 
results of Williams (2001) and is related to the length of the promoter used to make 
the construct. Other constructs investigated by Williams (2001) with extended 5’ 
sequences exhibited higher levels of induction. In addition, several authors have 
shown both in vivo and in vitro that the levels of induction of the CRP or reporter 
gene are dependent on the sequences present in the construct examined (Arcone et 
a l, 1988; Ganter et a l, 1989; Murphy et a l, 1995).
In summary, the results from these control experiments meant that the Hep 3B cell 
line could be tested as an in vitro system for studying promoter activity of the 
porcine ITIH4 gene.
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pCAT3B pCAT
Figure 5.2 (a): Expression of pCAT3B and pCAT (negative and positive control 
vectors) in Hep3B
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Figure 5.2(b): Expression of CRP-CAT in Hep3B 24 hours post-stimulation 
with IL-ip and lL-6. * refers to a significant increase in expression (p<0.05 
Mann Whitney U Test)
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5.3 Stimulation o f the PPR-CAT3B construct with various 
concentrations o f  cytokines
The first set of experiments in Hep 3B examined the expression of the PPR-CAT3B 
construct in the presence and absence of cytokines. Examination of the construct in 
the absence of stimulation was carried out to determine the background levels of 
expression of the construct. Attempts to induce expression of the CAT gene were 
carried out using recombinant human IL-1|3 and ÏL-6. These two pro-inflammatory 
cytokines are known to play a role in the induction of acute phase proteins and also 
act in synergy to induce and enhance expression of the human GRP gene. The effect 
o f each of these cytokines and a combination of both on induction of the porcine 
ITIH4 gene was investigated in Hep 3B as described in the following sections.
5.3.1 Stimulation with IL-6
In section 1.4.2.1 interleukin-6 was described as being the major mediator of the 
acute phase response. IL-6 has been reported to induce the expression of both the 
human and pig ITIH4 genes in vitro (Pineiro et al., 1999; Gonzâlez-Ramôn et al., 
2000). In the experiments described here, the effect of various concentrations of 
human recombinant IL-6 on the pig ITIH4 promoter was examined. The cells were 
stimulated with 5U, 5OU or 500U IL-6 in serum-free medium 24 hours post­
transfection and the cells were harvested 48 hours later. The amount of CAT 
produced was measured by ELISA (section 2.5.2.8).
Analysis of the samples following stimulation shows that even in the absence of 
stimulation the pig ITIH4 promoter is driving expression of the CAT gene. This 
cannot be accounted for by background transcription of the CAT gene because it is 
much higher than that of the pCAT3B vector alone. Following stimulation with 5 
and 50 units of IL-6 only a small increase in expression was seen. This increase in 
expression was less than two fold and was not significant (Mann Whitney U Test).
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However, following stimulation with 500U IL-6 there was a 6-fold increase in CAT 
expression which was significant (p <0.05 Mann Whitney U Test).
5.3.2 Stimulation with IL-IB
Pineiro et al. (1999) and Gonzâlez-Ramôn et al. (2000) reported that IL-ip did not 
have any effect on expression of the endogenous ITIH4 gene in humans and pigs. 
Therefore, the effect of IL-ip on the pig ITIH4 promoter in vitro was examined. 
Hep 3B cells were transfected with the PPR-CAT3B construct and stimulated with 
various concentrations (5-500U) of human recombinant IL -lp  24 hours post­
transfection. After a 48 hour incubation period the cells were harvested and 
analysed for CAT expression.
Figure 5.4 shows that stimulation with 5U IL-lp resulted in a small but significant 
increase in expression (p <0.05 Mann Whitney U Test). However, at higher 
concentrations (50 and 500U), there was no significant increase in expression. 
These results suggest that the porcine ITIH4 gene is a Class II acute phase protein as 
it is induced most strongly by IL-6.
5.3.3 Stimulation with a combination o f EL-6 and IL-K3
• The results from the above experiments showed that the promoter of the ITIH4 gene 
was inducible in Hep 3B when stimulated with IL-6. However, the level of 
induction was much lower than expected (induction of up to 30-fold has been 
reported in vivo (Lampreave et al., 1994)). Since it is unlikely that one cytokine is 
responsible for induction of any acute phase gene the combination of different 
concentrations of cytokines on promoter activity was examined. Induction of the 
human CRP gene has been reported to be the result of IL-ip and IL-6 acting in 
synergy (Ganter et al., 1989; Zhang et al, 1995). Therefore, the effect o f a 
combination of both IL-ip and IL-6 on induction of the porcine ITIH4 gene was 
investigated. 500U of IL-6 had been shown to result in a 6-fold increase in
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Interleukin concentration
Figure 5.3: Expression of PPR-CAT3B in Hep 3B 48 hours post-stimulation 
with various concentrations of IL-6. * refers to a significant increase in 
expression (p<0.05 Mann Whitney U Test)
O) 1.5
Interleukin concentration
Figure 5.4: Expression of PPR-CAT3B in Hep 3B 48 hours post-stimulation 
with various concentrations of IL-lp, * refers to a significant increase in 
expression (p<0.05 Mann Whitney U Test)
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expression, therefore the effect of 500U IL-6 plus various combinations of IL -lp  (5- 
500U) was examined. The results from these experiments are shown in Figure 5.5.
A combination of 500U IL-6 and 5U IL-lp  resulted in a 6-fold increase in 
expression, which was similar to that seen in cells stimulated with 500U IL-6 alone. 
Therefore, the addition of 5U IL-ip did not enhance the inducibility of the construct. 
A combination of 500U IL-6 and 50 or 500U of IL-ip resulted in a decrease in 
expression of the CAT gene, which was dose dependent. A combination of 50DU 
IL-6 and 5OU IL-lp only results in a 2.5 fold increase in expression, although this is 
still significantly higher than in cells receiving no stimulation (p <0.05 Mann 
Whitney U Test). The combination of 500U IL-6 and 500U IL-ip abolishes the 
inducibility of the construct by 500U IL-6 alone. The level of expression of the 
CAT gene is more or less the same as that of cells receiving no stimulation (Figure 
5.5).
The results obtained when the PPR-CAT3B construct was stimulated with IL-lp and 
IL-6 separately are in good agreement with those of Gonzâlez-Ramôn el a l (2000) 
who investigated the inducibility of the endogenous porcine ITIH4 gene in vitro 
following stimulation with IL-1 and IL-6. Although Gonzâlez-Ramôn et a l  (2000) 
did not examine the effect of a combination of IL-1 and IL-6 on expression of the 
endogenous porcine ITIH4 gene, the inhibition of the IL-6 induced activity of the 
ITIH4 promoter by IL-1 is consistent with ITIH4 being classed as a Class II acute 
phase protein. These findings suggest that Hep 3B may be suitable for a functional 
analysis of the porcine ITIH4 promoter in vitro. To verify this I wished to analyse 
the constructs in porcine hepatocytes. As mentioned previously, an immortalised 
porcine hepatocyte cell line is not currently available. However, I was able to source 
some primary porcine hepatocytes and I planned to test the ITIH4 constructs in these 
cells before carrying out any further work.
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Figure 5.5: Expression of PPR-CAT3B in Hep 3B 48 hours post-stimulation 
with 500U IL-6 and various concentrations of IL-lp. * refers to a significant 
increase in expression (p<0.05 Mann Whitney U Test)
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5.4 Analysis o f  the constructs in vrimarv vorcine hepatocytes
Before carrying out any further work on the pig ITIH4 promoter I wanted to confirm 
the findings from the above experiments in primary porcine hepatocytes. Primary 
porcine hepatocytes were kindly supplied by Mr L Nelson and Mr S Reach (Liver 
Research Group, Department of Medicine, University of Edinburgh, UK). The 
hepatocytes were isolated using the method described by Nelson et al. (2000). The 
cells were seeded in 6 well plates and transfected as described in section 2.5.2.5.2 
with 2pg of C3:EGFP. C3:EGFP is a vector containing the enhanced variant of GFP 
under the control of the CMV promoter. Preliminary experiments suggested that 
transfection was possible and successful because fluorescent cells could be seen 
when the cells were examined using a fluorescent microscope. Further experiments 
to confirm these findings, to optimise conditions and to test the porcine ITIH4 
constructs were not possible due to the outbreak of foot and mouth disease in the UK 
which prevented access to farms and the movement of samples.
5.5 Generation o f mutants to decrease basal level o f  expression and 
increase inducihilitv
Although I was not able to confirm the findings reported in section 5.3 in primary 
porcine hepatocytes, I believed that Hep 3B was a usable system for biological 
studies of the porcine ITIH4 promoter. In Hep 3B, the ITIH4 promoter was 
behaving as a typical Class II acute phase promoter. Although the levels of 
induction of the PPR-CAT3B construct were different to those of the endogenous 
ITIH4 gene in vitro and the ITIH4 gene in vivo, a similar phenomenon has already 
been reported for the human CRP gene (Arcone et a i, 1988). Transiently 
transfected constructs containing the human CRP promoter were induced stronger 
than the endogenous gene in vitro and the levels of induction never match those seen 
in vivo. Therefore, it was decided to continue our studies on the ITIH4 promoter 
using Hep 3B cells for analysis.
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5.5.1 Comparison of the human and oig ITIH4 promoters
Although the promoter region of the ITIH4 gene was driving expression of the CAT 
gene and was inducible, the fact that basal level expression could be detected was 
not acceptable for reasons already discussed in section 1.4. Therefore, it was 
attempted to create a construct whereby the basal level of expression would be 
reduced while maintaining or increasing the inducibility of the construct. As the 
human ITIH4 gene is not induced to the same extent as the porcine ITIH4 gene in 
vivo, the promoter regions of these two genes were compared to see if differences in 
binding sites for transcription factors could account for the differences in expression. 
As reported in section 4.3.3 although there is 65% homology between the human 
and the pig ITIH4 promoters the distribution and organisation of putative 
transcription factor binding sites is very different. The literature was searched to see 
if any of the putative transcription factor binding sites could influence or account for 
the different levels of expression of the human and porcine ITIH4 genes.
The work focused on the putative binding sites for the LF-Al transcription factor 
that had been identified by searching the pig ITIH4 promoter for transcription factor 
binding sites that had been reported by Saguchi et al. (1995) in the human ITIH4 
promoter. Hardon et a l (1988) suggested that the affinity of the LF-Al transcription 
factor for its binding site in the promoter region of the haptoglobin and haptoglobin- 
related genes as well as the number of binding sites to which LF-Al could bind 
strongly influenced the basal levels of expression of the gene. They proposed that 
decreased affinity of LF-Al for its binding site in the promoter of the haptoglobin 
gene due to a base substitution in its binding site was correlated with lower basal 
levels of expression. It was interesting to note that in the region Ikb upstream o f the 
human and porcine ITIH4 translation start codons there are three putative binding 
sites for LF-Al in the porcine ITIH4 promoter whereas there is only one binding site 
in the corresponding region of the human ITIH4 promoter (Figures 4,12 and 4.13). 
It was therefore decided to delete these binding sites from the porcine ITIH4 
promoter to see what effect it would have on the basal levels of transcription. Figure
90
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5.6 shows the location of the LF-Al binding sites in the pig ITIH4 promoter relative 
to each other. They LF-Al sites are found in a region approximately 300-550 bases 
upstream of the pig ITIH4 translation start codon. From 5’ to 3’ the LF-Al sites 
were termed the alpha, beta and gamma.
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5 ' AGCCCCTCTCGCTCCAGAAGTAAGGCATATAGCCATCCTGCTTTGGCCC
CAGCAGAGCGTGCCCCACTCGGGCACCCCAAGGACTGCTGGGTGCCTT
TGGGGCCCCACTGCCCAGTCACTCTGACCTGGCCTCTGGCCCCTGCCTCC
TGGAAGCCAGCCTCTGGCCCTCCTCTGCCTGGCTATCCCTCTGCTTCACC 
CATTCTGGGCTTAA?VGAGAGCTGGCCAGTTCACTGCGTGTCCCCCAGC 3 '
Figure 5.6: Location of the putative LF-Al binding sites with respect to each 
other. The region shown in this figure is from positions -556 to -312 relative to 
the first nucleotide of the translational start codon (+1). The binding sites are 
shown in green.
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5.5.2 Deleting the LF-Al binding sites from the pig ITIH4 promoter
The mutant constructs were created in a series of PCRs designed to knock out each 
binding site and to delete the entire region containing these binding sites (region 
underlined with dotted line in Figure 5.6). The method of creating the mutant 
constructs is illustrated in Figure 5.7.
Although the initial strategy was to use standard primers located in the PCRScript 
vector so that the restriction enzyme sites that had been introduced previously for 
cloning (section 5.1) could be used this was unsuccessful. Therefore, the primers 
that had been used to introduce the restriction enzyme sites at each end were used 
instead. The oligonucleotides to delete the LF-Al binding sites were designed so 
that one half of the oligonucleotide was from one side of the LF-Al binding site and 
the tail of the oligonucleotide was from the other. This resulted in an 
oligonucleotide with the LF-Al binding site missing. In the first set of PCRs the 
two halves of the fusion product were created. Figure 5.8 shows the amplification 
products from each half of the PGR. The expected size of the PGR products was 
approximately 1.3kb for the left-hand PGR and approximately 500bp for the right- 
hand PGR.
The third PGR was carried out to fuse the products of each half of the fusion 
together. The PGR products from the fusion PGR were then cloned in PGRScript and 
sequenced to ensure that the LF-Al binding sites had been deleted. These clones 
were then digested with Kpnl and Xhol to release the insert (Figure 5.9). The insert 
was then cloned in the pGAT3-Basic vector these constructs were subsequently 
analysed in Hep 3B.
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Figure 5,7: Generation of LF-Al mutants. The mutants were made by 
amplifying each half of the promoter by PCR with one primer from each set (the 
central primers in this figure) designed so that they lacked the LF-Al site and 
that their 5’ ends (shown with a red broken line) were complementary to each 
other. The other primers in each set contained engineered restriction enzyme 
sites to facilitate later cloning. PCR 1 and PCR 2 resulted in the creation of two 
PCR products with overhanging ends (red broken line) that were complementary 
to each other. The third PCR was carried out with a low annealing temperature 
for the first 3 cycles to allow the complementary ends to bind to each other. The 
PCR product created from PCR3 was, therefore, the pig ITIH4 promoter lacking 
a LF-Al site or the entire region containing the LF-Al sites.
KpnX
LF-Al
Xhol
V
7
PCR 1 PCR 2
S
s
PCR 3 with low annealing temperature for the first 3 cycles
S L IL
i
Cloning and sequencing o f  the constructs and analysis o f  
expression in Hep 3B
1 2 3  4 M 6  7 8 9 M
1635bp
# #
1 =AALL (PCR 1)
2 = Aa (PCR 1)
3 = A(3 (PCR 1)
4 = Ay (PCR 1)
M = marker
6 = AALL (PCR 2)
7 = Aa (PCR2)
8 = A(3 (PCR 2)
9 = Ay (PCR 2)
Figure 5.8: Amplification of each half of the fusion. Amplification of the 
left side of the fusion (PCR 1) is shown to the left of the marker and 
amplification of the right side of the fusion (PCR 2) is shown to the right of 
the marker. The 1.6kb band of the DNA ladder is indicated with an arrow.
M 1 2 3 4 5 6 7 8
1635bp
M = marker
1 = undigested PPR- 
AALL
2 = digested PPR-AALL
3 = undigested PPR-Aa
4 = digested PPR-Aa
5 = undigested PPR-Ap
6 = digested PPR-AP
7 = undigested PPR-Ay
8 = digested PPR-Ay
Figure 5.9: Clones containing the mutated pig ITIH4 promoter following 
digestion with Kpn\ and Xho\ to release the insert. All digests result in the 
release of a band of approximately 1.7kb. The 1.6kb band of the DNA ladder is 
indicated with an arrow.
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5.5.3 Analysis of the mutated constructs in Hep 3B
Hep3B cells were transfected with each of the constructs and the cells were 
stimulated with 500U IL-6. The cells were harvested 48 hours later and the amount 
of CAT produced measured. The results from these experiments are given in Table 
5.1.
The data from these experiments can be analysed in two ways: first of all the effect 
of the mutation on the inducibility of the constructs and secondly the effect on the 
basal levels of expression.
As shown in Table 5.1, the level of induction of the mutated constructs following 
stimulation with 500U IL-6 varies from 2.3 fold to 4.2 fold. Therefore, it appears 
the mutation has affected the inducibility of the construct to some extent as the wild- 
type construct was induced 6-fold following stimulation with 500U IL-6.
When compared with the wild-type construct it is seen that all the constructs exhibit 
increased basal levels of expression. This is particularly true for the PPR-Ay 
construct whose basal levels of expression are 6-fold higher than the wild-type 
construct. The level of expression of the constructs following stimulation with 500U 
IL-6 does not vary as much when compared to the wild-type in the absence of 
stimulation. In the presence of IL-6 the mutated constructs at best only exhibit a 2.4 
fold increase in expression over the wild-type construct under the same conditions. 
Both the PPR-AALL and PPR-Ay construct have higher levels o f CAT compared to 
the other two constructs when stimulated with IL-6. This suggests that the Ay -LF- 
Al site may be responsible for most of the effects seen with the PPR-AALL 
construct.
A summary of the effect of the mutation on the amount of CAT produced when 
compared with the wild-type construct is given in Table 5.2.
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Table 5.1; Expression of LF-Al mutants in Hep3B. Results are given as mean ± 
SEM. * refers to significant increases in expression (p<0.05 Mann Whitney U 
Test) a) following stimulation with 500U IL-6 and b) when compared with the 
wild-type construct.
Fold increase in expression 
over wild-type construct
Construct No
stimulation
(CAT
(pg/jLig total 
cell protein)
500U IL-6 
CAT (pg/pg 
total cell 
protein)
Fold
increase in 
expression
No
stimulation
500UIL-6
PPR-
CAT3B
1.16 ±0.265 6.83 ±0.183 5.9X*
PPR-AALL 4.38 ± 1.8 15.35 ±2.13 3.5X* 3.77X 2.24X *
PPR-Aa 3.67± 1.1 8.8 ±4.01 2.4X 3.16X» 1.29X
PPR-Ap 2.39 ±0.59 10.1 ±1.01 4.18X* 2.06X 1.46X*
PPR-Ay 7.25 ±0.56 16.47 ±0.91 2.27X 6.25X * 2.41X*
Table 5.2; Effect of deleting putative LF-Al binding sites on the background 
expression and stimulation of the PPR-CAT3B construct in Hep 3B following 
stimulation with IL-6. + refers to enhanced expression compared to the wild- 
type construct. -  refers to no significant change in expression compared to the 
wild-type constmct
Effect on background Effect on stimulation
PPR-AALL ± ±±±
PPR-Aa + -
PPR-AP - ±
PPR-Ay ±± +±+
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Mutation of the putative LF-Al sites was carried out in an attempt to reduce the 
basal level of expression of the construct while maintaining or increasing the 
inducibility of the construct. While I was successful in increasing the amount of 
CAT produced, the mutations have in fact increased the basal levels of expression 
and decreased the inducibility of the constructs. The y-LF-Al site appears to be 
responsible for these changes. In order to draw some conclusions about how the y- 
LF-Al site could be affecting the expression of the pig ITIH4 gene, the region 
absent from the AALL construct was analysed using the transcription factor search 
program Alibaba 2. The results from this analysis are shown in Figure 5.10. The 
results show that there are a number of putative binding sites for the ubiquitous 
transcription factor Spl. Spl has already been reported to associate with other 
inflammation induced transcription factors to modulate gene expression and it can 
affect gene expression in both a positive and negative manner (Look et al., 1995; Li 
et al., 1998b; Ripe et a l, 1999; Uhlar & Whitehead, 1999; Kato et a l, 2000; Ping et 
a l, 2000). In Figure 5.10 it can be seen that a number of the putative Spl sites 
overlap with the putative LF-Al sites including the y-site. Therefore, it could be 
hypothesised that the removal of the y-LF-Al site could disrupt the basal 
transcription machinery in some manner by affecting the binding of other 
transcription factors in this region.
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CHAPTER 5: RESULTS
Summary o f  results
1. Porcine ITIH4 promoter is induced by 500U IL-6, Induction by IL-6 is dose- 
dependent.
2. Porcine ITIH4 promoter is not induced by IL-1 at concentrations greater than 
50U. This result suggests the porcine ITIH4 gene is a Class II acute phase 
protein.
3. A combination of IL-1 and IL-6 inhibits the IL-6 induced activation of the 
porcine ITIH4 promoter. This result is further confinnation that pig ITIH4 is a 
Class II acute phase protein.
4. Hep 3B appears to be a usable system for studying the porcine ITIH4 promoter.
5. Primary porcine hepatocytes can be transfected with GFP.
6. A number of mutated constructs were made in an attempt to reduce the basal 
level of expression seen with the PPR-CAT3B while maintaining or increasing 
the inducibility of the construct. However, analysis of these constructs in Hep 
3B revealed that the basal level of expression was increased while the 
inducibility of the constructs was decreased.
The ability to transfect the primary porcine hepatocytes with GFP suggested that in 
the future this reporter gene could be used for studying gene expression in vitro. 
The main advantage of GFP reporter gene over the CAT reporter gene is that it 
would allow real-time analysis. In addition, if a suitable method for quantitating 
GFP fluorescence could be established then another advantage of the GFP reporter 
gene would be that quantitating changes in gene expression would be less labour 
intensive.
In this chapter a number of constructs have been described with varying levels of 
expression in Hep 3B. It was thought that these constructs could also be used to 
evaluate GFP as a reporter gene in Hep 3B. The following chapter describes the 
evaluation of GFP as a reporter gene of transient inducible gene expression.
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Chapter 6; Evaluation of GFP as a reporter gene 
of inducible gene expression
6.1 Introduction
In Chapter 5 use of the CAT reporter gene for analysing gene expression of the 
porcine ITIH4 gene was reported. However, this method for studying gene 
expression is laborious and expensive. In particular, it is not useful for studying 
inducible gene expression, as the cells have to be harvested at pre-detennined time 
points and so although changes in gene expression can be seen, the time these 
changes occur cannot be accurately determined. More importantly for us, because 
CAT is a stable protein which accumulates in the cell over time, the decrease in gene 
transcription and subsequently protein synthesis seen during resolution of the acute 
phase response in vivo will not be seen.
The green fluorescent protein (GFP) allows real-time analysis of gene expression in 
vitro as it is synthesised by the cells themselves and no exogenous substrates or co­
factors are required for its synthesis or detection. In addition, there have also been 
reports of GFP being used as a reporter gene in vivo (Chiocchetti et al. 1997). One 
of the main attractions of GFP is that it can be easily detected using a fluorescence 
microscope or UV light. There are several GFP mutants now available that have 
been created for optimised expression in mammalian cells as well as destabilised 
variants that can be used for studies of inducible gene expression since GFP itself is 
a very stable protein. In order to evaluate GFP as a reporter of gene expression in 
Hep 3B we used the promoter of the pig ITIH4 gene and the y-LF-Al mutant, as 
well as two forms of GFP -  a stabilised and destabilised variant.
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6.2 Transfection o f COS-7 and Hey 3B cells with C3:EGFP and 
GFP-C
6.2.1 Optimising the transfection conditions
In order to establish the system, COS-7 cells, a monkey kidney derived cell line, 
which has previously been reported to express GFP (Sakai et a l,  1997; Yano et a i, 
1997), was used. To determine the optimum amount of DNA to use in the 
transfection experiments the cells were seeded in 24 well plates and transfected with 
various amounts of the control vectors C3:EGFP and GFP-C ranging from 0.5pg to 
2]Lig. Similarly, Hep 3B cells were also transfected with the same amount o f the 
control GFP vectors. Following analysis of the cells over a 72 hour period it was 
deemed that 0.75jug DNA was suitable for the transfections as larger amounts of 
DNA were inducing cell death. Figure 6.1 shows some images from these 
experiments. It is seen that Hep 3B cells were transfected as well as COS-7 cells but 
the kinetics of expression of the two GFP vectors is different. The destabilised 
variant of GFP appeared much brighter compared to the stabilised variant. In 
addition, transfection with the C3:EGFP vector resulted in higher numbers of 
fluorescent cells compared with the GFP-C construct. These observations were 
observed in both COS-7 and Hep 3B cells at all time points examined. These 
observations were examined further in Hep 3B.
6.2.2 Comparison of the kinetics of expression of C3:EGFP and GFP-C in 
Hep3B
The C3:EGFP vector contains a stabilised variant of the enhanced green fluorescent 
protein. It is a vector that has been designed to allow cloning of heterogeneous 
proteins to the C-terminal of GFP. In this vector the Cytomegalovirus (CMV) 
promoter drives expression of the GFP gene. The GFP-C vector contains a 
destabilised variant of enhanced GFP with a half-life of 2 hours. This variant of 
GFP was purchased to enable studies of transient inducible gene expression to be
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Figure 6.1: GFP expression in Hep3B and COS-7 cells. The images on the left 
side of the figure show Hep 3B cells transfected with either the C3:EGFP 
construct (contains a stabilised variant of GFP) or GFP-C (contains a destabilised 
variant of GFP). The images on the right show COS-7 cells transfected with the 
same two vectors. In both cell lines it is clear that there are more fluorescent 
cells in the images from cells transfected with the C3:EGFP vector. Cells 
transfected with the GFP-C vector do appear to be brighter than those transfected 
with the C3:EGFP vector.
C3 : EGFP Hep3B 48h C3 EGFP COS-7 48h
GFP-C Hep3B 48h GFP-C COS-7 48h
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carried out. This vector has been designed as a control vector to optimise 
transfection conditions. The GFP gene in this vector is under the control of the 
SV40 promoter.
Due to the fact that the two vectors under examination contained different variants of 
GFP with GFP expression being driven by a different promoter, the expression of 
GFP from each vector was examined every 24h over a 120 hour period using a 
fluorescence microscope. Analysis of the cells was carried out in two ways:
1. The number of fluorescent cells per well was counted. However, if  this number 
was high, then an estimate of the number of fluorescent cells in a field of view 
was taken.
2. The fluorescence from a selection of cells was quantitated.
Following transfection of Hep 3B with C3:EGFP and GFP-C a cell count of 
fluorescent cells was taken as illustrated in Figure 6.2. Over time the number of 
fluorescent cells in wells transfected with both the C3:EGFP and GFP-C construct 
increases until 72h when the number stabilises. However, the number o f fluorescent 
cells in wells transfected with the GFP-C construct is much lower than wells 
transfected with the C3:EGFP construct. At 72h there are only 5-6 fluorescent cells 
in a field of view compared to 30+ cells in wells transfected with the C3:EGFP 
vector at the same time point. These differences are evident in images taken from 
the cells over a 72h period. (Figure 6.3).
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Figure 6.2: Number of fluorescent cells per field of view in Hep 3B cells 
transfected with either C3: EGFP or GFP-C. Arrows indicate cell counts of more 
than 30 cells. This graph shows that at all time points there are more fluorescent 
cells in wells transfected with the C3:EGFP vector compared to the GFP-C 
vector. It also appears that the number of fluorescent cells appears to increase 
with time although this can only be inferred from analysis of cells transfected 
with the GFP-C vector as fluorescent cells transfected with the C3:EGFP vector 
were too numerous to count.

Figure 6.3: Transfection of Hep 3B cells with C3:EGFP and GFP-C. This figure 
shows representative images from different fields of view taken over a 72h 
period. Images on the left show cells transfected with the C3:EGFP vector and 
images on the right show cells transfected with the GFP-C vector. At 24h post­
transfection not many fluorescent cells can be seen from cells transfected with 
either of the two vectors. However, cells transfected with the GFP-C vector do 
appear brighter than those transfected with the C3:EGFP vector. By 48h the 
differences are more pronounced and it can be seen that there are more 
fluorescent cells from cells that have been transfected with the C3:EGFP vector 
compared to those transfected with the GFP-C vector. However, cells 
transfected with the GFP-C vector appear much brighter compared to those 
transfected with the C3:EGFP vector. These differences are still apparent 72h 
post-transfection.
C3 : EGFP 24h GFP-C 24h
03 ; EGFP 48h GFP-C 48h
C3 : EGFP 72h GFP-C 72h
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The images taken over the 72h period also suggest that the fluorescence from the 
cells transfected with the GFP-C vector is much higher than that of cells transfected 
with the C3:EGFP construct. To quantitate the levels of fluorescence images from at 
least four different fields of view were taken from the wells transfected with the 
GFP-C and C3:EGFP constructs and the fluorescence intensity from a selection of 
cells was taken.
These results showed that the expression and the kinetics of expression appeared to 
be different for the two vectors. In cells transfected with the C3:EGFP vector a large 
number of fluorescent cells are visible at all time points but the fluorescence 
intensity at 24 hours is quite low (Table 6.1 and Figure 6.3). By 48 hours however, 
the fluorescence intensity appears stronger and the level of fluorescence intensity 
appears to peak around 72h post-transfection after which it stabilises. A statistical 
analysis by ANOVA (with Bonferroni correction) revealed that the only significant 
increases in expression were seen between 48h and 72h and between 24h and 120h 
and 48h and 120h.
In contrast, cells transfected with GFP-C always seem to fluoresce more strongly 
than those transfected with the C3:EGFP construct (Table 6.1 and Figure 6.3) 
although the number of cells fluorescing is much lower compared to that of the 
C3;EGFP construct (Figure 6.2 and 6.3). Cells transfected with GFP-C are almost 4 
times more fluorescent than those transfected with C3:EGFP. The fluorescence 
intensity of cells transfected with GFP-C also increases with time and also peaks at 
72h post-transfection after which time the fluorescence intensity stabilises (Table 
6.1). However, a statistical analysis by ANOVA (with Bonferroni correction) 
showed that there was no significant difference between the fluorescence intensity at 
any time point.
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Table 6.1: Comparison of the levels of fluorescence exhibited by the stabilised 
GFP (C3:EGFP) and destabilised GFP (GFP-C) control vectors in Hep 3B 
24-120h post-transfection
Mean fluorescence per cell (pixels) post-transfection
Construct 24h 48h 72h 96h 120h
C3:EGFP 6942 ± 
772.5
7349.9 ± 
606.3
11533.6 ± 
970.3
9380.1 ± 
831.5
13592.8 ± 
2392.5
GFP-C 23494.8 ± 
5968.7
26507.5 ± 
4590.5
49384± 
8462.8
40089.3 ± 
8018.3
47006.3
±10853.8
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The results of these experiments did lead to some concern that the destabilised 
variant of GFP may not be suitable for studying transient inducible gene expression 
due to the low number of fluorescent cells present in cells that were transfected with 
the destabilised variant. It has been reported that 10 000 molecules of GFP are 
necessary for accurate detection (Patterson et al,, 1997). Therefore, there was 
concern that the acute phase promoters, with their typically low basal levels of 
expression, would not be strong enough to allow enough GFP molecules to 
accumulate in the cell for detection and that this would be exacerbated by the 
destabilised nature of the GFP molecule. While this “problem” could be 
advantageous in the sense that basal levels of expression too low for detection may 
allow induction of the gene to be observed, it would cause problems if using GFP to 
quantitate levels of gene expression as it would not be possible to evaluate how well 
the construct is being regulated.
However, I could not rule out the possibility that the differences between the two 
control vectors were due to the promoters driving expression of the GFP gene since 
there have been reports of the CMV promoter functioning better than the SV40 
promoter in vitro in different cell lines (Sutherland & Williams, 1997; Zarrin et al., 
1999). The acute phase promoters, being liver-specific, could result in higher levels 
of GFP expression compared to the SV40 promoter and hence, a larger number of 
fluorescent cells. Therefore, it was decided to use the promoters of the pig ITIH4 
gene and the Ay-LF-Al mutant to drive expression of the GFP gene and to evaluate 
the system as a reporter of inducible gene expression.
6.3 Preparation o f  the GFP constructs
To detennine if the acute phase promoters described in this thesis could drive 
expression of GFP with acute phase kinetics the ability of the promoters to drive the 
expression of the stabilised variant of GFP as well as the destabilised variant was 
examined. Therefore, for these studies I examined the ability of the porcine ITIH4 
promoter as well as the Ay-LF-Al mutant to drive expression of the GFP mutant.
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The Ay-LF-Al mutant was chosen for these analyses because this promoter had 
given the highest levels of expression of the CAT gene. Due to the fact that the 
C3:EGFP vector was not designed for promoter studies it had to be slightly modified 
to allow the EGFP gene expression to be driven by the acute phase promoters rather 
than CMV.
6.3.1 Modification of the C3:EGFP vector
The C3:EGFP vector was modified by removing the CMV promoter and replacing it 
with the acute phase promoters. The C3;EGFP vector was digested with Vspl and 
Nhel to remove the promoter region as illustrated in Figure 6.4. This was then 
replaced with one of the acute phase promoters,
6.3.2 Amplification of the acute phase promoters for cloning in the modified 
C3:EGFP vector
For these analyses the following acute phase promoter sequences were used: the pig 
ITIH4 promoter (Chapter 4) and the pig ITIH4 promoter without the y-LF-Al site 
(section 5.5.2). For cloning in the modified C3:EGFP vector, the promoters were 
amplified again by PGR using primers that had engineered Vspl and Nhel sites at 
each end. Figure 6.5 shows the results of this PCR and all of the reactions give 
products of the expected size o f approximately 1.8kb.
The PCR products were cloned into PCRScript and transformed into XL-10 
competent cells. Following transformation and selection on X-gal/IPTG, colonies 
were screened for the presence of the insert by PCR using primers NHl and NH2, 
which amplify the middle section of the pig ITIFI4 promoter.
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EGFP,
orEYFPpECFP-CI 
pEGFP-Cl/2/3 
pEYFP-CI
HSVTK 
pofi'A
SV40 on
The region between the 
yspl and Nhel sites was 
removed and replaced 
with the promoter o f  the 
porcine 1TIH4 gene
MCS
Figure 6.4: Modification of the C3:EGFP expression vector
M 1 2 3
1635bp —
M = marker
2 = Amplification o f  porcine 
ITIH4 promoter with 
introduction o f  Vsp\ and Nhe\ 
sites
3 = Amplification o f  PPR-Ay 
promoter with introduction o f  
Vsp\ and Nhe\ sites
Figure 6.5: Amplification of the acute phase promoters for cloning in the 
modified C3:EGFP vector. The expected size of the PCR products is 1.7kb. 
Other bands seen may be due to non-specific binding of the primers to the 
template DNA.
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6.3.3 Cloning the acute phase promoters into C3:EGFP
Once positive clones had been identified the insert was cut from the PCRScript 
vector using Vspl and Nlwl. The bands of the correct size were cut from the gel and 
the purified fragments were then ligated to the previously digested and purified 
C3:EGFP vector and transformed into XL-10 competent cells. Following incubation 
overnight at 37°C, random colonies were picked from each plate and plasmid DNA 
was obtained. To check if  the colonies contained the correct insert the DNA was 
digested with Sad. This enzyme were known to have only one restriction site in the 
C3:EGFP vector as well as only cutting the ITIH4 promoter once. Figure 6,6 shows 
the results of some of these digests and the identification of positive clones. These 
results were confirmed by PCR using internal primers.
The constructs were named as follows:
Construct
PPR-EGFP
Ay-EGFP
Pig ITIH4 promoter as described in Chapter 4 and Chapter 5 
Pig ITIH4 promoter lacking the y-LF-Al site (section 5.5.2)
The promoters from these constructs were also cloned in the GFP-B vector as 
described in the following section.
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Gel A GelB
M 1 2 3 4 5 6 7
Figure 6.6: Identification of clones containing the pig ITIH4 promoter or the PPR- 
Ay promoter in the modified C3:EGFP vector.
Gel A: Top row: Screening for positive clones containing the pig 1TIH4 promoter by 
digesting plasmid DNA with Sad. Expected size of fragments are 2-3kb and 4-5kb. 
Putative positives are (indicated with arrows) give a bright band of approximately 
5kb and a fainter band of approximately 3kb.
Bottom row: Screening for positive clones containing the PPR- Ay promoter. 
Putative positives are expected to give fragments of the same size as those of the pig 
1TIH4 promoter and are shown in lanes 1 and 12 (indicated by arrows).
Gel B: PCR to confirm that the putative positive clones are positive. Expected size 
of PCR product is approximately 500bp. * = positive clones 
Lane 1 = Clone 1 (pig ITIH4 promoter)
Lane 2 = Clone 2 (pig 1TIH4 promoter 
Lane 3 = Clone 3 (pig 1T1H4 promoter 
Lane 4 = Clone 8 (pig 1T1H4 promoter 
Lane 5 = Clone 9 (pig 1T1H4 promoter)
Lane 6 = Clone 1 (PPR- Ay promoter)*
Lane 7 = Clone 12 (PPR- Ay promoter)*
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6.3.4 Cloning the acute phase promoters in GFP-B
The pig ITIH4 promoter and the LF-Al-Ay mutant cloned in the C3:EGFP vector 
were also cloned into the Kpnl and Xhdi sites in the MCS of the GFP-B vector. The 
promoters had already been amplified with a Kpnl site at the 5’ end and a Xhol site 
at the 3 ' end for cloning in the pCATSB vector (section 5.1). Therefore, plasmid 
DNA from the PCRScript vectors containing the acute phase promoters with the 
engineered Kpnl and XJrol sites was prepared and digested with Kpnl and Xhol. 
Similarly, the GFP-B vector was also digested with Kpnl and Xhol. The promoters 
were then ligated to the digested GFP-B vector and transformed into XL-10 
competent cells. Following transformation, random colonies were screened for the 
presence of the insert. Figure 6.7 shows the results of these analyses and the 
identification of positive clones.
The constructs were named as follows:
Construct
PPR-dEGFP
Ay-dEGFP
Pig ITIH4 promoter as described in Chapter 4 and 5 
Pig ITIH4 promoter lacking the y-LF-Al site (section 5.5.2)
DNA from all the constructs was prepared as described in section 2.5.1.2 in 
preparation for transfection in Hep 3B.
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Figure 6.7: Identification of clones containing the porcine ITIH4 promoter or the 
PPR-Ay promoter in the GFP-B vector
Clones containing the porcine ITIH4 promoter were identified by PCR (Gel A). 
Only Clone 2 (indicated) appears positive. This result was confirmed by 
digesting DNA from this clone with Kpnl m à X h o l to release the insert of 1.8kb 
(Gel B). Clones containing the PPR-Ay promoter were identified by digesting a 
number of clones with Kpnl to linearise the plasmid. This result was confirmed 
by PCR as shown in Gel C.
Gel A
1635bp
Gel B
M 1
G e l C
M l  2 3 4 M
1635bp
394bp
M = marker
1 -3 = PCR on putative 
positive clones
4 = negative control
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6.4 Transfectins Hep 3B with the stabilised and destabilised 
variants o f  GFP under the control o f  an acute vhase promoter
For analysis. Hep 3B cells were transfected with 0.75pg of each construct as 
described in sections 2.5.2.5.2. Following a 24 hour incubation period the cells were 
analysed using a fluorescence microscope and the number of fluorescent cells 
counted. Images were also taken at this time point and the fluorescence intensity of 
the cells measured. The cells were then stimulated with cytokines and examined 24h 
and 48h later. At each time point an estimate of the number of fluorescent cells in a 
field of view or per well if the number of fluorescent cells was low was taken and 
the fluorescence intensity from a number of cells was also measured.
6.5 Expression o f EGFP and d2EGFP under the control o f  an 
acute vhase vromoter in H ey 3B
The expression of GFP under the control of the acute phase promoters resembled 
that of the control constructs (section 6.2.2) with a high number of fluorescent cells 
in wells transfected with the stabilised variant and a lower number of fluorescent 
cells in wells transfected with the destabilised variant. The cells transfected with the 
destabilised variant also appeared to have higher levels of fluorescence compared to 
the stabilised variant (Figures 6.8 and 6.9 compared with Figures 6.13 and 6.14). 
The fluorescence intensity of the cells was measured arbitrarily (as described in 
section 2.5.2.10), and some variation is seen when experiments are repeated on 
different days. Therefore, for analysis of these results I examined the changes in 
expression rather than examining the exact levels of fluorescence.
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Figure 6.8: Representative image of Hep 3B cells transfected with the PPR- 
EGFP construct before and after stimulation with IL-6. 24h post-transfection (Oh 
post-stimulation) only a few fluorescent cells can be seen. The fluorescence 
from these cells is not very strong. 24h later, the number of fluorescent cells has 
increased and the cells appear much brighter. There appear to be more 
fluorescent cells from cells transfected with C3:EGFP and stimulated with IL-6 
compared to cells receiving no stimulation, both 24h and 48h post-stimulation. 
In addition cells that have been stimulated with IL-6 appear brighter than those 
receiving no stimulation.
Figure 6.9: Representative image of Hep 3B cells transfected with the Ay-EGFP 
construct before and after stimulation with IL-6. 24h post-transfection (Oh post­
stimulation) only a few fluorescent cells can be seen. The fluorescence from 
these cells is not very strong, although they do appear much brighter compared to 
cells transfected with PPR-EGFP at the same time period. 24h later, the number 
of fluorescent cells has increased and the cells appear much brighter. There 
appear to be more fluorescent cells from cells transfected with C3:EGFP and 
stimulated with IL-6 compared to cells receiving no stimulation, both 24h and 
48h post-stimulation. In addition cells that have been stimulated with IL-6 
appear brighter than those receiving no stimulation.
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6.5.1 Expression of PPR-EGFP and Ay-EGFP in Hep 3B
Cells in wells transfected with the stabilised variant of GFP under the control of the 
pig ITIH4 promoter or the pig ITIH4 promoter without the y-LF-Al site were 
already fluorescent 24h post-transfection (Oh post-stimulation in Figure 6.10). This 
result confirms the earlier experiments with the CAT reporter gene where it 
appeared the pig ITIH4 promoter was capable of driving constitutive expression of 
the reporter gene. Following stimulation with 500U IT-6 the fluorescence intensity 
increases with time. There is a significant increase in fluorescence intensity in cells 
transfected with PPR-EGFP and stimulated with IL-6 at both 24 hours and 48 hours 
post-stimulation (p<0.05 Mann Whitney U Test). Cells transfected with the Ay- 
EGFP construct also showed a small increase in fluorescence following stimulation 
with IL-6. However, these increases were not significant (Figure 6.10 a and b).
There were, however, some differences between the results in these experiments and 
those obtained with the CAT reporter system. The level of induction following 
stimulation with IL-6 was much lower compared to that seen with the CAT 
constructs. While stimulation of the PPR-CAT3B construct with 500U IL-6 resulted 
in a 6-fold increase in CAT expression, stimulation of the PPR-EGFP construct only 
resulted in a 1.3-fold increase in expression. Similarly, there was only a 1.5-fold 
(24h) and 1.6 fold (48h) increase in fluorescence in cells transfected with the Ay- 
EGFP construct following stimulation. A 2.4-fold increase in CAT was seen in cells 
transfected with PPR-Ay-CAT3B following stimulation compared to cells that 
received no stimulation. This suggests that quantitating GFP fluorescence with an 
imaging system is not as sensitive for detecting changes in gene expression as the 
CAT ELISA.
The number of fluorescent cells was also counted at each time point. It was thought 
that an increase in gene expression would be associated with a corresponding 
increase in cell number. This was because, as stated previously, a certain number of 
molecules of GFP need to be present in the cell to allow accurate detection of
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Figure 6.10 a and b: Expression of PPR-EGFP (top (a)) and Ay-EGFP (bottom 
(b)) in Hep 3B following stimulation with 500U IL-6. * refers to a significant 
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fluorescence. Therefore, the increased expression of GFP in cells following 
stimulation should allow the detection of fluorescence from cells that were 
previously expressing GFP at levels too low for detection. The results shown in 
Figure 6.11 not only agree with this but also agree with the results obtained with the 
CAT expression system. The lowest number of fluorescent cells was seen in wells 
transfected with the PPR-EGFP construct. Following stimulation the number of 
fluorescent cells increased. At 24 and 48 hours the number of fluorescent cells was 
roughly equivalent to those of cells transfected with the Ay-EGFP construct. 
Stimulation of cells transfected with the Ay-EGFP construct resulted in an increase 
in the number of cells to an extent that the numbers appeared to be similar to those 
seen in cells transfected with the C3:EGFP construct. Therefore, this method of 
analysis resembles more closely what was seen with the CAT reporter system than 
quantitating the fluorescence intensity o f the cells.
6.5.2 Expression of PPR-dEGFP and Av-dEGFP in Hen 3B
The results from the experiments with the stabilised variant of GFP showed that the 
acute phase promoters were capable of driving expression of the stabilised variant of 
GFP. Although the results suggested that there could be problems in quantitating the 
changes in gene expression, this problem could be due to the high levels of GFP 
present initially and the accumulation of GFP in the cell. Subsequent increases in 
GFP expression may therefore be difficult to visualise and detect. This problem 
would not have been expected with the destabilised variant due to the fact that the 
protein is not accumulating in the cell.
As before, the cells were examined over a 72h period post-transfection. 
Examination of cells transfected with both of the destabilised constructs revealed no 
fluorescent cells 24h post-transfection. In cells transfected with the PPR-dEGFP 
construct, fluorescent cells could be detected 24h post-stimulation and an increase in 
fluorescence was seen following stimulation with 500U IL-6 at both 24 and 48h 
post-stimulation. However, this increase was only significant at 48h (p<0.05 Mann
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stabilised variant of GFP under the control of the acute phase promoters. DO = 
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Whitney U Test). The increase in fluorescence was 2.4-fold which was more than 
seen with the PPR-EGFP construct at this time point (Figure 6.12)
Cells expressing dEGFP under the control o f the Ay-LF-Al mutant were also visible 
24h post-stimulation. However, no significant increases in fluorescence were seen 
in cells when stimulated with 500U IL-6 at any time point (Mann Whitney U Test) 
(Figure 6.12).
Although, as mentioned earlier, I did not analyse the actual values obtained in these 
experiments due to the arbitrary nature of the measurements, it was clear from the 
images of the cells (and also suggested by the measurements) that the fluorescence 
intensity of the dEGFP constructs was higher than that of the stabilised GFP 
constructs. This finding is in agreement with the earlier observation that the GFP-C 
vector had higher levels of fluorescence compared to the C3:EGFP vector (Figures 
6.13 and 6.14 compared with Figure 6.3).
The number of fluorescent cells in wells transfected with the dEGFP constructs was 
also examined. As with the control vector, the number of fluorescent cells was 
much lower compared to those transfected with the stabilised GFP under the control 
of the acute phase promoters. However, in agreement with the observations reported 
for the stabilised acute phase GFP constructs and the CAT reporter system, the wells 
with the lowest number of fluorescent cells were those transfected with the PPR- 
dEGFP construct (no stimulation) and the wells with the highest number of 
fluorescent cells were those transfected with the Ay-dEGFP construct and stimulated 
with lL-6 (Figure 6.15).
107
90000
80000
=  70000 
u
60000
50000
40000
30000
« 20000
10000
24h 48h
T im e p o s t- s t im u la t io n
50000
_  40000
&
% 30000
.Sa.
Sc
S 20000
é
oa
I  10000
24h
Time post-stim ulation
iNS
lL-6
48h
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Figure 6.13: Representative image of Hep 3B cells transfected with the PPR- 
dEGFP construct before and after stimulation with IL-6. In the absence of 
stimulation few cells can be seen at any time point. Stimulation with IL-6 results 
in the appearance of a few fluorescent cells. The number of fluorescent cells is 
much lower compared to that seen in cells transfected with the stabilised variant 
of GFP. However, the fluorescence from cells transfected with the destabilised 
variant appears much stronger compared to that from cells transfected with the 
stabilised variant (c.f. Figure 6.9).
Figure 6,14: Representative image of Hep 3B cells transfected with the Ay- 
dEGFP construct before and after stimulation with IL-6. In the absence of 
stimulation few cells can be seen at any time point. Stimulation with IL-6 results 
in the appearance of a few fluorescent cells. The number of fluorescent cells is 
much lower compared to that seen in cells transfected with the stabilised variant 
of GFP. However, the fluorescence from cells transfected with the destabilised 
variant of GFP appears much stronger compared to that from cells transfected 
with the stabilised variant (c.f. Figure 6.10).
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Figure 6.15: Number of fluorescent cells from Hep 3B cells transfected with the 
destabilised variant of GFP under the control of the acute phase promoters. DO = 
Ay and NS = no stimulation. Over time, the number of fluorescent cells increases 
both in the presence and absence of IL-6. However, stimulation with IL-6 does 
result in an increase in the number of fluorescent cells when compared with cells 
receiving no stimulation.
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Summary o f  results
1. Both stabilised and destabilised variants of GFP under control of a viral 
promoter are expressed in Hep 3B.
2. Both stabilised and destabilised variants of GFP under the control of the pig 
ITIH4 promoter and a mutated version (PPR-Ay) are also expressed in Hep 3B.
3. Although changes in the levels o f fluorescence following stimulation of the 
transfected cells with IL-6 could be detected these changes were much less than 
seen with the CAT reporter system.
4. Counting the number of fluorescent cells in the presence and absence of 
stimulation agreed with the hypothesis that following stimulation there would be 
an increase in the number of fluorescent cells due to the ability to detect 
fluorescence in cells where the levels had previously been too low for detection. 
The results from this analysis were also in agreement with those of the CAT 
reporter system, in terms of the relative strength and inducibility of the two 
promoters examined.
In conclusion, while GFP could be used as a means of visualising inducible gene 
expression, quantitating its fluorescence is more difficult. A combination of the 
arbitrary nature of the measurements, the small changes in fluorescence that are 
detected, the heterogeneous nature of fluorescence between individual cells, the need 
to analyse individual cells and the variation in day to day experiments complicates 
quantification of inducible gene expression using GFP as a reporter gene. Another 
method of quantitation, such as FACS, may be more suitable for quantitating the 
changes in fluorescence.
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Chapter 7: Discussion
This project had three main aims:
1. Sequencing and analysis of the 30kh fragment containing the human CRP 
gene
2. Isolation and characterisation of the promoter of the major acute phase 
protein in pigs
3. Evaluation of GFP as a reporter of inducible gene expression.
From these analyses it was hoped to develop an improved acute phase expression 
vector based on the CRP gene for use in transgenic mice as well as a modified 
expression vector based on either the human CRP gene or the porcine ITIH4 
gene for use in pigs. The development of GFP as a reporter system would have 
facilitated these studies.
Chapter 3 described the sequencing and analysis of the 30kb CRP fragment and 
the identification of a number of sequences that may be involved in the negative 
regulation of this gene and the sexually dimorphic pattern of the human CRP 
gene that is seen in transgenic mice. In Chapter 4, the isolation of the promoter 
of the porcine ITIH4 gene was described. Once this sequence had been isolated 
it had been planned to develop the acute phase expression vector for use in pigs 
using the information we had gained from analysis of the 30kb CRP fragment. 
However, due to the fact that these promoters were completely different, we 
instead concentrated on characterising the promoter of the porcine ITIH4 gene 
and establishing an in vitro system for its analysis (Chapter 5). Rather than 
comparing the porcine ITIH4 promoter with the hiunan CRP promoter, the 
porcine ITIH4 promoter was compared with its human homologue in an attempt 
to identify sequences that would allow modification of either the porcine ITIH4 
promoter or the human CRP promoter. Sequences of interest were those for 
responsible for increased inducibility and/or low basal levels of expression of the 
ITIH4 gene. Finally, to analyse these sequences we evaluated GFP as a reporter 
gene of inducible gene expression using the acute phase promoters to drive 
expression of the gene (Chapter 6).
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The results from these experiments give new insight into the factors regulating 
expression of acute phase proteins as well as an evaluation of a number of in vitro 
systems for studying the acute phase response. In this chapter, these findings and 
their contribution to the further understanding of the acute phase response will be 
discussed.
7,1 Seauendns and analysis o f  the 30kb frasment containins the 
human CRP sene
Sequencing the 30kb fragment containing the human CRP gene was deemed 
necessary in order to identify the sequences necessary for tightly controlled 
expression of the CRP gene and for parallel studies to modify the expression vector 
for use in pigs. The aim of the sequence analysis was to identify elements that are 
responsible for the low basal levels of expression of the human CRP gene, as well as 
those responsible for the increased basal levels of expression of the CRP/GM-CSF 
transgene in male transgenic mice. The results from this analysis could be used to 
design a more tightly controlled expression vector based on either the promoter of 
the human CRP gene or the porcine ITIH4 gene.
Genomic strategies to identify mammalian regulatory sequences were reviewed 
recently by Pennacchio & Rubin (2001). Some of the points raised in this review 
will be discussed here in relation to the analysis of the 30kb fragment containing the 
human CRP gene.
The first point raised by Pennacchio & Rubin (2001) is that analysis of non-coding 
DNA with a view to identifying regulatory elements and predicting their function is 
extremely difficult compared to the analysis of coding DNA where function can 
sometimes be predicted from sequence analysis alone. Analysis of the 30kb 
fragment using NIX showed that at least 25kb of the fragment is composed of non­
coding DNA. Therefore, sequence analysis alone, as it does not take into account 
other factors such as DNA bending, conformation changes, chromatin remodelling.
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will not be sufficient to identify regulatory elements and needs to be carried out in 
parallel with functional studies.
Early studies to understand the regulation of the human CRP gene have been 
experimental based (Arcone et al.  ^ 1988; Toniatti et ah, 1990; Murphy et ah, 1995). 
The study by Murphy et ah (1995), however, revealed that functional studies need to 
be carried out in transgenic mice as constructs sufficient for controlled expression in 
vitro were not sufficient for controlled expression in vivo. As transgenic mice are 
expensive to produce and maintain, as well as requiring individuals with expertise to 
generate and analyse the mice, this may in part explain why, since the mid-1990s, 
very few papers have been published on the molecular aspects of the regulation of 
the human CRP gene.
In the last few years, the completion of the sequencing of mammalian genomes and 
the availability of transcription factor search programs and databases (for example, 
the TRANSFAC (Wingender et ah, 2001) and COMPEL (Kel-Margoulis et ah, 
2000) databases) means that computational analysis is another means for analysing 
non-coding DNA for regulatory elements (reviewed by Pennacchio & Rubin, 2001). 
This was the approach that was employed for analysing the 30kb fragment. 
Pennacchio & Rubin (2001) describe three strategies for computational sequence 
analysis of non-coding regions. The main strategy employed by us was using 
information from sequence analyses of other acute phase genes or genes regulated in 
a similar manner to acute phase genes to predict regions of the 30kb fragment that 
may be important for its regulation. It was evident from the initial analysis of the 
30kb fragment, as described in section 3.3.2, that it would not be possible to predict 
regions that could be important for regulation of the CRP gene by this approach 
alone. Therefore, the results described in Chapter 3 are at the moment speculative 
and a functional analysis needs to be carried out to confirm the predictions.
As mentioned earlier this functional analysis will need to be carried out in vivo. As 
it was not possible for us to make new lines of transgenic mice we began to
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investigate an alternative means for analysing the 30kb fragment in vivo. During the 
course of this project it was reported that CRP is expressed in the human respiratory 
tract (Could & Weiser, 2001). We have now begun investigations (in collaboration 
with Dr Weiser) to see if  we can detect human CRP in the respiratory tract of our 
CRP transgenic mice. Preliminary data show that the CRP transgene is being 
expressed in cells of the respiratory tract of the transgenic mice. Therefore, in the 
future it may be possible to deliver the constructs to these cells using a genetically 
engineered respiratory virus. This would be an alternative to making transgenics 
and would facilitate the in vivo study of a larger number of constructs.
Analysis of the 30kb fragment resulted in the identification of a number of putative 
regulatory elements that may responsible for the low basal levels of expression of 
the CRP gene, as well as those that may be responsible for the increased expression 
of the CRP transgene in male transgenics. The CT rich region found about 2kb 
upstream of the human CRP gene was particularly interesting because a similar type 
of element, found in the promoter of a heat-shock gene, was shown to have an 
important role in the regulation of this gene (Glaser et al., 1990). One of the ways 
this region was thought to affect gene expression was by the formation of a 
conformational structure known as H-DNA (reviewed by Wells et at., 1988). The 
CRP promoter has already been described as having elements similar to those found 
in heat shock promoters (Arcone et al., 1988). Therefore, it was interesting that the 
CT rich region present in the 30kb fragment also has the potential to adopt the H- 
DNA structure due to the presence of a mirror repeat (Figure 3.15). If this structure 
was formed in vivo there is a strong possibility that transcription factors binding in 
its vicinity would be affected. It is particularly noteworthy that a putative silencer 
element would be affected by the formation of this structure. Since formation of H- 
DNA is dependent on the pH and/or high helicity of the DNA, this may affect when, 
for example, transcription factors can bind to the silencer element and consequently 
would determine when transcription of the CRP gene will occur.
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If these elements were shown to be functional then they could be used to modify 
expression of the pig ITIH4 gene. In Chapter 5 it was described how a comparative 
genomic analysis was carried out to identify, regulatory elements responsible for the 
lower levels of expression and inducibility of the human ITIH4 gene compared with 
the pig ITIH4 gene. This analysis was carried out in order to decrease the basal level 
expression seen with the section of the pig ITIH4 promoter that I had isolated. An 
alternative approach would be to make a series of deletion constructs of the pig 
ITIH4 promoter, as done for the human CRP promoter by Arcone et a l  (1988) to 
identify the minimal sequences required for promoter activity and inducibility of the 
gene. The promoter of the pig ITIH4 gene could then be modified by introducing 
the CT rich element or the silencer element, Haecker et al. (1995) reported that the 
silencer element found in the promoter of the hen ovalbumin gene was position 
independent, could function upstream or downstream of a reporter gene and was 
able to affect the promoter activity of a heterologous gene. Analysis of the promoter 
region of the pig ITIH4 gene did not reveal the presence of a sequence that matched 
the consensus for the silencer element. Therefore, it would be interesting to 
investigate what effects these elements would have on the basal levels of expression 
of the pig ITIH4 promoter.
The significance of the ORF of the LI element found in the 5’ end of the 30kb 
fragment is presently not clear. This element contained the antisense promoter 
(ASP) described by Speek (2001) (Figure 3.12). One of the ways Speek suggests 
that the ASP could affect the regulation of downstream genes is based on the 
observation by Greger et al. (1998) that activation at an upstream promoter could 
affect activation of a downstream promoter if transcription of the upstream gene 
continued past the PolyA site and into the promoter of a downstream gene. 
Although I did not find any evidence that there was another gene in the 30kb 
fragment 5’ to the CRP gene. Woo et a l (1985) reported the presence of a PolyA 
signal 5’ of the CRP TATA box.
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Another possible role for the LI element was the creation of the CRP pseudogene. 
Esnault et al. (2000) have shown that LINE elements which transpose through the 
reverse transcription of their own transcript can also mobilise transcribed DNA not 
associated with a LINE sequence. This results in the retroposition of the transcribed 
gene and the formation of new copies that have features characteristic of naturally 
occurring processed pseudogenes (Esnault et a l, 2000). The LINE ORFl has been 
shown to be essential for pseudogene formation.
The other aim of the sequence analysis was to identify putative growth hormone 
regulated elements with a view to removing them in order to eliminate the sexually 
dimorphic pattern of expression seen in the CRP and GM-C79 transgenic mice. The 
analysis has focused on the GM-C79 construct and on binding sites for the 
transcription factor STATS. STATS has been implicated in the mediation of the 
sexually dimorphic pattern of expression o f a number of murine liver-specific genes. 
Analysis of the GM-C79 construct showed that it contained a number of STATS 
binding sites that exhibited considerable homology to those that were identified 
experimentally by Varin-Blank et al. (1998) to be involved in mediating the sexually 
dimorphic pattern of expression of the C4~Slp gene. The pulsatile pattern of 
expression of growth hormone in male rodents has been suggested to mediate the 
translocation of activated STATS into the nucleus (Subramanian et al., 199S). The 
continuous secretion of growth hormone in female rodents has been shown to 
dephosphorylate STATS (Gebert et at., 1999) and so it is not expected that it would 
be translocated to the nucleus. Consequently, it can be speculated that the activation 
of STATS in male rodents and its binding to the DNA could enhance transcription 
from the CRP promoter. It is interesting to note that Szalai et al. (1998) proposed 
that the mediator of the sexually dimorphic pattern of expression in the CRP 
transgenic mice would be comparable to growth hormone and display a sexually 
dimorphic pattern of expression. They also suggested that in humans, this mediator 
did not appear to be under androgen control. STATS thus appears as a strong 
candidate for the proposed mediator of the sexually dimorphic pattern of expression 
of the human CRP gene in transgenic mice - it has a sexually dimorphic pattern of
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expression in mice due to the different patterns of growth hormone secretion in male 
and female mice. Because humans do not exhibit the same patterns of growth 
hormone secretion as mice, STATS would not be expected to be regulated the same 
way in humans, and consequently no sexually dimorphic pattern of expression of 
CRP would be expected to be seen in humans (and this is the case).
Although the role of STATS in regulation of acute phase genes is unknown it has 
been shown that signal transduction does not occur via the gpl30 pathway (the 
pathway used by IL-6 to induce expression of acute phase genes) (Heinrich et al,, 
1998). Binding sites for the various STAT factors exhibit considerable homology to 
each other with binding sites for STATl also being reported as binding sites for 
STATS and STAT6 on one strand and STAT3 on the other. While deleting or 
mutating elements that are binding sites for STAT3 as well as STATS may affect the 
inducibility of the construct, removing or mutating binding sites specific for STATS 
may be one way of eliminating the sexually dimorphic pattern of expression o f the 
human CRP gene in transgenic mice.
It should be bom in mind that while removing the STATS binding sites may make a 
more tightly controlled construct in mice, the effect this modification of the 
constmct would have if the constmct was used in other species is unknovm. It is not 
clear if the sexually dimorphic pattern of expression of acute phase and other 
transgenes (e.g.GM-CSF (Metcalf, 1988)) seen in transgenic mice is rodent-specific 
and a result of how these genes are regulated nonnally in rodents or the consequence 
of introducing a transgene.
In summary, the sequence analysis has identified a number of elements that may be 
involved in regulating CRP expression in transgenic mice. A functional analysis of 
these sites can now be carried out.
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7,2 Characterisation o f  the v is  ITÏH4 promoter in vitro
One of the reasons for the analysis of the 30kb CRP fragment was to facilitate the 
modification of the acute phase expression vector for use in pigs. However, 
isolation and sequence analysis of the pig ITIH4 promoter revealed that it did not 
have any homology to the human CRP promoter. As mentioned several times in this 
thesis, one of the advantages of using CRP as the backbone for our acute phase 
expression vector is that regulation of this gene is partially characterised. Therefore, 
the presence of the same regulatory sequences in the porcine ITIH4 promoter would 
have greatly facilitated the design of an acute phase expression vector based on the 
porcine ITIH4 gene. Now, before this can be seriously attempted some 
understanding of the regulation and the elements affecting the regulation of the 
porcine ITIH4 gene needs to be carried out. The experiments described in Chapter 5 
describe two things: firstly, they are functional studies on the porcine ITIH4 
promoter. Secondly, they examine the possibility of using a human hepatoma cell 
line as a means of studying the porcine acute phase response at the molecular level 
in the absence, at present, of any better in vitro system.
The experiments carried out investigated the basal expression and inducibility of the 
1.8kb region upstream of the porcine ITIH4 gene. The analyses were carried out 48 
hours post-stimulation, as this had been shown to be the peak time of expression of 
the pig ITIH4 gene both in vivo and in vitro (Lampreave et al., 1994; Gonzalez- 
Ramon et al, 2000). CAT was always detected, even in the absence of stimulation. 
Control experiments confirmed that this expression of CAT was due to the ITIH4 
promoter rather than background expression.
Stimulation with the cytokines IL-6 and BL-ip confirmed the in vitro findings from 
studies on the endogenous ITIH4 gene in primary porcine hepatocytes (Gonzalez- 
Ramon et ah, 2000). As reported in the literature, stimulation with IL-ip does not 
affect expression of the porcine or human ITIH4 gene (Gonzalez-Ramon et ah, 
2000). Therefore, our results were in good agreement with this although a small
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increase in expression was seen following stimulation with 5Ü IL-1 p (section 
5.3.2). These findings support the classification of the pig ITIH4 gene as a Class II 
acute phase protein.
Stimulation with IL-6 induced expression of the CAT gene and the level of 
induction was dose dependent. The increase in expression seen in cells transfected 
with the PPR-CAT3B following stimulation with IL-6 was twice as high as that seen 
when the endogenous porcine ITIH4 gene was stimulated (Gonzalez-Ramon et a i , 
2000). This is in spite of the fact that in our experiments a lower concentration of 
IL-6 was used (500U compared to lOOOU) and I did not use dexamethasone. 
Although dexamethasone, a synthetic glucocorticoid, is frequently used along with 
cytokines to enhance the stimulation of acute phase genes in vitro, there have been 
some reports of dexamethasone having a negative effect on gene expression (Steel & 
Whitehead, 1991). Therefore, dexamethasone was omitted from our experiments 
since it was unknown what effect it would have on expression of the ITIH4 gene.
In both our experiments, and those of Gonzalez-Ramon et a l (2000), the level of 
induction seen following stimulation with cytokines was much lower (6-fold and 3- 
fold respectively) than that seen in vivo. Lampreave et a l (1994) reported that in 
vivo synthesis of the pig ITIH4 gene increased 30-fold following a turpentine 
injection. Gonzalez-Ramon et a l (2000) offer several possibilities for the lower 
levels of expression seen with the endogenous ITIH4 gene in vitro compared to in 
vivo including the use of human cytokines rather than porcine cytokines for 
stimulation. In their experiments human cytokines may not have bound effectively 
to their receptors on porcine hepatocytes and the signal transduced may have been 
affected. For our experiments, the use of human cytokines was deemed to be 
justified as the analyses were being carried out in a human cell line. Using porcine 
cytokines with a human cell line may have resulted in the same problem as using 
human cytokines with a porcine cell line.
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Hep 3B cells were chosen for our analysis because they have been used extensively 
in studies of the acute phase response and at present an immortalised porcine 
hepatocyte cell line is not commercially available. Therefore, another possibility for 
the difference in results between Gonzalez-Ramon et al (2000) and the results 
reported here is the fact that different cells were used for the analyses. There have 
been several reports of different results being obtained when different cell lines and 
primary cells are used (Weinhold et a l ,  1997) as well as differences between in vivo 
and in vitro results (Simar-Blanchet et a l ,  1998). For this reason I wanted to test the 
constructs in primary porcine hepatocytes. Transfection of the primary porcine 
hepatocytes with the C3:EGFP construct suggested that transfection of these cells 
would be possible. However, due to the outbreak of foot and mouth disease in the 
UK in February 2001 we were unable to get any primary porcine hepatocytes to 
carry out these analyses.
An interesting observation in the literature is that almost all studies on the acute 
phase response in vitro are carried out at 3TC. In vivo, an acute phase response is 
likely to be accompanied by fever and a study by Karlsson et al (1998) reported that 
induction of acute phase proteins by IL-6 in vitro had a different effect at 40°C 
compared to 37®C. For example, they found that expression of the human 
haptoglobin gene increased 4-7 fold following stimulation with IL-6 at 37®C. 
However, at 40°C there was a 23-fold increase in expression compared to controls 
following stimulation with IL-6. It may be speculated that carrying out the 
experiments with the PPR-CAT3B construct at a higher temperature could affect the 
inducibility of the construct and possibly result in higher levels of induction.
A simple explanation for the differences between the results of Gonzalez-Ramon et 
al. (2000) and those reported in this thesis may be that the promoter region I isolated 
does not contain all of the elements necessary for controlled expression. It may also 
be due to the nature of the construct since Arcone et al (1988), in their study on 
expression of the human CRP gene in vitro, found that it was more difficult to 
induce expression of the endogenous gene compared to transiently transfected
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constructs. Overall though, our findings support those of Gonzalez-Ramon et a l 
(2000) in the classification of the porcine ITIH4 gene as a Class II acute phase 
protein and the use of Hep 3B as an in vitro system for studying the regulation of the 
porcine ITIH4 gene.
The most unexpected finding from our experiments was that stimulation with a 
combination of IL-6 and IL-lp affected the inducibility of the PPR-CAT3B 
construct. This result was inititally unexpected, as IL-ip had not been shovm to 
have any effect on the inducibility of the construct. However, this phenomenon, 
whereby IL-lp inhibits the activity of IL-6 and inducibility of the gene in 
question has already been reported for another two acute phase genes, fibrinogen and 
C l inhibitor. A study by Zuraw & Lotz (1990) showed that stimulation o f Hep G2 
cells with IL-6 or IFN-y results in an increase in Cl inhibitor secretion which is dose 
dependent. A combination of IL-6 and IFN-y has an additive effect on C l inhibitor 
secretion whereas a combination of IL-1 and IFN-y synergistically increases Cl 
inhibitor secretion. However, in contrast they showed that IL-1 antagonises the 
effect of IL-6 on Cl inhibitor. This effect was maximal when IL-1 was added prior 
to or at the same time as IL-6.
In the case of the fibrinogen gene, a Class II acute phase gene, IL-1 is believed to act 
by inhibiting the activation of STATl by IL-6. This activity has been shown to be 
specific for STATl as another IL-6 inducible STAT, STAT3, is not affected (Shen 
et a l,  2000). The ability of STATl to form heterodimers is known and it has also 
been proposed that the IL-1 inducible transcription factor NF-kB can reduce the 
binding affinity of STAT1/STAT3 to acute phase gene promoters (Zhang & Fuller, 
1997). Further experiments, such as EMSA, could be carried out to determine if 
there are members o f the STAT family binding to the ITIH4 promoter and if so, 
which ones.
In summary, the conclusion from these experiments was that the porcine ITIH4 gene 
encodes a Class II acute phase protein and that the human hepatoma cell line. Hep
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3B, is a usable system for studying the regulation of the porcine ITIH4 gene in vitro. 
The results of these experiments, in particular the downregulation o f IL-6 induced 
activation of the porcine ITIH4 gene, may be of interest to those interested in 
understanding the signal transduction pathways involved in the regulation of the 
acute phase genes.
7,3 What makes an acute phase yrotein an acute phase protein?
The results from the sequence analysis of the fragment containing the regulatory 
elements for the human CRP gene and the promoter of the pig ITIH4 gene gave us 
the opportunity to study the elements involved in regulating acute phase protein gene 
expression. The species-specificity of the acute phase response and the exact role of 
the acute phase proteins during the acute phase response have puzzled researchers 
for some time. Acute phase proteins in one species are not necessarily acute phase 
proteins in another. For example, the major acute phase protein in pigs is only a 
minor acute phase protein in humans. Our finding that the promoter of major acute 
phase protein in pigs had more homology to its human homologue, a minor acute 
phase protein in humans, than to the major acute phase protein in humans allowed 
some sequence analysis to be carried out to investigate the species-specificity of the 
acute phase response.
Ciliberto et al. (1987a) proposed that the species specificity of the acute phase 
response was due to the absence of specific transcription factors or changes in the 
DNA sequence of the promoter which affects binding of the transcription factors and 
consequently gene expression. In mice, CRP is only a minor acute phase protein, 
yet transgenic mice for the human CRP gene express human CRP as it is in humans 
(Ciliberto et al., 1987a). This suggests that it is changes in the promoter that affects 
the binding of transcription factors rather than the absence of the necessary 
transcription factors. The work in this project involved the analysis of the promoters 
of the major acute phase proteins in humans and pigs as well as comparison of the 
promoter of the major acute phase protein in pig and its human homologue. The
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results of these analyses, discussed in the following sections, may give some insight 
into the species-specificity of the acute phase response.
7.3.1 Comparison of the pig ITIH4 promoter with the CRP promoter
The pig ITIH4 promoter did not have any homology to the CRP promoter as 
revealed by a BLAST search of the nucleotide database. Comparison of the pig 
ITIH4 promoter and the human CRP promoter by searching them for the binding 
sites of elements known to affect the regulation of acute phase genes showed that the 
two genes had a very different promoter organisation (Figures 4.11 and 4.12). In 
fact, elements that had been identified by Arcone et al. (1988) to be involved in the 
acute phase induction o f the human CRP gene were absent in the pig ITIH4 
promoter. This result seems to suggest that acute phase genes are regulated 
independently, in the sense that just because a protein is a major acute phase protein 
does not mean that its promoter will have homology to the promoters of other major 
acute phase proteins.
7.3.2 Comparison of the pig ITIH4 promoter with the human ITIH4 promoter
Further insights into how the promoter can affect the regulation o f the acute phase 
genes can be gained by comparing the promoter of the pig ITIH4 gene with that of 
the human ITIH4 gene. The promoters of pig and human ITIFI4 genes have 
homology of 65%. This is suiprising on the one hand because ITIH4 in pigs is a 
major acute phase protein whereas ITIH4 in humans is only a minor acute phase 
protein so one would not expect so much homology. It is surprising on the other 
hand because the ITIH4 genes in pigs and human are quite homologous (over 75%), 
therefore the homology between the promoters is maybe lower than expected. The 
most surprising aspect is that when the promoters are compared the promoter 
organisation is completely different. Even though there are binding sites for the 
transcription factors analysed in both the promoters of the ITIH4 genes, their
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position and number varies and it can be postulated that this is the key to the 
differences in gene expression of the human and pig ITIH4 genes.
I attempted to use this information to manipulate expression of the pig ITIH4 gene. 
Harden et a l (1988) had suggested a correlation between the binding of the 
transcription factor LF-Al to its binding site and the levels of gene expression. As 
mentioned in section 5.5.1 the presence of three putative binding sites for LF-Al in 
the promoter of the pig ITIH4 gene and only one in the human ITIH4 gene 
suggested that this may account for the lower inducibility of the human ITIH4 gene. 
It was hoped that mutating these sites in the pig ITIH4 gene would reduce the basal 
levels of expression while maintaining or increasing the inducibility of the 
constructs. The results showed though that the mutation did affect not only the 
inducibility of the construct but also the basal transcription machineiy. This may be 
because the LF-Al transcription factor is a bi-functional transcription factor 
involved in both induction and regulation of the basal transcription machinery. 
Alternatively, deleting the binding site for this transcription factor affected the 
structural organisation of the promoter. For example, the LF-Al transcription factor 
may function by steric hindrance -  allowing or preventing the access of other 
transcription factors to the promoter. In addition, two of the LF-Al sites were 
shown to overlap with putative Spl binding sites (Figure 5.10). Spl, a ubiquitous 
transcription factor has been reported as being capable of both inducing and 
repressing gene expression (see section 5.5.3). It is therefore possible that making a 
base substitution in the binding site for LF-Al would only have decreased its affinity 
for the binding site and consequently may have had a different effect on gene 
expression.
7.4 Develovins GFP as a reporter o f  transient sene expression
Sequence analysis allows the identification of a whole range of putative regulatory 
elements and regions. However, without a functional analysis the significance of 
these findings can only be speculated. It is clear from the literature that regulation of
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the CRP gene and eukaryotic genes in general is complex. Therefore, attempting to 
identify the regions important in regulating the CRP and pig ITIH4 genes will 
involve numerous in vitro expression studies. This was one of the reasons for 
wanting to develop GFP as a reporter system. GFP also allows real time analysis 
and would be interesting to see the switching on and off of gene expression in 
response to various stimuli. In the future, there is also the possibility of creating 
transgenic mice where an acute phase promoter drives expression of GFP. This 
would allow the expression of the acute phase gene to be monitored in vivo.
Initial experiments comparing transfection of the two GFP control vectors in COS-7 
(control cell line) and Hep 3B (experimental cell line) showed that both cell lines 
could be transfected with both the GFP vectors. The main difference was the 
expression of the two vectors, both the levels of fluorescence and the number of 
fluorescent cells. This was investigated further in Hep 3B over a 120h period.
One of the differences between the two constructs is the number of fluorescent cells 
present following transfection. Transfections with the C3:EGFP vector result in a 
large number of fluorescent cells whereas the GFP-C vector results in a few 
fluorescent cells although the number increases with time but never to the extent of 
that seen with the C3:BGFP vector. The reason for these differences was originally 
thought to be due to the expression levels and half-life of the GFP-C vector. Viral 
promoters have been reported to have varying levels of efficiency depending on the 
cell line (Sutherland & Williams, 1997; Zarrin et a l, 1999) with the CMV promoter 
often being reported to be stronger than the SV40. Therefore, since GFP in the 
C3 :EGFP vector is under the control of the CMV promoter and the GFP in the GFP- 
C vector under the control of the SV40 promoter it was thought that this may be 
contributing to the differences seen. Lower levels of expression of GFP in cells 
transfected with the GFP-C construct would be exacerbated by the short half-life of 
the GFP molecule. Consequently there was a possibility that a sufficient number of 
GFP molecules were not accumulating in the cell to allow detection.
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However, this theory did not make sense when the fluorescence intensity of the cells 
was measured because cells transfected with the destabilised variant of GFP were 
much brighter compared to cells transfected with the C3:EGFP vector. It was 
suggested that mutations may have been introduced to the destabilised GFP variant 
to enhance its fluorescence due to the low number of GFP molecules expected to be 
produced (Dr G Palmer, Clontech, personal communication). Further evidence that 
the differences in expression of the two vectors are connected to the GFP molecule 
rather than the promoters was obtained when the acute phase promoters were used to 
drive expression of the stabilised and destabilised variants of GFP. As seen with the 
control vectors, transfections with the stabilised variant resulted in a higher number 
of cells but with lower levels of fluorescence compared to cells whereas the opposite 
was the case with cells transfected with the destabilised variant. This suggests that 
intrinsic properties of GFP may be responsible for the differences in the levels of 
expression seen.
The intrinsic properties of GFP may limit its use as a reporter system for inducible 
gene expression, particularly when using the destabilised variant for the following 
reasons:
1. Fluorescence is dependent on the formation of a chromophore. This process is 
oxygen-dependent and a delay of more than one hour can occur between 
chromophore formation and detection of fluorescence (Piston ei a l, 1999). 
Therefore, the protein may be degraded before a sufficient number of molecules 
can accumulate in the cells.
2. Only ~ 20% of GFP molecules are expected to fold correctly (Tsien, 1998). This 
limitation in combination with a slow rate of chromophore formation and a 
short-half life of the protein would be particularly problematic due to the fact 
that GFP cannot be detected if a sufficient number of molecules folded correctly 
are not present in the cell.
3. Mutations introduced to GFP and creation of fusion proteins can affect the 
transcription and translation of the molecule (Sacchetti et ah, 2001). The
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destabilised GFP vector used in our experiments was designed by fusing the 
degradation domain of the mouse ornithine decarboxylase to the C-terminal of 
EGFP (Li et al., 1998a). The effect of this modification on transcription or 
translation of the GFP gene has not been investigated.
4. Transfection efficiency of the plasmids. Analysis of the cells appears to suggest 
that the C3:EGFP vector has a higher transfection efficiency compared to the 
GFP-C vector. However, this is misleading because the apparent lower 
transfection efficiency of the GFP-C vector may be due to the fact that a 
sufficient number of GFP molecules are not present in the cells to allow 
detection.
Although studies have been carried out to correlate transcription and translation of 
the GFP gene (Sacchetti et a l, 2001), no work has been done to determine the 
relationship between transcription and translation and fluorescence of the 
destabilised variant. This is an important relationship to establish as it has 
implications for studying inducible gene expression as discussed in the next section. 
It may also help determine if the low number of fluorescent cells is due to the 
intrinsic properties of GFP or the absence or low levels of fluorescence or the 
transfection efficiency of the plasmid. Some of these questions could be answered 
by analysing the RNA content of the cells to see if  the GFP gene is being transcribed 
and to what extent.
7.4.1 Quantitating GFP fluorescence
Although GFP would possibly allow the visualisation of switching on and off of 
gene expression, quantitating the fluorescence over time is difficult. Niswender et al 
(1995); Subramanian et a l (1996); Patterson et a l  (1997) and Piston et a l (1999) 
have discussed the problems encountered with quantitating fluorescence in studies of 
transient gene expression. The problems not only include those mentioned in 
section 7.4 but also the fact that the fluorescence is not homogeneous between the 
cells. When the cells are examined using a fluorescence microscope considerable
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variation in the fluorescence intensity between one cell and another is seen. As 
stated in section 2.5.2,10, the mean fluorescence per cell was calculated by summing 
the total fluorescence intensity values from, if possible, at least 100 cells. The 
variation in fluorescence from cell to cell has the effect of decreasing the mean value 
from these analyses and consequently the differences between cells receiving 
stimulation and those receiving none is reduced. Analysing cells in this manner (i.e. 
measuring the fluorescence from individual cells) also makes quantitating 
fluorescence over time difficult because it is difficult to choose the same cells for 
analysis each time. In addition, over time, as the cells divide, the fluorescence will 
also appear to decrease but this may be due to plasmid loss from the cell during cell 
division rather than a decrease in gene expression. Therefore, an alternative method, 
such as FACS, may be better.
Although some changes in fluorescence intensity were detected following 
stimulation with IL-6, these changes were usually small. It is not yet clear how 
changes in the number of protein molecules are related to fluorescence and gene 
expression. For example, if 10 000 molecules of GFP are necessary for accurate 
detection, how many molecules are necessary to detect a change in expression? If a 
large number of molecules are required then a big increase in gene expression may 
only be correlated with small but significant changes in fluorescence intensity. 
Detecting changes in fluorescence intensity may also be complicated, at least in the 
case of the destabilised GFP molecule if it has been mutated to enhance 
fluorescence, by the fact that the levels of fluorescence present in the cell initially 
may be so high as to prevent any further changes being detectable. This would 
explain why no significant changes in expression following stimulation with IL-6 
were seen when the Ay-dEGFP and Ay-dEGFP constmcts were examined.
The idea that levels of fluorescence need to be low initially in order to detect 
changes in fluorescence appears to be supported by the observation that in cells 
transfected with dEGFP there was an increase in the number of fluorescent cells 
following stimulation with IL-6. This was presumably related to an increase in gene
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expression allowing detection of fluorescence in cells where previously the 
fluorescence levels were too low for detection. The results from these analyses (i.e. 
comparing the number of fluorescent cells) were in agreement with what was seen 
with the CAT reporter system in terms of the relative strength of the promoters to 
each other.
GFP and CAT as reporter systems have been compared (Albano et a l,  1998) and 
this study found that GFP was as good as CAT for quantitating heterologous protein 
production. GFP has also been reported to be more sensitive than other reporter 
systems in vivo (Chiochetti et a l, 1997). However, the results from the experiments 
described in this thesis suggest that GFP is not as sensitive as other reporter genes 
for quantitating small changes in gene expression.
7.5 Modification o f the acute phase expression vectors -  is it possible?
7.5.1 Modification of the CRP acute phase expression vector
The identification of regulatory sequences is difficult because it may be the 
organisation and interactions of transcription factors that is important rather than 
specific sequences. Ogbourne & Antalis (1998) have also suggested a similar idea 
in that it is DNA sequences and their context within a given promoter rather than the 
DNA binding proteins that determine the repressor mechanisms at a given promoter. 
These hypotheses are supported by the work done in this project on the pig ITIH4 
promoter. Although the promoters of the pig and human 1TIH4 gene exhibit a 
reasonable amount of homology, the promoter organisation is very different.
Ideally, we want to clone the CRP/GM-CSF fusion in the background of the 30kb 
fragment. Although sequencing of the 30kb fragment meant it was possible to 
generate a restriction map of unique restriction sites, none of the sites would have 
been suitable for cloning. Nonetheless, this project has identified at least two 
regions that may have an influence on regulation of the CRP gene and are worth
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exploring further. In particular, if  the CT repeat located approximately 2kb 
upstream of the CRP gene is important in regulating its expression, this would still 
allow a small but more tightly controlled acute phase expression vector to be made.
The second aim of the analysis was to identify putative growth hormone responsive 
elements. The sexually dimorphic pattern of expression of human CRP in transgenic 
mice is seen both in mice with the full length 30kb fragment and the smaller C79 
construct. Therefore, identification o f these elements is important since even if we 
are successful in cloning the CRP/GM-CSF fusion into the background of the 30kb 
fragment this pattern of expression will remain. A number o f binding sites for 
growth hormone responsive elements were identified -  two putative GAGA boxes 
and several binding sites for STAT5. In future constructs these sites could be 
mutated and analysed in transgenic mice to see if they have any effect on the 
sexually dimorphic pattern of expression. Alternatively, analysis could be carried 
out to see if STAT5 actually binds to the putative STATS binding sites in the GM- 
C79 construct.
7.5.2 Modification of the acute phase expression vector for use in pigs
For the acute phase expression system to function effectively, tightly controlled 
expression of the heterologous gene is essential. At this stage the elements 
necessary for controlled expression of the porcine ITIH4 gene are unknown and 
there is no model system available for its analysis in vitro. The work in this project 
is the first step to understanding the regulation of the porcine ITIH4 gene and the 
establishment of a model system for molecular analysis of the porcine acute phase 
response. The results of the gene expression studies show that the section of the 
promoter I have isolated is both functional and inducible in Hep 3B and that it 
behaves as a Class II acute phase protein.
Although we believe Hep 3B is a usable system for studying the porcine acute phase 
response at the molecular level there is obviously some concern about analysing the
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porcine constmcts in a human cell line. For this reason, I wanted to analyse the 
constructs in primary porcine hepatocytes in order to verify the findings in Hep 3B. 
Initial experiments to see if  it was possible to transfect the cells with GFP appeared 
to be successful. This was an important breakthrough because it means that a) the 
constmcts made during the course of this project can be tested in primary porcine 
hepatocytes and b) it can be attempted to make an immortalised porcine liver cell 
line, for example using the vector and method described by Park et al. (1996).
It is important that a model system for studying ITIFI4 gene expression in vitro that 
reflects the in vivo situation is established to facilitate studies of the porcine acute 
phase response. Studies with the human CRP gene in vitro have shown that analyses 
in different cell lines will give different results. They have also shown that the 
minimal promoter for controlled expression varies from cell line to cell line and that 
the minimal promoter for controlled expression in vitro is not sufficient for 
controlled expression in vivo. Studies on the endogenous porcine ITIH4 gene 
(Gonzalez-Ramon et a i, 2000) and the porcine ITIH4 promoter (this thesis) show 
that they are not induced to the same extent as in vivo. It should be stressed though 
that while it is important to be aware of the limitations of the in vitro systems and to 
exercise caution when interpreting the results, these systems have contributed 
greatly to our understanding of the acute phase response. At present, the lack of 
knowledge on the porcine acute phase response, particularly at the molecular level 
and the absence of established systems for studying the porcine acute phase response 
both in vivo and in vitro hinders further development of the acute phase expression 
vector for use in pigs.
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7.6 Conclusion
The ultimate goal of this project was to develop a modified expression vector for use 
in pigs. Although we did not achieve this, the work carried out during the course of 
this project has opened up numerous areas for further development, both for us to 
develop the acute phase expression system and for those that are interested in 
understanding the acute phase response at the molecular level.
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Appendix 2: List of constructs
Name of construct Description
pCSI Clal/Spel subclone for sequencing 30kb GRP fragment
pCKI Clal/Kpnl subclone for sequencing SOkbCRP fragment
pSI Spel/Spel subclone for sequencing 30kb GRP fragment
pSK7 Spel/Kpnl subclone for sequencing 3kb GRP fragment
pCRP-CAT ~260bp of the GRP promoter in promoterless pCAT 
enliancer (Shirley Hanley)
pPPR Pig ITIH4 promoter and some coding sequence in PGR 
Script
pPPR(K/X) Pig ITÏH4 promoter with engineered Kpn\ and sites 
and without coding sequence in PGRScript
pPPR-CAT3B Pig ITIH4 promoter in pCAT3-Basic vector
pPPR-EGFP Pig ITIH4 promoter in G3:EGFP
pPPR-dEGFP Pig ITIH4 promoter in dEGFP-Basic
pPPR-AALL Pig ITIH4 promoter with all LF-Al sites deleted in 
PGRScript
pPPR-AALL-
CAT3B
Pig ITIH4 promoter with all LF-Al sites deleted in 
pGAT3-Basic
pPPR-Aa Pig ITIH4 promoter with a  LF-Al site deleted in 
PGRScript
pPPR-Aa-CAT3B Pig ITIH4 promoter with a  LF-Al site deleted in pCAT3~ 
Basic
pPPR-Ap Pig ITIH4 promoter with P LF-Al site deleted in 
PGRScript
pPPR-A|3-CAT3B Pig ITIH4 promoter with p LF-Al site deleted in pCAT3- 
Basic
pPPR-Ay Pig ITIH4 promoter with y LF-Al site deleted in 
PGRScript
pPPR-Ay-CAT3B Pig ITIH4 promoter with y LF-Al site deleted in pCAT3- 
Basic
178
pPPR-Ay-EGFP Pig 1TIH4 promoter with y LF-Al site deleted in 
C3;EGFP
pPPR-Ay-GFP Pig ITIH4 promoter with y LF-Al site deleted in dEGFP- 
Basic
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